The use of miRNAs for stroke patient prognosis and as targets for stroke treatment
By measuring the levels of specific miRNAs in the blood of stroke patients, prognosis can be determined and miRNA inhibitors can be used. This addresses the lack of effective biomarkers and treatments in existing technologies, enabling rapid and effective treatment and recovery for stroke patients.
Patent Information
- Application Number
- CN202580028744.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-03-04
- Filing Date
- 2025-03-04
- Publication Date
- 2026-11-17
AI Technical Summary
Current technologies lack effective biomarkers to assess the severity of neurological damage and patient outcomes following stroke events, and lack therapies that can protect, restore, and regenerate the nervous system during stroke.
By measuring the expression levels of miR-376c-3p, miR-199a, miR-134-5p, miR-4463, and miR-584-5p in the blood of stroke patients, patient prognosis can be determined, and personalized treatment can be administered using corresponding miRNA inhibitors.
It enables rapid and effective determination of stroke patient prognosis and provides personalized neuroprotective therapy, improving the targeting of treatment and recovery outcomes.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
[0001] This application claims the benefit of European patent application EP 24382236.8, filed on March 4, 2024. Technical Field
[0002] This invention relates to the fields of prognosis and therapeutic treatment. In particular, the invention provides a non-invasive method for predicting the prognosis of patients who have already suffered a stroke based on the measurement of specific miRNAs in bodily fluids. The invention also provides miRNA inhibitors for treating stroke patients. Background Technology
[0003] A stroke (also known as a cerebrovascular accident or brain injury) is a medical condition caused by insufficient blood flow to the brain, leading to cell death. There are two main types of stroke: ischemic stroke (IS), caused by insufficient blood flow; and hemorrhagic stroke, caused by bleeding. Both types of stroke result in some part of the brain ceasing to function normally. It is estimated that 87% of strokes are ischemic, and the rest are hemorrhagic.
[0004] According to the WHO, stroke (especially ischemic stroke) is the leading cause of disability in adults and the second leading cause of death worldwide. Approximately 13 million people suffer a stroke each year, and five million of these strokes result in long-term disability.
[0005] Functional outcomes following stroke vary among individuals, regardless of clinical factors such as the severity of the initial stroke. Multiple biological processes are involved in the response to brain injury resulting from stroke events, and their activity can be regulated by many different mechanisms that may contribute to individual variability in recovery. Some of these mechanisms are epigenetic processes, including DNA methylation, histone modifications, and their regulation via long non-coding RNAs and microRNAs (miRNAs).
[0006] MicroRNAs are short, non-protein-coding RNA molecules that regulate gene expression at the post-transcriptional level primarily through interactions with messenger RNA (mRNA). miRNAs typically recognize binding sites located in the 3' untranslated region (3' UTR) of mRNA to inhibit mRNA translation or, less frequently, induce its degradation. miRNAs regulate the expression of approximately 60% of human protein-coding genes, and a single miRNA can regulate multiple target genes simultaneously. Furthermore, these molecules are involved in a wide range of physiological and pathological processes, such as cell differentiation, development, proliferation, apoptosis, migration, and cellular stress responses.
[0007] Recent studies have demonstrated that miRNAs also regulate neuroprotection and neurodegenerative processes, both of which are highly involved in post-stroke recovery. Furthermore, multiple different miRNAs and their target genes are believed to be involved in the pathophysiological mechanisms of stroke. However, most research focuses on the potential of miRNAs as biomarkers for the diagnosis of acute stroke (IS) and their role in the pathogenesis of IS, rather than on the prognosis of stroke patients or the identification of targets for neurological recovery in stroke patients.
[0008] Furthermore, most current stroke treatments focus on the causative event. For example, in the case of ischemic stroke, treatment typically aims to restore cerebral blood flow, such as by administering thrombolytic agents like recombinant tissue plasminogen activator (rtPA) or performing mechanical thrombectomy. In the case of hemorrhagic stroke, most treatments aim to regulate blood pressure or promote coagulation, such as by administering prothrombin or clotting factors; or, in severe cases, by performing emergency surgery to remove blood clots and relieve pressure on the brain. However, effective therapies (aside from cognitive rehabilitation) aimed at protecting, restoring, and / or regenerating the nervous system damaged during ischemic or hemorrhagic strokes remain lacking.
[0009] Therefore, there is a need in the field to identify effective biomarkers to assess the severity of neurological damage following stroke events and the outcomes and prognoses of patients who have already experienced a stroke; and to identify effective neuroprotective therapies for the recovery of daily life in stroke patients. Summary of the Invention
[0010] The authors of this invention unexpectedly found that, compared with blood samples from stroke patients with poor outcomes (modified Rankin Scale (mRS) less than 3) 3–6 months after the stroke event, the expression levels of miRNAs miR-376c-3p, miR-199a, miR134-5p, miR-4463, and miR-584-5p were higher in blood samples from stroke patients with poor outcomes (modified Rankin Scale (mRS) 3–6) 3–6 months after the stroke event.
[0011] As illustrated in the examples, miRNAs miR-376c-3p, miR-199a, miR-134-5p, miR-4463, and miR-584-5p are robust biomarkers for determining stroke patient outcomes by simply analyzing their expression levels in blood samples from stroke patients.
[0012] Therefore, in a first aspect, the present invention relates to an in vitro method for determining the prognosis of a patient suffering from stroke, the method comprising: (i) Determine the expression level of at least one miRNA selected from the group consisting of miR-376c-3p, miR-199a, and combinations thereof in samples isolated from the patient. (ii) Compare the expression level obtained in step (i) with the corresponding reference value. If the expression level determined in step (i) is higher than the corresponding reference value, the patient is considered to have a poor prognosis.
[0013] Depending on the patient's prognosis, different treatments can be provided, such as personalized endovascular therapy; and in cases of poor prognosis, personalized endovascular therapy can be combined with neuroprotective drugs or treatments. Therefore, the advantage of this approach is that it allows for the determination of the most suitable medical treatment and subsequent medical follow-up care for the patient.
[0014] Furthermore, a key feature of this method is its simplicity and time-saving efficiency. Therefore, it can be performed quickly in an outpatient setting or ambulance. Extensive literature documents that early and appropriate therapeutic intervention is crucial for optimal treatment outcomes for most known medical treatments for stroke patients. Therefore, a significant advantage of this method is that it not only allows for the determination of the best treatment to be provided to stroke patients, but also allows for the determination of the best treatment shortly after the onset of stroke symptoms, which is essential for both the patient and for better outcomes.
[0015] In a second aspect, the present invention relates to an in vitro method for determining or recommending whether to initiate a medical program for a patient suffering from stroke, the method comprising the following steps: (i) Determine the expression level of at least one miRNA selected from the group consisting of miR-376c-3p, miR-199a, and combinations thereof in samples isolated from the patient. (ii) Compare the expression level obtained in step (i) with the corresponding reference value. If the expression level determined in step (i) is higher than the corresponding reference value, then the decision is made or the initiation of the medical treatment plan is recommended.
[0016] In a third aspect, the present invention relates to an in vitro method for determining the response of a patient diagnosed with stroke to a medical regimen for treating stroke, the method comprising the following steps: (i) Determine the expression level of at least one miRNA selected from the group consisting of miR-376c-3p, miR-199a, and combinations thereof in samples isolated from the patient. (ii) Compare the expression levels obtained in step (i) with the expression levels of the same one or more miRNAs identified at the start of the treatment regimen or at an earlier stage of the treatment regimen. A decrease in the expression level of one or more miRNAs relative to their expression levels at the start of the treatment or at an earlier stage of the treatment indicates a good response to the treatment.
[0017] Furthermore, the identified miRNAs have been annotated to target genes in gene ontology (GO) pathways associated with biological processes such as angiogenesis, neuronal morphogenesis, transforming growth factor β (TGF-β), endothelial development, and cognition; all of which are related to stroke recovery (see, for example...). Figure 3 and Figure 5 Therefore, the miRNAs represent useful targets for the treatment of nerve injury and for neuroprotection in stroke patients. Furthermore, miR199a-3p and miR376c-3p have a negative impact on stroke recovery, as shown in the scratch assay in Example 3, and miR199a-3p inhibits the expression of proteins functionally associated with stroke recovery, such as YAP1, as shown in Example 4.
[0018] Therefore, in a fourth aspect, the present invention relates to a miRNA inhibitor targeting a list of miRNAs selected from miR-376c-3p, miR-199a, and combinations thereof, for use in the treatment or prevention of stroke in patients.
[0019] In a fifth aspect, the present invention relates to a combination of miRNA inhibitors for use in the treatment or prevention of stroke in a patient, wherein the combination of miRNA inhibitors comprises miRNA inhibitors as defined in the fourth aspect, and further comprises: - A miRNA inhibitor that targets miRNAs selected from the group consisting of miR134-5p, miR-4463, miR-584-5p, and combinations thereof. - Two miRNA inhibitors, each of which is a miRNA inhibitor selected from different miRNAs in the group consisting of miR134-5p, miR-4463, miR-584-5p, and combinations thereof. - Three miRNA inhibitors, each of which is a miRNA inhibitor selected from different miRNAs in the group consisting of miR134-5p, miR-4463, miR-584-5p and combinations thereof, and in particular, each miRNA inhibitor is a miRNA inhibitor selected from different miRNAs in the group consisting of miR134-5p, miR-4463 and miR-584-5p.
[0020] In a sixth aspect, the present invention relates to a pharmaceutical composition for use in the treatment or prevention of stroke, the pharmaceutical composition comprising a miRNA inhibitor as defined in the fourth aspect or a combination of miRNA inhibitors as defined in the fifth aspect. Attached Figure Description
[0021] Figure 1 Study Design. In the discovery phase, next-generation sequencing (NGS) was used to measure 2083 circulating plasma miRNAs in 215 ischemic stroke patients, and differential expression and gene set enrichment analyses were performed. In the replication and validation phase, selected candidate miRNAs from an independent cohort of 191 patients were sequenced by RT-PCR.
[0022] Figure 2 Discovery Phase - Differential Expression Analysis Results. Inset A depicts the bootstrap results for the significant miRNA subset. Circles indicate whether a candidate was significant after bootstrap: significant (solid black circle), insignificant (white-centered black circle). Inset B compares the distribution of miRNAs with FC higher than 1.5 between patients with good prognosis (left box in each boxplot) and patients with poor prognosis (right box in each boxplot). All results were adjusted for age, sex, previous mRS, 24-hour NIHSS, and rTPA.
[0023] Figure 3 Functional annotations of significant miRNAs obtained during the discovery phase. The heatmap shows six clusters of miRNAs based on their similar functions with their target genes. Rows represent pathways, grouped into 18 families according to the processes they participate in (numbered 1-18 on the left side of the inset), and columns represent miRNAs. Colors depend on the number of genes regulated by the miRNA in the pathway. Lighter colors indicate a larger number of genes, while darker colors indicate that the miRNA does not regulate any gene belonging to a particular pathway. The numbers on the left side of the inset represent the following pathway families: 1: TGFβ response, 2: angiogenesis, 3: synapsis, 4: myocardial hyperplasia, 5: neuronal morphogenesis, 6: cardiac and arterial development, 7: cognition and behavior, 8: DNA transcription, 9: growth regulation, 10: brain development, 11: muscle tissue development, 12: cell adhesion, 13: endothelial development, 14: catabolic regulation, 15: cell localization, 16: receptor binding, 17: phosphorus metabolism, 18: chromatin.
[0024] Figure 4Results of the replication validation phase. Inset A shows the fold change in miRNA candidates and the miRNAs found to be significant (miRNA names are marked with black circles on the Y-axis) or insignificant (miRNA names are not marked with any circles on the Y-axis). Inset B shows the results after the bootstrap test, where miRNAs that remain significant are marked with circles in their names on the Y-axis. It can be seen that miR-376c-3p, miR-4463, miR-134-5p, miR-199a-3p, and miR-584-5p remain significant. The β coefficient corresponds to the ΔCt value (the difference in ΔCt between the two groups), where a negative value indicates higher miRNA expression in patients with adverse outcomes. Inset C depicts the difference in ΔCt values between patients with good outcomes and those with adverse outcomes (lower ΔCt values indicate higher miRNA expression). Inset D shows the interaction between stroke outcome and sex regarding miR-134-5p concentration. All results were adjusted for age, sex, previous mRS, 24-hour NIHSS, rTPA treatment, and RNA quantification.
[0025] Figure 5 Functional annotations of miRNAs validated during the replication-validation phase. In small figure A, rows represent pathways and are grouped into 22 families according to the processes they participate in, and columns represent miRNAs. The color depends on the number of genes regulated by the miRNA in the GO entry family. Lighter gray indicates a larger number of genes, while darker gray indicates that the miRNA does not regulate any genes belonging to a certain pathway. Small figure B shows the functional network of replicate-validated miRNAs. Nodes represent validated miRNAs (blue squares), gene targets (green triangles), or GO entry clusters (red circles). Edges (gray dashed lines) are weighted according to the strength of evidence supporting the miRNA-gene relationship (number of published articles) or the importance of the gene in a certain class of biological processes (number of gene sets to which the gene belongs).
[0026] Figure 6 Wound closure under normoxic conditions. C+ indicates cells transfected with control RNA. A) Images of cells cultured under normoxic conditions transfected with control RNA (C+), miR-199a-39 (199), and miR-376c-3p (376). B) Quantification of data obtained from A) using Image J.
[0027] Figure 7Wound closure under hypoxic conditions. C+ indicates cells transfected with control RNA. A) Images of cells cultured under hypoxic conditions transfected with control RNA (C+), miR-199a-39 (199), and miR-376c-3p (376). B) Quantification of data obtained from A) using ImageJ.
[0028] Figure 8 YAP protein levels in cells transfected with a scramble or miR-199a-3p mimic. Scramble: miRNA without a known target in the human genome. A) Western blot (WB) of cells transfected with a scramble or miR-199a-3p mimic (miR-199a-3p mimic). Scramble (Scr): miRNA without a known target in the human genome. B) Quantification of the data shown in A), where the mimic corresponds to the miR-199a-3p mimic.
[0029] Figure 9 YAP1, actin filaments, and cell stiffness. A) Confirmation of YAP KO and effective transfection by Western blotting. B) YAP-KO cells exhibit a higher F / G-actin ratio. C) Immunofluorescence of phalloidin shows increased filamentation in YAP-KO cells, and the addition of YAP reduces stress fibers. D) YAP-KO cells exhibit higher stiffness and decreased cell flexibility. Detailed Implementation
[0030] Unless otherwise stated, all terms used herein should be understood in their ordinary sense as known in the art. Unless otherwise expressly listed, more specific definitions of certain terms used herein are set forth below and are intended to apply throughout the specification and claims.
[0031] As used herein, the indefinite articles “a” and “an” are synonymous with “at least one” or “one or more”. Unless otherwise indicated, the definite articles used herein (such as “the”) also include the plural form of the noun.
[0032] For the purposes of this invention, any range given includes both the lower and upper endpoints of the range. Unless otherwise specified, ranges given (such as concentrations) should be considered approximate values. The term "about" means a deviation of ±10%, preferably ±5%.
[0033] 1. The method of the present invention 1.1 Definition As used herein, the terms “stroke,” “cerebrovascular accident,” or “cerebral infarction” refer to a medical condition in which impaired blood flow to the brain leads to cell death. Strokes can be classified into two main categories: ischemic stroke and hemorrhagic stroke. An ischemic stroke is caused by an interruption of blood supply to the brain (an ischemic infarction in a part of the brain), while a hemorrhagic stroke is caused by the rupture of a blood vessel or abnormal vascular structure (cerebral hemorrhage). IS can be classified as thrombotic IS (or cerebral thrombosis) or embolic IS (cerebral embolism). Thrombotic IS is the most common type of ischemic stroke, characterized by the formation of a blood clot within a diseased or damaged artery in the brain caused by atherosclerosis (containing cholesterol deposits called plaques), obstructing blood flow. Embolic IS is caused by a blood clot or small plaque that forms in one of the arteries leading to the brain or in the heart, propelled by blood flow and becoming lodged in a narrower cerebral artery. Due to the blockage, the blood supply to the brain is cut off. Hemorrhagic stroke can be classified as either ischemic stroke (ICH) or subarachnoid hemorrhage (SAH) based on the brain regions affected by the hemorrhage. ICH is characterized by blood flowing into the brain parenchyma, while SAH is characterized by blood flowing into the subarachnoid space. In both cases (ischemic or hemorrhagic stroke), the stroke causes certain parts of the brain to cease normal functioning.
[0034] Ischemic infarction can be caused by atherosclerosis or thromboembolism, and more rarely by trauma, infection, or tumors. In ischemic stroke, the pathogenic stroke cascade comprises two main phases. The first phase is characterized by acute injury and neuronal loss occurring within minutes, hours, and days due to ischemia. The second phase includes neurodegenerative processes that occur days, weeks, or even months after the ischemic event. Hemorrhagic stroke is caused by blood flowing directly into the brain or the space between the meninges. Hemorrhage can be caused by cerebral aneurysms (abnormal bulging of blood vessels in locations where the walls are thinner than normal), brain tumors, and may occur due to ruptured aneurysms, blood-thinning drugs, head injury, or a history of secondary hemorrhage in ischemic stroke.
[0035] Bleeding can occur in ischemic areas, a condition known as "hemorrhagic transformation." Some cases of hemorrhagic stroke have reportedly actually begun as ischemic strokes.
[0036] Signs and symptoms of stroke may include loss of movement or sensation on one side of the body, difficulty understanding or speaking, dizziness, or loss of vision in one side. Signs and symptoms usually appear shortly after a stroke. If symptoms last less than one or two hours, the stroke is called a transient ischemic attack (TIA), also known as a mini-stroke. Hemorrhagic stroke may also be associated with severe headache. Stroke symptoms can be permanent. Long-term complications may include pneumonia and loss of bladder control.
[0037] Diagnosis is typically based on physical examination and supported by medical imaging, such as computed tomography (CT) scans or magnetic resonance imaging (MRI) scans. The method can also be used to determine how much time has passed since the stroke event occurred.
[0038] Perform additional tests (such as an electrocardiogram (ECG) and blood tests) to identify risk factors and rule out other possible causes. Low blood sugar can cause similar symptoms.
[0039] Current treatment options remain primarily limited to etiological reperfusion therapy (such as systemic thrombolysis and interventional thrombectomy for ischemic stroke) or blood pressure and coagulation therapy. Non-limiting examples of such treatments for stroke patients include (depending on the type of stroke): - Ischemic stroke: Focus on relieving the obstruction and restoring blood flow to the brain, especially to ischemic but not yet infarcted areas of the brain. o. Medications: Administer thrombolytic agents, such as tissue plasminogen activator (tPA), or biosynthetic forms of human tPA (such as alteplase). tPA must be administered within a 4.5-hour time window from symptom onset to achieve optimal effect. Unfortunately, only 3%–5% of stroke patients arrive at the hospital in time to consider this treatment. This medication carries an increased risk of intracranial hemorrhage. Alteplase is the most widely used thrombolytic agent (rTPA) manufactured using recombinant DNA technology. Thrombolytic agents can be administered intravenously for intravenous thrombolysis (IVT) or via microcatheter-based surgical intervention to deliver them to the site of the brain obstruction for intra-arterial thrombolysis (IAT).
[0040] o Surgical intervention: Thrombectomy, which involves inserting a catheter through a blood vessel (usually in the groin) and up to the blood clot. It uses an intra-arterial mechanical device (stent thrombectomy device) or a suction device to remove the blood clot and reopen the blocked artery so that blood can flow freely again.
[0041] Intravenous thrombolysis (IVT) and mechanical thrombectomy (MT): For most patients who are candidates for both reperfusion therapies, IVT is recommended before MT, a procedure known as bridging therapy. Potential advantages of performing IVT before MT include complete or partial dissolution of the thrombus causing large vessel occlusion (the target of MT), dissolution of thromboemboli in distal vessels inaccessible to MT, and faster relief of cerebral ischemia. Potential disadvantages of prioritizing IVT include a delay in the initiation of the MT procedure, an increased risk of symptomatic intracerebral hemorrhage, and partial dissolution of large vessel thrombi (which allows them to move to more distal vessels inaccessible to MT).
[0042] -Hemorrhagic stroke: o. Medications: These are designed to regulate blood pressure or blood clotting and are well-known to those skilled in the art. Examples of blood pressure regulating medications include labetalol, or osmotic diuretics (such as mannitol), to reduce intracranial pressure in the subarachnoid space.
[0043] Examples of coagulation medications include vitamin K therapy, prothrombin, or coagulation factors well known to those skilled in the art.
[0044] Surgical interventions are sometimes necessary in cases of intracranial hemorrhage to drain the blood clot in order to reduce rising intracranial pressure and minimize damage from compression. In cases of subarachnoid hemorrhage, surgery aims to treat aneurysms, such as by clipping the aneurysm after craniotomy (surgically opening the skull) to isolate it from normal blood flow, or by endovascular microcoil embolization, as is well known to those skilled in the art. Other non-limiting examples of surgical interventions aimed at relieving elevated intracranial pressure include craniectomy, in which a portion of the skull is removed and temporarily left unrepositioned.
[0045] Rehabilitation programs and physical therapy focus on the patient's functional recovery. They are adapted to the severity of symptoms and the patient's ability to tolerate more challenging or easier training programs.
[0046] Neuroprotective agents with the potential to promote neuronal plasticity and improve functional recovery can be provided in both cases, especially if the patient is considered to have a poor outcome. However, neuroprotective therapies designed to protect, restore, and / or regenerate the nervous system by interfering with the cascade response triggered by stroke events remain lacking.
[0047] As used herein, the term "stroke event" refers to an event that directly triggers cell death detected in the brain of a stroke patient and thus results in partial or complete loss of brain function. Therefore, as used herein, a stroke event refers to an event that triggers a cascade of neurological damage occurring in a stroke patient. Thus, as used herein, a stroke event (or ischemic event) in an ischemic stroke patient corresponds to a process in which the blood supply to the brain is interrupted (infarction event), and this triggers cell death detected in the brain of an IS patient. As indicated above, this ischemic event can be caused by a variety of mechanisms, such as atherosclerosis or thromboembolism, and more rarely by trauma, infection, or tumors.
[0048] In patients with hemorrhagic stroke, as used in this article, a stroke event refers to a process caused by the rupture of a blood vessel, during which blood flows into the brain and triggers cell death detected in the brain of patients with hemorrhagic stroke.
[0049] Damage resulting from stroke can be classified using the well-known National Institutes of Health Stroke Scale (NIHSS). The NIHSS consists of 11 items, each rated on a scale of 0 to 4 for a specific ability. For each item, a score of 0 typically indicates normal functioning in that specific ability, while a higher score indicates a certain level of impairment (details on each item and scoring method can be found, for example, HP Adams Jr. et al., Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology, July 1, 1999, Vol. 53, No. 1, p. 126). Individual scores from each item are summed to calculate the patient's total NIHSS score. The maximum possible NIHSS score is 42, and the minimum is 0.
[0050] The final NIHSS score was used to classify the severity of the stroke in the patient: -NIHSS score of 0: No stroke symptoms -NIHSS score 1-4: Mild stroke -NIHSS score 5-15: Moderate stroke -NIHSS score 16-20: Moderate to severe stroke -NIHSS score 21-42: Severe stroke As used herein, the terms “prognosis,” “determined prognosis,” or “monitoring prognosis” refer to the prediction of medical outcomes, such as poor or good outcomes (e.g., the likelihood of long-term survival, overall survival, disease-specific survival, progression-free survival, or disease-free survival). “Negative prognosis,” “poor prognosis,” or “bad outcome” includes prediction of moderate to severe disability, recurrence, or death. “Positive prognosis,” “good prognosis,” or “good outcome” includes disease stability or absence of residual stroke symptoms to mild disability. Outcomes in stroke patients can be defined using the Modified Rankine Score (mRS), the most widely used outcome measure in stroke clinical trials. The term “Modified Rankine Score” or “mRS” refers to a 6-point disability scale, with possible scores ranging from 0 to 5. For deceased patients, a separate category of 6 is typically added. A standardized interview is recommended at 3 months (90 days) after discharge to obtain the mRS score.
[0051] Based on the outcome approximately 3 months after the stroke event, the following figures were assigned to stroke patients according to the mRS system: -0: The patient has no residual symptoms.
[0052] -1: The patient has no obvious disability; he / she is able to perform all pre-stroke activities.
[0053] -2: The patient has a mild disability; unable to perform all pre-stroke activities, but able to take care of themselves without daily assistance.
[0054] -3: The patient has a moderate disability; requires some external assistance, but is able to walk without the help of another person.
[0055] -4: The patient has a moderate to severe disability; unable to walk or care for their physical functions without the assistance of another person.
[0056] -5: The patient has a severe disability; is bedridden, incontinent, and requires continuous care.
[0057] -6: The patient has died (during hospitalization or after discharge).
[0058] As those skilled in the art will understand, prediction (though preferred) does not need to be accurate for 100% of the subjects to be evaluated. However, the term requires that a statistically significant subset of subjects can be identified as having an increased probability of having a given outcome. Those skilled in the art can readily determine whether a subset is statistically significant using a variety of well-known statistical evaluation tools, such as determining confidence intervals, determining p-values, Student's t-tests, Mann-Whitney tests, etc. Further details can be found in Dowdy and Wearden, Statistics for Research, John Wiley and Sons, New York, 2004. Preferred confidence intervals are at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99%. P-values are preferably 0.1, 0.05, 0.01, 0.005, or 0.0001. More preferably, at least 60%, at least 70%, at least 80%, or at least 90% of the subjects in the population can be appropriately identified by the method of the present invention. Any parameter widely accepted for determining patient prognosis may be used in this invention, including, but not limited to, an increased disability grade compared to the grade observed at hospitalization (poor prognosis), and a decreased or stable disability grade compared to the grade observed at hospitalization due to a stroke event (good prognosis); and preferably includes the use of mRS, more preferably, wherein grades 0-2 are assigned as good prognosis and grades 3-6 are assigned as poor prognosis.
[0059] As used herein, the terms "patient" or "subject" refer to any subject who has experienced a stroke event, particularly a mammalian subject of any sex. Mammal subjects include males or females, humans, domesticated animals, farm animals, and zoo animals, sporting animals, or pet animals such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, cows, etc. In a particular embodiment of the invention, the subject is a mammal. In a more particular embodiment of the invention, the subject is a human. Specifically, a human as referred to herein has any age, sex, or race. In another particular embodiment, the patient is an elderly person, particularly over 50, 55, 60, 65, 70, 75, or 80 years of age, particularly over 70 years of age, and more particularly over 75 years of age. In yet another particular embodiment, the patient, as defined in the embodiments herein, is male or female, particularly male.
[0060] As indicated in the examples, the experimental data were obtained from samples from a Spanish multicenter cohort, making these findings more applicable to Caucasian populations compared to previous studies primarily using Asian populations. In this regard, some studies have described differences in miRNA expression between Asian and Caucasian populations (Jaegil Kim et al., "..."). Racial Differences in Expression Levels of miRNA Machinery-Related Genes, Dicer, Drosha, DGCR8, and AGO2, in Asian Korean Papillary Thyroid Carcinoma and Comparative Validation Using the Cancer Genome Atlas [Ethnic Differences in Expression Levels of miRNA Machine-Related Genes Dicer, Drosha, DGCR8, and AGO2 in Papillary Thyroid Cancer in an Asian Korean Population and Comparative Validation Using Cancer Genome Atlas], International Journal of Genomics, 2017; Xianglin Yang et al., “ Association of miR-27a polymorphism with the risk of digestive system cancers [The association between miR-27a polymorphism and the risk of digestive system cancers]”, Pathol ResPract [Pathological Research and Practice], 216(10):153115, 2020).
[0061] Therefore, in certain embodiments, the patients mentioned in different aspects of the invention are Caucasian subjects, particularly European or European-American subjects. In certain embodiments, the patients mentioned in aspects of the invention are non-Asian subjects.
[0062] As used herein, the term “Caucasian” or “Caucasian subject” refers to a term commonly known to those skilled in the art, and in particular to a subject with a skin color typically associated with people native to Europe.
[0063] As used herein, the term "European" or "European subject" refers to a term commonly known to those skilled in the art, and in particular to subjects who are native to Europe or whose ancestry is predominantly European. As used herein, the term "European American" refers to a term commonly known to those skilled in the art, and in particular to subjects who are native to the United States and whose ancestry is predominantly European. As will be fully understood by those skilled in the art, the skin color of European or European American subjects is generally associated with that commonly found in native European populations.
[0064] As used herein, the terms "Asian" or "Asian subject" refer to terms commonly known to those skilled in the art, particularly subjects whose ancestry is predominantly native to Asian (especially East Asian) countries such as China, Korea, or Japan. As those skilled in the art fully understand, the skin color of an Asian subject is generally associated with the skin color of native East Asian (especially Chinese, Korean, or Japanese) people. In a particular embodiment, the Asian subject is a subject native to China, Korea, or Japan.
[0065] As used herein, the term "patient with ischemic stroke" or "ischemic patient" refers to a stroke patient who has experienced an ischemic stroke as defined above. As used herein, the term "patient with hemorrhagic stroke" refers to a stroke patient who has experienced a hemorrhagic stroke as defined above.
[0066] As used herein, the term "sample" refers to biological material isolated from a subject. A sample can originate from or correspond to a representative amount of any fluid or tissue of the subject. In a particular embodiment, the sample is isolated from any suitable biological fluid of the subject as defined herein, including blood, plasma, serum, urine, cerebrospinal fluid (CSF), saliva, sputum, sediment, tears, mucus, and sweat. In a more particular embodiment, the sample is isolated from the blood of the subject as defined herein. The blood sample can be whole blood, plasma, or serum, particularly plasma. Thus, in a particular embodiment of the invention, the isolated sample used in the method of the invention is a fluid biological sample. In a more particular embodiment, the isolated sample used in the method of the invention is a blood sample, plasma sample, or serum sample, more particularly a plasma sample. The sample comprises the patient's cells and / or non-cellular material, particularly non-cellular material. In this invention, the sample comprises genetic material from the patient under study, such as RNA, circulating RNA, miRNA, circulating miRNA, heterogeneous nuclear RNA (hnRNA), mRNA, DNA, genomic DNA (gDNA), complementary DNA (cDNA), etc. In certain embodiments, the genetic material is RNA, more particularly miRNA, and still more particularly circulating miRNA. In more specific embodiments, the sample contains RNA, particularly miRNA, and still more particularly circulating miRNA, but does not contain DNA. Methods for obtaining samples (including blood, plasma, or serum samples) from subjects are well known to those skilled in the art.
[0067] As used herein, the term "test sample" means a separated sample as defined herein, which is derived from a patient analyzed in the method of the present invention and used in step (i) of the method. As used herein, the term "control sample" means a separated sample as defined herein, which is obtained from a control subject or control subject group as referred to in the definition of "reference value".
[0068] In embodiments, the samples analyzed in step (i) of the method of the present invention are isolated from the patient within 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 20, 22, 24, 28, 30, 36, 40, 42, 45, and 48 hours after the stroke event, particularly within 24 hours after the stroke event. In specific embodiments, the samples analyzed in step (i) of the method of the present invention are isolated from the patient within 0-48 h, 0-36 h, 0-24 h, 0-18 h, 0-12 h, 0-8 h, 0-4 h, 0-3 h, 0-2 h, and 0-1 h after the stroke event, particularly within 0-24 h after the stroke event. In another specific embodiment, the samples analyzed in step (i) of the method of the present invention are isolated at 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 20, 22, 24, 28, 30, 36, 40, 42, 45, and 48 hours after the stroke event. In another specific embodiment, the samples analyzed in step (i) of the method of the present invention are isolated from the patient within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 20, 22, 24, 28, 30, 36, 40, 42, 45, and 48 hours after the first visible symptoms of the stroke, particularly within 24 hours. In a particular embodiment, the sample analyzed in step (i) of the method of the present invention is isolated from the patient within 0-48 h, 0-36 h, 0-24 h, 0-18 h, 0-12 h, 0-8 h, 0-4 h, 0-3 h, 0-2 h, and 0-1 h after the first visible symptoms of stroke, particularly within 0-24 h after the first visible symptoms of stroke. In another particular embodiment, the sample analyzed in step (i) of the method of the present invention is isolated at 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 20, 22, 24, 28, 30, 36, 40, 42, 45, and 48 hours after the first visible symptoms of stroke, particularly at 24 hours.
[0069] The terms “miRNA” or “microRNA” used interchangeably in this document refer to endogenous RNAs, some of which are known to regulate the expression of protein-coding genes at the posttranscriptional level. As used herein, the term “miRNA” refers to any type of micro-interfering RNA, including but not limited to endogenous and artificial microRNAs. Typically, endogenous miRNAs are small RNAs encoded in the genome that regulate the efficient utilization of mRNAs. Mature miRNAs are single-stranded RNA molecules of approximately 21–23 nucleotides in length that are complementary to and hybridize with target RNA sequences to repress their function, particularly their translation. miRNAs themselves are encoded by genes transcribed from DNA but are not translated into proteins (non-coding RNAs); instead, they are processed by primary transcripts called primary miRNAs into short stem-loop structures called precursor miRNAs, and ultimately into functional miRNAs. Mature miRNA molecules are partially complementary to one or more messenger RNA (mRNA) molecules (one or more target mRNAs referred to herein as miRNAs), which triggers downregulation of gene expression of one or more of their target mRNAs, particularly repression of translation of one or more of their target mRNAs. In addition to their intracellular functions, miRNAs can also be exported or released from cells into the circulating bloodstream in a very stable form. As used herein, the terms “circulating miRNA” or “c-RNA” (also known as “cell-free miRNA” or “cf-RNA”) refer to extracellular miRNAs that circulate in the bloodstream.
[0070] Precursor miRNAs are called "mir," while mature miRNAs are called "miR." This prefix is followed by a hyphen and a number, the latter usually indicating the naming order. miRNAs with nearly identical sequences except for one or two nucleotides are annotated with an additional lowercase letter. Precursor miRNAs that produce 100% identical mature miRNAs but are located at different positions in the genome are indicated with an additional hyphen-number suffix. Species origin is named using a three-letter prefix. Some "mir" can have two mature products. For example, hsa-mir-199a has two mature products, named hsa-miR-199a-5p and hsa-miR-199a-3p. The mature product annotated with 5p originates from the 5' arm of the mir-199a hairpin precursor, and the mature product annotated with 3p originates from the 3' arm of the mir-199a hairpin precursor. As indicated in the definition of miR-199a below, two miRNA precursors (mir-199a-1 and mir-199a-2) have been identified in the human genome, which produce 100% identical mature miRNAs. Therefore, as used herein, when referring to mir-199a precursors, particularly in the context of miRNA precursors of human origin, it is intended to refer to either the has-mir-199a-1 precursor or the has-mir-199a-2 precursor. In certain embodiments, the terms “mir-199a-1” and “mir-199a-2” are used interchangeably herein.
[0071] In the context of this invention, miR-199a refers to the mature product of its mir-199a precursor, particularly miR-199a-5p and / or miR-199a-3p. In a particular embodiment, as used herein, miR-199a refers to the mature mir-199a product miR-199a-5p or miR-199a-3p. In another particular embodiment, as used herein, miR-199a refers to the mir-199a products miR-199a-5p and miR-199a-3p. In yet another particular embodiment, as used herein, miR-199a refers to the mir-199a product miR-199a-5p. In a more specific embodiment, as used herein, miR-199a refers to the mature mir-199a product miR-199a-3p. Regarding miR-4463, the mature product of the mir-4463 precursor is generally known to be derived from the 3' arm. Therefore, as used herein, the term miR-4463 refers to the mature miRNA product derived from the 3' arm of the mir-4463 precursor.
[0072] As used herein, the term "miR-376c-3p" refers to the mature microRNA from the 3' arm of "hsa-mir-376c," which has the sequence accession number NR_029861.1 in the National Center for Biotechnology Information (NCBI) database as of October 14, 2023. In certain embodiments, the term "miR-376c-3p" refers to the miRNA having SEQ ID NO. 7.
[0073] As used herein, the term "miR-199a" refers to the mature microRNA product derived from the precursor "hsa-mir-199a". As indicated above, two hsa-miR-199a precursors (miR-199a-1 and miR-199a-2) have been identified in the human genome, producing the following 100% identical mature products: mir-199a-5p and / or miR-199-3p. Therefore, as used herein, "miR-199a" refers to the mature microRNA product derived from either "hsa-miR-199a-1" or "hsa-miR-199a-2". In a specific embodiment, "miR-199a" refers to the mature microRNA product derived from "hsa-miR-199a-1", which has the sequence accession number NR_029586.1 in the NCBI database as of January 15, 2024. In another specific embodiment, as used herein, “miR-199a” refers to the mature microRNA product from “hsa-miR-199a-2”, which has the sequence accession number NR_029618.1 in the NCBI database as of January 15, 2024.
[0074] Therefore, in a particular embodiment, as used herein, the term "miR-199a-5p" refers to the mature product from the 5' arm of has-mir-199a-1 or has-miR-199a-2 as defined herein, and has SEQ ID NO. 10. In another particular embodiment, as used herein, the term "miR-199a-3p" refers to the mature product from the 3' arm of has-mir-199a-1 or has-miR-199a-2 as defined herein, and has SEQ ID NO. 9.
[0075] As used herein, the term "miR134-5p" refers to the mature microRNA from the 5' arm of "hsa-mir-134," which has the sequence accession number NR_029698.1 in the NCBI database as of January 1, 2024. Therefore, in a particular embodiment, the term "miR-134-5p" refers to the miRNA having SEQ ID NO. 8.
[0076] As used herein, the term "miR-4463" refers to the mature microRNA derived from the 3' arm of "has-mir-4463," which has the sequence accession number NR_039670.1 in the NCBI database as of July 3, 2022. Therefore, in certain embodiments, as used herein, the term "miR-4463" refers to the miRNA having SEQ ID NO. 11.
[0077] As used herein, the term "miR-584-5p" refers to the mature microRNA from the 5' arm of "has-mir-584," which has the nucleotide sequence accessed in the NCBI database as of December 25, 2023, with accession number NR_030310.1. Therefore, in certain embodiments, as used herein, the term "miR-584-5p" refers to the miRNA having SEQ ID NO. 12.
[0078] As used herein, the term "expression level" or "gene expression level" refers to a measurement of the amount of nucleic acid (e.g., RNA, miRNA, or mRNA) or protein in a particular sample or body fluid. In the context of this invention, expression level is related to a measurement of the amount of nucleic acid (particularly RNA, more particularly miRNA, and even more particularly miR-376c-3p, miR-199a, miR134-5p, miR-4463, and / or miR-584-5p). As will be fully understood by those skilled in the art, in the context of this invention, the expression level is measured or determined in isolated samples from the subjects studied, as defined herein.
[0079] Methods for determining or measuring the expression levels of RNA, mRNA, or miRNA in a sample are well known to those skilled in the art. Non-limiting examples of such methods include gene expression analysis techniques for measuring RNA in solution, such as quantitative reverse transcription polymerase chain reaction (RT-qPCR), RNAscope™, Nanostring®, QuantiGene®, gNPA®, microarrays, next-generation sequencing (NGS) technologies, or RNA sequencing (RNA-seq). Specific methods for performing RT-qPCR and NGS are well known to those skilled in the art and include those described in the examples below. Methods for performing RNA sequencing are also well known to those skilled in the art and include, for example, obtaining libraries using the Lexogen CORALL RNA-Seq library preparation kit, and then sequencing these libraries (e.g., using an Illumina® NovAseq sequencer). The obtained sequencing data can then be analyzed using known bioinformatics tools (such as those described in the examples below) to obtain the expression level of the target miRNA. Therefore, in certain embodiments, miRNA expression levels are determined in the method of the present invention by RT-qPCR, RT-PCR, next-generation sequencing (NGS) technology, or RNA sequencing, particularly by RT-qPCR or NGS. In another embodiment, gene expression levels are determined using RNAscope™, Nanostring®, QuantiGene®, gNPA®, or microarray technology.
[0080] In this invention, as used herein in any method of the invention, the term "reference value" or "reference level" should be understood as an expression level value / data of miRNA determined in step (i) of the method of the invention, or a reference value for each miRNA. In a preferred embodiment, when the expression levels of multiple miRNAs are determined in step (i) of the method of the invention, a reference value is provided independently for each of the miRNAs. A reference value or reference level according to any method of the invention can be an absolute value; a relative value; a value with an upper and / or lower limit; a range of values; an average; a median, mean, or a value compared to a specific control value or baseline value. A reference value can be based on a single sample value, such as a value obtained from one or more samples from a test subject at an earlier time point. A reference value can be based on a large number of samples, such as from control subjects or a group of subjects (also called a control group or control subjects, formed by subjects in a fully age-matched group); or based on a sample pool that includes or excludes the sample to be tested. When determining a reference value for a biomarker miRNA, a variety of considerations are taken into account. Such considerations include the patient's age, weight, sex, general physical condition, etc. For example, the control group consists of at least 2, at least 10, at least 50, at least 100, at least 150, at least 200, at least 500 to preferably more than 1,000 subjects, particularly categorized according to the aforementioned considerations (e.g., according to multiple age categories).
[0081] In a particular embodiment, the control group is a group of healthy subjects, particularly a group of subjects who have never had a stroke. In another particular embodiment, the control group is a group of subjects who have had a stroke before the method of the present invention and have shown a good outcome at least 3-6 months after their stroke event, particularly at least 3 months, and before the method was performed. In a more specific embodiment, the control group, as defined above, is of the same age range or sex as the patients analyzed by the method of the present invention, particularly the same age and sex. In another particular embodiment, the control group is a healthy subject. In another embodiment, the control group is a subject who has never had a stroke. In another particular embodiment, the control group is a subject who has had a stroke before the method of the present invention and has shown a good outcome at least 3-6 months after their stroke event, particularly at least 3 months, and before the method was performed. In a more specific embodiment, the control group is a subject of the same age range or sex as the patients analyzed by the method of the present invention, particularly the same age and sex. In a particular embodiment, the control group is a patient analyzed in the method of the present invention at an earlier time point, particularly before the subject's stroke event. In a particular embodiment, one or more samples used to determine the reference value (referred to herein as control samples) are the same sample type used in step (i) of the method of the present invention. As will be fully understood by those skilled in the art, the unit of the corresponding reference level is preferably the same as the unit of the one or more expression levels determined in step (i) of the method of the present invention. For example, if the expression level is provided in counts, the reference value is also provided in counts.
[0082] The methods used to obtain reference values from the selected subject group are well known in the art (Burtis CA et al., 2008, Chapter 14, Section “Statistical Treatment of Reference Values”).
[0083] In a particular embodiment, the “reference value” is a cutoff value defined by conventional ROC analysis. As those skilled in the art will understand, the optimal cutoff value will be defined based on the specific application of the method: purpose, target population of the method being performed, balance between specificity and sensitivity, etc.
[0084] As used in the context of miRNA expression levels herein, the term “above the corresponding reference value” means that the expression level of the miRNA is increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 120%, at least 130%, at least 150%, at least 170%, at least 180%, at least 190%, at least 200%, at least 250%, at least 300%, at least 350%, at least 400%, or at least 500% relative to the corresponding reference value. In a particular embodiment, "above the corresponding reference value" in the context of miRNA expression level means that the miRNA expression level is at least 1.05 times, at least 1.1 times, at least 1.15 times, at least 1.2 times, at least 1.25 times, at least 1.3 times, at least 1.4 times, at least 1.5 times, at least 1.55 times, at least 1.6 times, at least 1.7 times, at least 1.8 times, at least 1.9 times, at least 2 times, at least 2.1 times, at least 2.2 times, at least 2.3 times, at least 2.4 times, at least 2.5 times, at least 2.7 times, at least 2.8 times, at least 2.85 times, at least 2.9 times, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, or at least 10 times the corresponding reference value, particularly at least 1.2 times, and more particularly at least 1.5 times. Methods for determining whether the expression level of a miRNA is higher or lower than a reference value are well known to those skilled in the art and include determining the expression level of the miRNA using any of the methods provided above in the definition of the term "expression level" and comparing it to a reference value determined using any of the methods provided above in the definition of "reference value".
[0085] The terms “medical regimen” and “therapeutic intervention” are interchangeable and, herein, refer to the intervention or administration to a subject by means of a drug or any therapeutic intervention, including surgery, in an attempt to alleviate, reduce, or reduce at least one symptom of the subject’s illness. For example, in the case of stroke, these terms include administering a drug or performing surgery to a subject to treat the physical and / or psychological consequences of the stroke. Non-limiting examples of such treatments have been provided above in the definition of stroke for both IS and hemorrhagic stroke, respectively. These terms also cover preventative treatments that attempt to delay or prevent onset before clinical manifestations or stroke symptoms appear, and / or reduce the risk of developing or worsening neurological damage resulting from a stroke event. In a particular embodiment, a medical regimen includes the administration of an inhibitor of the fourth aspect, a combination of miRNA inhibitors of the fifth aspect, or a pharmaceutical composition of the sixth aspect. In another embodiment, a medical regimen includes any known neuroprotective agents, such as those disclosed in the second aspect of the invention.
[0086] In embodiments, as used herein, therapeutic interventions are used to treat or prevent stroke, particularly to treat or prevent neurological damage resulting from a stroke event. In specific embodiments, therapeutic interventions for treating or preventing neurological damage resulting from a stroke event include administration of an inhibitor of the fourth aspect, a combination of miRNA inhibitors of the fifth aspect, or a pharmaceutical composition of the sixth aspect, or a combination thereof.
[0087] In another specific embodiment, the stroke event is a hemorrhagic stroke event, and therefore therapeutic interventions or treatments for the treatment or prevention of hemorrhagic stroke, particularly for the treatment or prevention of neurological damage resulting from a hemorrhagic stroke event, more particularly include the administration of an inhibitor of the fourth aspect, a combination of miRNA inhibitors of the fifth aspect, or a pharmaceutical composition of the sixth aspect, or a combination thereof. Non-limiting examples of known treatments for hemorrhagic stroke have already been provided in the definition of stroke above.
[0088] In a more specific embodiment, the stroke event is an ischemic stroke event, and therefore therapeutic interventions or treatments for the treatment or prevention of ischemic stroke, particularly for the treatment or prevention of neurological damage resulting from ischemic stroke, more particularly include the administration of an inhibitor of the fourth aspect, a combination of miRNA inhibitors of the fifth aspect, or a pharmaceutical composition of the sixth aspect, or a combination thereof. Non-limiting examples of known treatments for IS have already been provided in the definition of stroke above.
[0089] Therefore, as used herein, the terms “initiating a medical protocol,” “initiating a therapeutic intervention,” or “starting a medical protocol” refer to the commencement of administration of a medical protocol or therapeutic intervention to a patient. In a particular embodiment, the medical protocol or therapeutic intervention is any of those provided above in the definition of “medical protocol.”
[0090] As used herein, the term “determining a patient’s response to a treatment regimen” means determining whether a patient who has been diagnosed with stroke and has received a therapeutic intervention or treatment regimen for stroke treatment has a favorable response to the therapeutic intervention or treatment regimen, or has a good response to the therapeutic intervention or treatment regimen. As those skilled in the art fully understand, an effective treatment for stroke can alleviate, reduce, or reduce the symptoms of a patient’s disease, particularly at least one symptom, and more particularly at least one target symptom. Ineffective treatments for stroke do not alleviate, reduce, or reduce the symptoms of a patient’s disease, particularly at least one symptom, and more particularly at least one target symptom. In a particular embodiment, as used herein, “target symptom” means nerve damage, nerve injury, mRS equal to or greater than 2, mRS equal to or greater than 3, or an NIHSS value of at least 2. In more specific embodiments, as used herein, the intended symptom refers to an NIHSS value of at least 1, at least 2, at least 4, at least 5, at least 8, at least 9, at least 10, at least 11, at least 12, at least 15, at least 16, at least 18, at least 20, at least 21, at least 25, at least 30, at least 35, at least 40, at least 41, or 42, particularly at least 9. In more specific embodiments, as used herein, the intended symptom refers to an NIHSS value of about 1, 2, 4, 5, 8, 9, 10, 11, 12, 15, 16, 18, 20, 21, 25, 30, 35, 40, 41, or 42, particularly about 9. In another embodiment, as used herein, the intended symptom refers to an NIHSS value included in the range of 1-4, 2-4, 5-15, 16-20, or 21-42, particularly about 5-15. In a particular embodiment, an effective treatment for stroke, as defined herein, includes reducing a patient's NIHSS value by approximately 1, 2, 3, 4, 5, 6, 7, 10, 12, 15, 20, 30, or even 40 NIHSS values. In another particular embodiment, it includes reducing a patient's NIHSS level by at least one, two, or three, particularly at least one stroke severity grade, before initiating the treatment program.
[0091] As used herein, the term "good response to a medical protocol" or "good response to a therapeutic intervention" refers to the fact that, at a certain point in time after receiving a medical protocol or therapeutic intervention, the patient exhibits a reduction in the intensity of all or some of the symptoms associated with stroke symptoms compared to the start of the medical protocol or an earlier stage of the medical protocol. Specifically, one or more symptoms exhibiting a reduction in intensity as indicated herein are selected from those indicated above as "target symptom." As those skilled in the art will fully understand, in the context of a target symptom characterized by a specific NIHSS value or range of values, a good response to a medical protocol means that the application of said medical protocol results in a reduction in the corresponding NIHSS value or range of values. This reduction can be approximately 1, 2, 3, 4, 5, 6, 7, 10, 12, 15, 20, 30, or even 40 NIHSS values. In another particular embodiment, the reduction includes lowering the NIHSS level (or the stroke severity grade indicated above in the definition of NIHSS) to an NIHSS level (or stroke severity grade) assigned to at least one, at least two, at least three, at least four, at least five, particularly at least one level lower than the stroke severity grade.
[0092] As used in this article, the term “initiation of a medical protocol” refers to the moment when a medical protocol for the treatment of stroke begins, and therefore refers to the moment when the first dose of medication is administered to the patient, or the moment when a medical intervention (such as surgery) for the treatment of stroke is performed on the patient.
[0093] As used herein, the term "at an earlier stage of a medical protocol" means any time between the commencement of a medical protocol as defined above and the commencement of the method of the third aspect of the invention.
[0094] 1.2 Methods for determining the prognosis of patients with stroke In a first aspect, the present invention relates to an in vitro method for determining the prognosis of a patient suffering from stroke, the method comprising: (i) Determine the expression level of at least one miRNA selected from the group consisting of miR-376c-3p, miR-199a, and combinations thereof in samples isolated from the patient. (ii) Compare the expression level obtained in step (i) with the corresponding reference value. If the expression level determined in step (i) is higher than the corresponding reference value, the patient is considered to have a poor prognosis.
[0095] In an embodiment of the first aspect of the invention, the stroke is a hemorrhagic stroke. As those skilled in the art will fully understand, the patients analyzed in the first aspect of the invention are therefore hemorrhagic stroke patients. In a particular embodiment, hemorrhagic stroke is "hemorrhagic transformation". In another particular embodiment, hemorrhagic stroke is intracerebral hemorrhage (ICH) or subarachnoid hemorrhage (SAH). In a more specific embodiment of the first aspect of the invention, the stroke is an ischemic stroke (IS). As those skilled in the art will fully understand, the patients analyzed in the first aspect of the invention are therefore ischemic stroke patients. In another more specific embodiment, IS is thrombotic IS or embolic IS.
[0096] In another embodiment, the patient analyzed in the first aspect of the invention is a patient diagnosed with stroke (particularly by any of the methods provided in the definition of stroke above, particularly by CT or MRI)).
[0097] In another embodiment, the patients analyzed in the first aspect of the invention are stroke patients with NIHSS scores of 1-4, 2-4, 5-15, 16-20, or 21-42, particularly 5-15. In another embodiment, the patients analyzed in the first aspect of the invention are stroke patients with NIHSS scores of at least 1, at least 2, at least 4, at least 5, at least 8, at least 9, at least 10, at least 11, at least 12, at least 15, at least 16, at least 18, at least 20, at least 21, at least 25, at least 30, at least 35, at least 40, at least 41, or 42, particularly at least 9. In a more specific embodiment, the analyzed patients have NIHSS values of about 1, 2, 4, 5, 8, 9, 10, 11, 12, 15, 16, 18, 20, 21, 25, 30, 35, 40, 41, or 42, particularly about 9. In another embodiment, the NIHSS values of the analyzed patients are included in the range of 1-4, 2-4, 5-15, 16-20, or 21-42, particularly about 5-15. In a particular embodiment, the patients analyzed in the first aspect of the invention have NIHSS scores determined at h, h, 2 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 20 h, 24 h, 30 h, 36 h, 48 h after the stroke event, particularly at 24 h after the stroke event, particularly selected from the NIHSS scores mentioned in the embodiments of this paragraph. In a particular embodiment, the NIHSS scores mentioned in the embodiments of this paragraph are determined at the time of performing the method of the first aspect. As used herein, the term "at the time of performing the method of the first aspect" means the time between 3 hours before and 3 hours after performing the method of the first aspect of the invention, particularly the time between 1 hour before and 1 hour after performing the method of the first aspect of the invention, and more particularly the time between 0.5 hours before and 0.5 hours after performing the method of the first aspect of the invention.
[0098] In another embodiment, the patients analyzed in the first aspect of the invention had functional independence prior to the stroke event, particularly with an mRS score below 2, especially below 3, prior to the stroke event.
[0099] In another embodiment, prior to performing the method of the first aspect, the patient analyzed in the first aspect of the invention does not have a confounding disease, such as vegetations, demyelinating and autoimmune diseases or vasculitis.
[0100] In a more specific embodiment, the patient analyzed in the first aspect of the invention has been diagnosed with stroke (particularly by any of the methods provided above in the definition of stroke, more particularly by CT or MRI); has an NIHSS score of at least 2, particularly about 9, wherein the NIHSS score is determined 3-4 h after the stroke event, particularly 24 h; and has an mRS value of less than 2, particularly less than 3 before the stroke event.
[0101] In a more specific embodiment, the stroke event in the patient analyzed in the first aspect of the invention occurs in a region of the brain other than the cerebellum and brainstem. In another specific embodiment, the stroke event in the patient analyzed in the first aspect of the invention is not a lacunar stroke. As is well known to those skilled in the art, a lacunar stroke or lacunar infarction (LACI) refers to an ischemic stroke caused by the occlusion of small perforating arteries supplying blood to deep brain structures.
[0102] In a particular embodiment, the patients analyzed in the first aspect of the invention had been diagnosed with stroke 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 12 h, 15 h, 20 h, 24 h, 36 h, 48 h, 72 h, 5 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 6 months, and especially 24 hours before performing the method of the first aspect.
[0103] In another embodiment of the first aspect of the invention, the patient analyzed in the method of the first aspect has only been diagnosed with stroke once (particularly within 6 months, 2 months, 1 month, 3 weeks, 2 weeks, 1 week, 5 days, 72 hours, 48 hours, 24 hours, 12 hours, 6 hours, 4 hours, 3 hours, 2 hours, and 1 hour prior to performing the method of the first aspect). In a particular embodiment, the stroke patient analyzed in the first aspect of the invention is a patient with recurrent stroke. In a particular embodiment, if the patient analyzed in the method of the first aspect has experienced multiple stroke events, then as used throughout this disclosure, the term "stroke event" refers to the last stroke event that the patient has experienced or has been diagnosed with prior to performing the method of the first aspect.
[0104] In another embodiment of the first aspect, step (i) of the method is performed using a separated blood sample from the patient, particularly a separated plasma sample.
[0105] In another embodiment, step (i) of the method of the first aspect includes determining, or consisting of, the expression level of miR-376c-3p in the sample. In another embodiment, step (i) of the method of the first aspect includes determining, or consisting of, the expression level of miR-199a-3p or miR-199a-5p, more particularly miR-199a-3p, in the sample. In another embodiment, step (i) of the method of the first aspect includes determining, or consisting of, the expression level of miR-199a, particularly miR-199a-3p and miR-199a-5p, in the sample. In a more specific embodiment, step (i) of the method of the first aspect includes determining the expression levels of miR-376c-3p and miR-199a in the sample, particularly miR-376c-3p and miR-199a-3p or miR-376c-3p and miR-199a-5p, more particularly miR-376c-3p, miR-199a-3p and miR-199a-5p, and even still more particularly miR-376c-3p and miR-199a-3p, or composed thereof.
[0106] In another specific embodiment, step (i) of the method of the first aspect includes determining the expression level of any miRNA mentioned in the preceding paragraph and at least one miRNA selected from the list consisting of miR134-5p, miR-4463, miR-584-5p and combinations thereof, or consisting thereof, in the sample.
[0107] In a particular embodiment, step (i) of the method of the first aspect includes determining the expression level of miR-376c-3p and at least one miRNA selected from a list consisting of miR134-5p, miR-4463, and miR-584-5p, or a combination thereof. In another particular embodiment, step (i) of the method of the first aspect includes determining the expression level of miR-376c-3p and one miRNA selected from a list consisting of miR134-5p, miR-4463, and miR-584-5p, or a combination thereof. In yet another particular embodiment, step (i) of the method of the first aspect includes determining the expression levels of miR-376c-3p and two miRNAs selected from a list consisting of miR134-5p, miR-4463, and miR-584-5p, or a combination thereof. In another specific embodiment, step (i) of the method of the first aspect includes determining, or consisting of, the expression levels of miR-376c-3p, miR134-5p, miR-4463, and miR-584-5p.
[0108] In another specific embodiment, step (i) of the method of the first aspect includes determining the expression level of miR-199a (particularly miR-199a-3p or miR-199a-5p) and at least one miRNA selected from a list consisting of miR134-5p, miR-4463, and miR-584-5p, or a combination thereof. In another specific embodiment, step (i) of the method of the first aspect includes determining the expression level of miR-199a (particularly miR-199a-3p or miR-199a-5p) and at least one miRNA selected from a list consisting of miR134-5p, miR-4463, and miR-584-5p, or a combination thereof. In another specific embodiment, step (i) of the method of the first aspect includes determining the expression levels of miR-199a (particularly miR-199a-3p or miR-199a-5p) and two miRNAs selected from a list consisting of miR134-5p, miR-4463, and miR-584-5p, or a combination thereof. In another specific embodiment, step (i) of the method of the first aspect includes determining the expression levels of miR-199a (particularly miR-199a-3p or miR-199a-5p) and miR134-5p, miR-4463, and miR-584-5p, or a combination thereof.
[0109] In a more specific embodiment, step (i) of the method of the first aspect includes determining the expression level of at least one miRNA, or a combination thereof, of miR-376c-3p, miR-199a (particularly miR-199a-3p or miR-199a-5p) and a list consisting of miR134-5p, miR-4463, and miR-584-5p. In another specific embodiment, step (i) of the method of the first aspect includes determining the expression level of one miRNA, or a combination thereof, of miR-376c-3p, miR-199a (particularly miR-199a-3p or miR-199a-5p) and a list consisting of miR134-5p, miR-4463, and miR-584-5p. In another specific embodiment, step (i) of the method of the first aspect includes determining the expression levels of miR-376c-3p, miR-199a (especially miR-199a-3p or miR-199a-5p) and two miRNAs selected from a list consisting of miR134-5p, miR-4463, and miR-584-5p, or a combination thereof. In another specific embodiment, step (i) of the method of the first aspect includes determining the expression levels of miR-376c-3p, miR-199a (especially miR-199a-3p or miR-199a-5p) and miR134-5p, miR-4463, and miR-584-5p, or a combination thereof.
[0110] In a particular embodiment, the expression levels of one or more miRNAs identified in step (i) of the method of the first aspect are determined by NGS. In other particular embodiments, the expression levels of one or more miRNAs identified in step (i) of the method of the present invention are determined by RT-qPCR.
[0111] To normalize the expression levels of miRNAs across different samples, the expression levels of the target miRNA in the test sample can be compared with those of the reference RNA.
[0112] In embodiments, the expression level determined in step (i) of the method of the first aspect is normalized by the expression level of a reference RNA or a set of reference RNAs. In a particular embodiment, the reference RNA is a housekeeping gene, an incorporation control, or a control RNA as defined above. In another particular embodiment, the set of reference RNAs is selected from a list consisting of housekeeping genes, incorporation controls, control RNAs, or combinations thereof. In an embodiment, the housekeeping gene is selected from a list consisting of hsa-miR-16-5p, hsa-miR-93-5p, hsa-miR-191-5p, and combinations thereof, particularly hsa-miR-16-5p. In another embodiment, the incorporation control is selected from a list consisting of ath-miR159a, cel-miR-54-3p, cel-miR-39-3p, cel-miR-238-3p, and combinations thereof. In a specific embodiment, the normalized incorporation controls for expression levels in step (i) of the method of the first aspect are ath-miR159a, cel-miR-54-3p, cel-miR-39-3p, and cel-miR-238-3p. In another embodiment, the control RNA is a hemolysis control RNA selected from a list consisting of hsa-miR-451a, hsa-miR-23a-3p, and combinations thereof. In a specific embodiment, the RNA controls are the hemolysis controls hsa-miR-451a and hsa-miR-23a-3p. In more specific embodiments, when the hemolytic RNA controls are hsa-miR-451a and hsa-miR-23a-3p, a miR-451a / miR23a ratio (miR-451a / miR23a ratio) below 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 7, 6, and 5, particularly below 60, indicates no significant hemolysis. Non-limiting examples of methods for determining said ratio include... Optimized Collection Protocol for Plasma MicroRNA Measurement in Patients with Cardiovascular Disease Those disclosed in [Optimized Collection Protocol for Plasma MicroRNA Measurement in Patients with Cardiovascular Disease], Wu C.-S. et al., Biomed Res Int. [International Biomedical Research] 2016 (doi: 10.1155 / 2016 / 2901938).
[0113] As used in this article, the term "hsa-miR-16-5p" refers to the mature miRNA with NCBI accession number LM378756.1 (version as of March 3, 2015).
[0114] As used in this article, the term "hsa-miR-93-5p" refers to the mature miRNA with NCBI accession number LM378780.1 (version as of March 3, 2015).
[0115] As used in this article, the term "has-miR-191-5p" refers to the mature miRNA with NCBI accession number LM379058.1 (version as of March 3, 2015).
[0116] As used in this article, the term "ath-miR159a" refers to the mature miRNA with TAIR accession number AT1G73687.1 (version as of November 2, 2018).
[0117] As used in this article, the term "cel-miR-54-3p" refers to the mature miRNA with NCBI accession number LM378714.1 (version as of March 3, 2015).
[0118] As used in this article, the term "cel-miR-39-3p" refers to the mature miRNA with NCBI accession number LM378699.1 (version as of March 3, 2015).
[0119] As used in this article, the term "cel-miR-238-3p" refers to the mature miRNA with NCBI accession number LM378932.1 (version as of March 3, 2015).
[0120] As used in this article, the term "hsa-miR-451a" refers to the mature miRNA with NCBI accession number LM379535.1 (version as of March 3, 2015).
[0121] As used in this article, the term "hsa-miR-23a-3p" refers to the mature miRNA with NCBI accession number LM378765.1 (version as of March 3, 2015).
[0122] The terms "reference value" or "reference level" have been defined above and apply to the reference level used in step (ii) of the method of the first aspect. In a particular embodiment, the control group used to determine the reference value used in step (ii) of the method of the first aspect is a group of stroke patients who, at the time of performing the method of the invention, had shown good outcomes at least 3-6 months after their stroke event, particularly at least 3 months, and prior to performing the method. As those skilled in the art will fully understand, the aforementioned control group had experienced a stroke event at least 3-6 months, particularly at least 3 months, prior to performing the method.
[0123] As indicated in the definition of “reference value” above, the unit of the reference value for one or more miRNAs used in step (ii) of the method of the present invention is preferably the same as the unit used to determine the expression level of the same one or more miRNAs in step (i) of the method. Therefore, in a particular embodiment, where the expression level in step (i) of the method of the first aspect is normalized using a reference RNA as indicated in any of the embodiments above, the expression level used to determine the corresponding reference value used in step (ii) of the method is normalized using the same procedure as the expression level in step (i) of the method.
[0124] The term “above the corresponding reference level” has been defined in the previous section “1.1 - Definitions”, and values that are considered to fall within the definition have been defined in that section. This term and these values apply to the first aspect of the invention.
[0125] The term "poor prognosis" has been defined above. In a specific embodiment of the first aspect, poor prognosis means a prediction that the analyzed patient will exhibit an mRS value of at least 2, at least 3, at least 4, at least 5, or 6, particularly at least 3, as defined therein, 3-6 months after undergoing the methods of the first aspect. In a specific embodiment, the predicted mRS value indicated in the preceding embodiments is expected to be assigned to the patient approximately 6 months after undergoing the methods of the first aspect, more particularly approximately 3 months. In another embodiment of the first aspect, poor prognosis means a prediction that the analyzed patient will exhibit an mRS value of 2, 3, 4, 5, or 6 3-6 months after undergoing the methods of the first aspect. In a specific embodiment, the predicted mRS value indicated in the preceding embodiments is expected to be assigned to the patient approximately 6 months after undergoing the methods of the first aspect, more particularly approximately 3 months. In another specific embodiment of the first aspect, "poor prognosis" means a prediction that the patient analyzed in the first aspect will show an mRS equal to or higher than that assigned to the patient before or at the time of the first aspect at 3–6 months after the first aspect of treatment, particularly at about 6 months after the first aspect of treatment, and even more particularly at about 3 months after the first aspect of treatment. As used herein in the context of two mRS values, the term "equal to" means a situation where the two mRS values correspond to the same natural number. As used herein in the context of two mRS values, the term "higher than" means a situation where one mRS value is at least one mRS grade higher than the other mRS value, at least two mRS grades higher, at least three mRS grades higher, at least four mRS grades higher, or five mRS grades higher, particularly at least one mRS grade higher.
[0126] In another specific embodiment of the first aspect, a poor prognosis means a prediction that the patient will display an NIHSS score equal to or higher than the score at or before the administration of the first aspect at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, or at least 6 months after the administration of the first aspect. In yet another specific embodiment, a poor prognosis means a prediction that the patient will display an NIHSS score equal to or higher than the score at or before the administration of the first aspect at 3–6 months after the administration of the first aspect, particularly at about 6 months, and even more particularly at about 3 months. As used herein in the context of two NIHSS score values, the term “equal to” means a situation where one NIHSS score is a natural number corresponding to the other NIHSS score ± 1, wherein both NIHSS scores are within the range of NIHSS score values assigned to the same stroke severity level. In certain embodiments, as used herein in the context of NIHSS scores, the term "above" means that one NIHSS score is higher than another NIHSS score by at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 10, at least 12, at least 15, at least 20, at least 25, at least 30, at least 40, and particularly at least 3 NIHSS scores. In another specific embodiment of the first aspect, a poor prognosis means a prediction that the analyzed patients will exhibit an NIHSS score assigned to a higher stroke severity grade (i.e., higher stroke severity) than the NIHSS score determined at or before the implementation of the first aspect at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, or at least 6 months after the implementation of the first aspect. In another specific embodiment of the first aspect, a poor prognosis means a prediction that the analyzed patients will exhibit an NIHSS score assigned to a higher stroke severity grade (i.e., higher stroke severity) than the NIHSS score determined at or before the implementation of the first aspect at 3–6 months after the implementation of the first aspect, particularly at approximately 6 months, and even more particularly at approximately 3 months.
[0127] The term "at the moment of carrying out the first aspect of the method" has already been defined above.
[0128] In specific embodiments, as used herein in the context of the NIHSS score or mRS of a patient analyzed in the method assigned to the first aspect, the term "before performing the method of the first aspect" refers to an NIHSS score or mRS determined after a stroke event, particularly at 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 8 h, 9 h, 10 h, 12 h, 20 h, 24 h, 30 h, 36 h, 48 h, and more particularly at 24 h after a stroke event. Specifically, "before performing the method of the first aspect" means an NIHSS score or mRS determined at least 3 hours, more particularly at least 1 hour, before performing the method of the first aspect. More specifically, "before the first aspect of the procedure" means at least 3 hours, more particularly at least 1 hour, before the first aspect of the procedure, and specifically the NIHSS score or mRS determined at 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 8 h, 9 h, 10 h, 12 h, 20 h, 24 h, 30 h, 36 h, 48 h, and more particularly 24 h after the stroke event. Methods for determining the time of stroke event are well known to those skilled in the art and, as indicated in the definition of "stroke," include the use of imaging techniques such as MRI or CT.
[0129] In another embodiment of the first aspect, a poor prognosis means a prediction that the patient's stroke severity is higher at least 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months after performing the method of the first aspect than the stroke severity at the time of performing the method of the first aspect of the invention. In another embodiment of the first aspect, a poor prognosis means a prediction that the patient's stroke severity is higher at 3-6 months after performing the method of the first aspect, particularly at about 6 months, and even more particularly at about 3 months, than the stroke severity at the time of performing the method of the first aspect of the invention. Stroke severity grades have been provided in the definition of NIHSS scores above and are particularly applicable herein.
[0130] In a specific embodiment of the first aspect, when determining the miR-134-5p expression level in step (i) of the method, the patient being analyzed is preferably female.
[0131] In another embodiment of the first aspect, step (ii) of the method of the first aspect is further specified, wherein if the expression level determined in step (i) of the method is lower than the corresponding reference value, the patient is considered to have a not bad prognosis, particularly a good prognosis. As used herein, the term "lower than the corresponding reference value" means a situation in which the expression level of the corresponding miRNA is lower than the corresponding reference value by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 120%, at least 130%, at least 150%, at least 170%, at least 180%, at least 190%, at least 200%, at least 250%, at least 300%, at least 350%, at least 400%, or at least 500%.
[0132] 1.3 Methods for deciding or recommending whether to initiate a medical program for a patient with stroke In a second aspect, the present invention relates to an in vitro method for determining or recommending whether to initiate a medical program for a patient suffering from stroke, the method comprising the following steps: (i) Determine the expression level of at least one miRNA selected from the group consisting of miR-376c-3p, miR-199a, and combinations thereof in samples isolated from the patient. (ii) Compare the expression level obtained in step (i) with the corresponding reference value. If the expression level determined in step (i) is higher than the corresponding reference value, then the decision is made or the initiation of the medical treatment plan is recommended.
[0133] The term "initiating a medical protocol" has been defined in the preceding section "1.1 - Definitions" and applies to the second aspect of the invention. The term "medical protocol" has also been defined therein, and examples of medical protocols for treating stroke patients have been provided therein; this term and these examples also apply to the second aspect of the invention. In a particular embodiment, the stroke is ischemic stroke, and the medical protocol is selected from the list of treatments provided in the definition of "medical protocol" or "stroke" in the preceding section "1.1 - Definitions" for treating ischemic stroke. In another particular embodiment, the stroke is hemorrhagic stroke, and the medical protocol is selected from the list of treatments provided in the definition of "medical protocol" or "stroke" in the preceding section "1.1 - Definitions" for treating hemorrhagic stroke. In yet another particular embodiment of the second aspect, the medical protocol is suitable for patients with a poor prognosis. For example, the medical protocol includes rehabilitation procedures and / or physical therapy, as indicated above in the definition of "stroke," and / or the application of neuroprotective therapy. In a particular embodiment, the rehabilitation procedures and physical therapy are also suitable for patients with a poor prognosis, such as long-term rehabilitation procedures rather than intensive rehabilitation procedures. In another specific embodiment of the second aspect of the invention, the medical regimen includes providing neuroprotective therapy. Non-limiting examples of neuroprotective therapy include administration of one or more of the following: NA-1 (nerinetide), uric acid, activator protein C or 3K3A-APC activator protein C, α1-antitrypsin, fingolimod, metformin, glyburide, glibenclamide, TLR-4 inhibitors, IL-1 inhibitors (IL-1-RA, anakinin), nitric oxide donors, glyceryl trinitrate (GTN), cilostazol, ginkgo biloba extract and derivatives, antioxidants, edaravone and edaravone derivatives, resveratrol, melatonin, NAD, anti-intercellular adhesion molecule-1 (ICAM-1) antibody, enmumab, calcium stabilizers, and anti-excitotoxic agents, M... axipost (BMS-204352), nalmefone (Cervene), fosphenytoin, enoxaparin, triflumigrin, anclobetasol propionate, magnesium, UK-279,276, ONO-2506, dipyridamole, repinotan, simvastatin, rubeluzidazole, buspirone, nimodipine, heparin, YM872, ateganaxole (CNS-1102, Cerestat), diazepam, chloromethazine, natezil, ibuprofen, flunarizine, pentoxifylline, abciximab, meperidine, dextromethorphan, granulocyte colony-stimulating factor (G-CSF) and other growth factors, pituitary adenylate cyclase-activating peptide, MMP-9 inhibitor, minocycline, or combinations thereof or combinations thereof with other relevant neuroprotective agents.Neuroprotective therapy also includes the recommended combination of one or more of the previously listed compounds with other neuroprotective strategies such as hypothermia, remote limb ischemia-reperfusion (RIPC), collateral cerebral blood flow enhancement, blood pressure regulation, etc.; this method can be performed in an ambulance.
[0134] In a particular embodiment, the neuroprotective therapy comprises, or consists of, administration of a miRNA inhibitor of the fourth aspect, a combination of miRNA inhibitors of the fifth aspect, or a pharmaceutical composition of the sixth aspect. In another particular embodiment, the neuroprotective therapy comprises, or consists of, any neuroprotective medicine listed in the preceding paragraph and administration of a miRNA inhibitor of the fourth aspect. In yet another particular embodiment, the neuroprotective therapy comprises, or consists of, any neuroprotective medicine listed in the preceding paragraph and administration of a miRNA inhibitor of the fifth aspect, or a pharmaceutical composition of the sixth aspect.
[0135] In another particular embodiment, neuroprotective therapy is combined with any treatment provided in the definition of “stroke” in the previous section “1.1 - Definitions”.
[0136] In another specific embodiment of the second aspect, the medical regimen includes, or consists of, administration of a miRNA inhibitor of the fourth aspect, a combination of miRNA inhibitors of the fifth aspect, or a pharmaceutical composition of the sixth aspect. Specifically, the medical regimen includes, or consists of, any treatment mentioned in Section 1.1 - Definitions and a miRNA inhibitor of the fourth aspect. More specifically, the medical regimen includes, or consists of, any treatment mentioned in Section 1.1 - Definitions and a combination of a miRNA inhibitor of the fifth aspect or a pharmaceutical composition of the sixth aspect.
[0137] In a particular embodiment, the medical solution of the second aspect of the present invention is a first-line or second-line medical solution intended to treat stroke. In a particular embodiment, the medical solution mentioned in the second aspect of the present invention refers to a first-line medical solution. In another particular embodiment, the medical solution of the second aspect of the present invention refers to a second-line or third-line medical solution. In yet another particular embodiment, the medical solution in the context of the second aspect of the present invention refers to an adjunct medical solution for treating stroke. As is well known in the art, first-line treatment refers to the first choice for treating a specific condition because it is considered to be highly effective for the condition and has the lowest likelihood of causing side effects. As is well known in the art, second-line treatment refers to the treatment of a disease or condition after initial treatment (first-line treatment) has failed, ceased to be effective, or has unacceptable side effects. Meanwhile, third-line treatment refers to the treatment of a disease or condition after initial treatment (first-line and second-line treatments) has failed, ceased to be effective, or has unacceptable side effects.
[0138] The terms “sample,” “patient,” “expression level,” “reference value,” “comparing the expression level obtained in step (i) with the corresponding reference value,” and “above the corresponding reference value” have been defined in the preceding section “1.1 - Definitions” and in the first aspect of the invention, and also apply to the second aspect of the invention. The definitions and embodiments of the first aspect of the invention are equally applicable to the second aspect of the invention. Therefore, by replacing the term “first aspect” with “second aspect,” embodiments of the first aspect of the invention are also applicable to the second aspect of the invention.
[0139] In a more specific embodiment, the patient of the second aspect is as defined in any definition and embodiment of the first aspect of the invention. In another specific embodiment, one or more expression levels determined in step (i) of the method of the second aspect are as defined in any definition and embodiment of the first aspect. In another specific embodiment, one or more miRNAs whose expression levels are determined in step (i) of the method of the second aspect are as defined in any definition and embodiment of the first aspect. In another specific embodiment, the reference value used in step (ii) of the method of the second aspect is as defined in any definition and embodiment of the first aspect. In another specific embodiment, "above the corresponding reference value" is as defined in any definition and embodiment of the first aspect.
[0140] In a particular embodiment, step (ii) of the method in the second aspect is further specified that if the expression level determined in step (i) is lower than a corresponding reference value, then no medical intervention is decided or recommended. The term "lower than a corresponding reference value" has been defined in the first aspect of the invention and also applies to the second aspect of the invention.
[0141] 1.4 Methods for determining the response of patients who have been diagnosed with stroke In a third aspect, the present invention relates to an in vitro method for determining the response of a patient diagnosed with stroke to a medical regimen for treating stroke, the method comprising the following steps: (i) Determine the expression level of at least one miRNA selected from the group consisting of miR-376c-3p, miR-199a, and combinations thereof in samples isolated from the patient. (ii) Compare the expression levels obtained in step (i) with the expression levels of the same one or more miRNAs identified at the start of the treatment regimen or at an earlier stage of the treatment regimen. A decrease in the expression level of one or more miRNAs relative to their expression levels at the start of the treatment or at an earlier stage of the treatment indicates a good response to the treatment.
[0142] The term "determining the patient's (...) response to the medical treatment" has been defined above and applies to the third aspect of the invention. In a particular embodiment, the medical treatment is any of those indicated in the definition of stroke or in the second aspect of the invention. As will be fully understood by those skilled in the art, when the stroke is ischemic, the medical treatment is preferably a treatment suitable for the patient with ischemic stroke. When the stroke is hemorrhagic, the medical treatment is preferably a treatment suitable for the patient with hemorrhagic stroke.
[0143] In a particular embodiment, the medical solution of the third aspect of the present invention is a first-line or second-line medical solution intended to treat stroke. In a particular embodiment, the medical solution mentioned in the third aspect of the present invention refers to a first-line medical solution. In another particular embodiment, the medical solution of the third aspect of the present invention refers to a second-line or third-line medical solution. In yet another particular embodiment, the medical solution in the context of the third aspect of the present invention refers to an adjunct medical solution for treating stroke. The terms first-line, second-line, or third-line treatment have already been defined in the second aspect of the present invention.
[0144] The term "good response to a medical treatment" has been defined in the previous section "1.1 - Definitions" and applies to the third aspect of the invention. In a particular embodiment of the third aspect, a good response to a medical treatment includes, or consists of, a reduction in the patient's neurological damage or neurological impairment compared to when the medical treatment began or at an earlier stage of the treatment. In a particular embodiment, a good response to a medical treatment refers to a situation where a stroke patient exhibits complete recovery from neurological damage or neurological impairment caused by the stroke event.
[0145] In a more specific embodiment of the third aspect, as used herein, a good response to a medical protocol means a situation where the stroke patient shows a lower mRS value at a time point after the start of the medical protocol, particularly after the end of the medical protocol, than at the start of the medical protocol or in earlier stages. In a specific embodiment, as used herein in the context of two mRS values, the term "lower" means a situation where one mRS value is at least one mRS grade lower than the other mRS value, at least two mRS grades lower, at least three mRS grades lower, at least four mRS grades lower, or at least five mRS grades lower, particularly at least one mRS grade lower.
[0146] More specifically, a good response to a treatment regimen is defined as a situation in which stroke patients show a mRS value below 3, especially below 2, even more especially below 1 or even 0, at a time point after the start of the treatment regimen, particularly after the end of the treatment regimen, and even more especially below the value at the start of the treatment regimen or in earlier stages.
[0147] In another embodiment of the third aspect, a good response to a medical protocol means a situation where the stroke patient shows a lower NIHSS score at a time point after the start of the medical protocol, particularly after the end of the medical protocol, than at the start of the medical protocol or at an earlier stage of the medical protocol. As used herein in the context of two NIHSS scores, the term “lower” means a situation where one NIHSS score is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 19, at least 12, at least 15, at least 20, at least 30, or even at least 40, particularly at least 3 NIHSS score values, lower than the other NIHSS score.
[0148] In another specific embodiment of the third aspect, a good response to a medical protocol means that a stroke patient, at a time point after the start of the medical protocol, particularly after the end of the protocol, shows an NIHSS score assigned to a stroke severity level lower than the NIHSS score determined at the start of the protocol or at an earlier stage of the protocol (i.e., a lower stroke severity). In another specific embodiment of the third aspect, the reduction in NIHSS level at a time point after the start of the medical protocol, particularly after the end of the protocol, relative to the NIHSS score determined at the start of the protocol or at an earlier stage of the protocol, is any of those indicated in the definition of "good response to a medical protocol" in Section 1.1 - Definitions above.
[0149] In a particular embodiment, the method of the third aspect is performed at least 0.5 h, at least 1 h, at least 2 h, at least 3 h, at least 4 h, at least 5 h, at least 7 h, at least 10 h, at least 12 h, at least 18 h, at least 24 h, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3 months, at least 6 months, at least 9 months, at least 1 year, at least 2 years, at least 3 years, at least 5 years, at least 7 years, or at least 10 years after the commencement of the medical protocol. In a particular embodiment, as used in the context of the third aspect, the term "time point after the commencement of the medical protocol" corresponds to the moment when the method of the third aspect is performed.
[0150] The term "initiation of a medical procedure" has been defined in the previous section "1.1 - Definitions" and applies to the third aspect of this invention.
[0151] As used herein, the term "earlier stage of a medical protocol" refers to the time between the commencement of a medical protocol as defined above and the commencement of the method of the third aspect of the invention. In a particular embodiment, an earlier stage of a medical protocol means at least 0.5 h, at least 1 h, at least 2 h, at least 3 h, at least 4 h, at least 5 h, at least 7 h, at least 10 h, at least 12 h, at least 18 h, at least 24 h, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3 months, at least 6 months, at least 9 months, at least 1 year, at least 2 years, at least 3 years, at least 5 years, at least 7 years, at least 10 years, and after the commencement of a medical protocol as indicated in the definition of "commencement of a medical protocol".
[0152] As used herein, the term "expression level at the start of a treatment regimen or at an earlier stage of a treatment regimen" is also referred to herein as a reference value determined for one or more corresponding miRNAs in step (ii) of the method of the third aspect. In a particular embodiment, the reference value determined in step (ii) of the method of the third aspect is a reference level as defined above, particularly as defined in any definition and embodiment of the first aspect, wherein one or more samples used to determine the reference value have been isolated from the patient analyzed in the method of the third aspect at an earlier time point, particularly at the start of a treatment regimen or at an earlier stage of a treatment regimen. In another particular embodiment, the reference value determined in step (ii) of the method of the third aspect corresponds to a reference value as defined in section "1.1 - Definitions" or in the first aspect of the invention, wherein the control subject is a patient analyzed in the method of the third aspect but at an earlier time point, particularly at the start of a treatment regimen or at an earlier stage of a treatment regimen.
[0153] As used herein, the term “reduced expression level of one or more miRNAs relative to their expression level at the start of a medical protocol or at an earlier stage of a medical protocol” refers to a situation where the expression level of said miRNA is at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 100%, at least 120%, at least 130%, at least 150%, at least 170%, at least 180%, at least 190%, at least 200%, at least 250%, at least 300%, at least 350%, at least 400%, or at least 500% lower than a corresponding reference value, wherein the reference value is the reference value determined in step (ii) of the method of the third aspect as defined above.
[0154] The method for determining whether the expression level of a miRNA is lower than another expression level or reference value is as described in the definition of "above the corresponding reference value", wherein the comparison is made to determine whether the expression level is lower than rather than higher than the reference value.
[0155] The terms “sample,” “patient,” “expression level,” “comparing the expression level obtained in step (i) to the corresponding reference value,” and “above the corresponding reference value” have been defined in the preceding section “1.1 - Definitions” and in the first aspect of the invention, and also apply to the third aspect of the invention. The definitions and embodiments of the first and second aspects of the invention also apply to the third aspect of the invention. Therefore, by replacing the term “first aspect” or “second aspect” with “third aspect,” embodiments of the first or second aspect of the invention also apply to the third aspect of the invention.
[0156] In a particular embodiment, the patient of the third aspect is as defined in any definition and embodiment of the first aspect of the invention. In another particular embodiment, the one or more expression levels determined in step (i) of the method of the third aspect are as defined in any definition and embodiment of the first aspect. In another particular embodiment, the one or more miRNAs whose expression levels are determined in step (i) of the method of the third aspect are those indicated in any embodiment of the first aspect and whose expression levels are the one or more miRNAs determined in step (i) of the method of the first aspect. In another particular embodiment, the one or more miRNAs whose expression levels are determined in step (i) of the method of the third aspect are the one or more miRNAs whose expression levels are determined in step (i) of the method of the first aspect. In another particular embodiment, the reference values used in step (ii) of the method of the third aspect are as defined in any definition and embodiment of the first aspect.
[0157] In an embodiment of the third aspect, step (ii) of the method of the third aspect further specifies that an increase in the expression level of one or more miRNAs determined in step (i) of the method, relative to the expression level at the start of the medical regimen or at an earlier stage of the medical regimen, does not indicate a favorable response to the medical regimen. As used herein, the term "increased miRNA expression level" is the term "above a corresponding reference value" as defined above and in the first aspect of the invention, wherein the reference value is the reference value determined in step (ii) of the method of the third aspect as defined above.
[0158] 2. Products used in the treatment of stroke In a fourth aspect, the present invention relates to a miRNA inhibitor that reduces the expression of miRNAs selected from a list consisting of miR-376c-3p, miR-199a, and combinations thereof, for use in the treatment or prevention of stroke in patients.
[0159] In a fifth aspect, the present invention relates to a combination of miRNA inhibitors for use in the treatment or prevention of stroke in a patient, wherein the combination of miRNA inhibitors comprises miRNA inhibitors as defined in the fourth aspect, and further comprises: - A miRNA inhibitor that targets miRNAs selected from the group consisting of miR134-5p, miR-4463, miR-584-5p, and combinations thereof. - Two miRNA inhibitors, each of which is a miRNA inhibitor selected from different miRNAs in the group consisting of miR134-5p, miR-4463, miR-584-5p, and combinations thereof. - Three miRNA inhibitors, each of which is a miRNA inhibitor selected from different miRNAs in the group consisting of miR134-5p, miR-4463, miR-584-5p and combinations thereof, and in particular, each miRNA inhibitor is a miRNA inhibitor selected from different miRNAs in the group consisting of miR134-5p, miR-4463 and miR-584-5p.
[0160] In a sixth aspect, the present invention relates to a pharmaceutical composition for use in the treatment or prevention of stroke, the pharmaceutical composition comprising a miRNA inhibitor as defined in the fourth aspect or a combination of miRNA inhibitors as defined in the fifth aspect.
[0161] 2.1-Definition As used herein, the term "miRNA inhibitor" refers to a molecule or molecular complex that neutralizes or inhibits the activity or function of microRNAs (miRNAs) in cells. Indeed, the activity of a miRNA is reduced in the presence of its inhibitor compared to the absence of the miRNA inhibitor. Therefore, the gene expression of the target mRNA of the miRNA is increased (or "de-inhibited") in the presence of the miRNA inhibitor compared to the absence of the miRNA inhibitor. It has been reported that the inhibition of the target miRNA by a miRNA inhibitor is mediated by the degradation of the target miRNA, or also by a steric hindrance blocking mechanism. As used herein in the context of miRNA inhibitors, the term "steric hindrance blocking" is a term well known to those skilled in the art, specifically referring to a mechanism in which a miRNA inhibitor binds to its target miRNA and blocks cellular machinery, particularly the cellular machinery required to trigger the function of the miRNA (i.e., the machinery required for the miRNA to inhibit the expression of its target mRNA), from approaching the miRNA. In certain embodiments, the miRNA inhibitor is a miRNA antagonist, and more specifically, the terms "miRNA inhibitor" and "miRNA antagonist" are used interchangeably. Methods for determining whether a molecule is a miRNA inhibitor are well known to those skilled in the art. Non-limiting examples include determining the expression level of a miRNA for which a molecule has been designed (i.e., the target miRNA of a probable miRNA inhibitor) in the presence and absence of the molecule using any technique known to those skilled in the art (such as PCR, RT-PCR, or RT-qPCR); and indicating that the molecule is a miRNA inhibitor if the expression level of the miRNA in the presence of the analyzed molecule is significantly lower than in the absence of the molecule. Furthermore, the expression level of the target mRNA of the miRNA for which a molecule has been designed (i.e., the mRNA target of the target miRNA of a probable miRNA inhibitor) can also be determined in the presence and absence of the analyzed molecule using any technique known to those skilled in the art (such as those indicated above). If the expression level of the target mRNA in the presence of the molecule is higher than in the absence of the molecule, this also indicates that the molecule is a miRNA inhibitor. Other techniques are well known to those skilled in the art, including, for example, CRISPR-based methods disclosed in, for example, Kaminski MM et al., CRISPR-based diagnostics; Nature Biomedical Engineering, 2021, 643:656.
[0162] Furthermore, those skilled in the art recognize that the sequence of the target miRNA can be readily used to design miRNA inhibitors using conventional methods. Non-limiting examples of such methods include designing oligonucleotides complementary to at least the seed region (as defined herein) of the target miRNA, or, for higher specificity, oligonucleotides complementary to nucleotides at positions 3-20 or all of the target miRNA. Methods for determining the complementarity of two nucleotide sequences are well known to those skilled in the art and can be based on those provided below in the definition of “specific binding.” Additionally, nucleotide or backbone modifications that enhance oligonucleotide properties (such as their stability) are provided below in the definition of “oligonucleotides” and can be implemented by those skilled in the art using conventional techniques well known to them. Non-limiting examples of methods for synthesizing oligonucleotides include synthesis via solid-phase synthesis using a phosphoramidite method and phosphoramidite structural units derived from protected 2'-deoxynucleosides (dA, dC, dG, and T), ribonucleosides (A, C, G, and U), or chemically modified nucleosides (e.g., LNA or BNA). Confirmation of the sequence of the resulting oligonucleotide and correct synthesis can be further performed by those skilled in the art using sequencing techniques well known. Non-limiting examples include liquid chromatography-mass spectrometry (LC-MS or HPLC-MS) or capillary electrophoresis-mass spectrometry (CEMS). Furthermore, methods for determining whether the obtained oligonucleotides are inhibitors of the desired miRNA have been provided in the preceding paragraphs.
[0163] As used herein, the term “target miRNA” refers to a miRNA that is targeted or inhibited by a miRNA inhibitor as defined herein. As used herein, the expressions “miRNA inhibitor of miRNA” and “miRNA inhibitor that inhibits the activity of the miRNA indicated therein”, or “miRNA inhibitor whose miRNA target is the miRNA indicated therein”, or “miRNA inhibitor that targets the miRNA indicated therein” are interchangeable.
[0164] Well-known miRNA inhibitors consist of, or are composed of, nucleotide sequences or oligonucleotides that bind to their target miRNAs through base pairing.
[0165] The nucleotide sequence of the miRNA inhibitor that pairs with the corresponding miRNA target sequence is also referred to herein as the miRNA binding sequence (MBS) of the mRNA inhibitor.
[0166] Meanwhile, the nucleotide sequence in the target miRNA that is complementary to its miRNA inhibitor (or to an oligonucleotide contained in or composed of the miRNA inhibitor), particularly to the MBS of the miRNA inhibitor, is referred to herein as the “miRNA inhibitor target sequence” or “miRNA inhibitor target sequence”.
[0167] The target sequence of a miRNA inhibitor typically contains the seed region of the miRNA. As is well known to those skilled in the art, the seed region of a miRNA refers to the nucleotides located at positions 2-8 in the 5' to 3' direction of the mature miRNA, and is considered to be the minimum element required for the miRNA to bind to its target mRNA in the cell. Simultaneously, the MBS of a miRNA inhibitor typically contains, or is composed of, a nucleotide sequence complementary to, the seed region of the target miRNA of the miRNA inhibitor. Therefore, in a particular embodiment, the target sequence of the miRNA inhibitor contains, or is composed of, the seed region of the target miRNA.
[0168] As will be fully understood by those skilled in the art, when referring to miRNA inhibitors that pair with or specifically bind to target miRNA bases, it should be understood herein that a miRNA inhibitor comprises or is composed of oligonucleotides that comprise or specifically bind to a nucleotide sequence that pairs with or specifically binds to the target miRNA sequence. Therefore, in certain embodiments, a miRNA inhibitor comprises or is composed of oligonucleotides, particularly oligonucleotides that specifically bind to the target miRNA, more particularly those that specifically bind to the target miRNA sequence, and still more particularly those that specifically bind to the miRNA seed region.
[0169] As used herein, the term "miRNA inhibitor oligonucleotide" or "oligonucleotide" refers to an oligonucleotide contained in or composed of a miRNA inhibitor as defined herein. In the context of this disclosure, the term "oligonucleotide" or "polynucleotide" refers to an oligomer of nucleotides typically defined by a nucleotide sequence. A nucleotide consists of a naturally occurring nitrogenous or nucleobase (purine (adenine and guanine) and pyrimidine (cytosine, uracil, and thymine)) covalently bonded at the 1' position to a 5-carbon sugar (deoxyribose or ribose), which in turn covalently bonds to a phosphate group at its 5' position. Oligonucleotides are generally classified as deoxyribonucleotides or ribonucleotides, which are oligomers of "deoxyribonucleotides" or "ribonucleotides," respectively. Oligonucleotides formed from deoxyribonucleotides may be referred to as "DNA oligonucleotides," "DNA molecules," or simply "DNA"; and oligonucleotides formed from ribonucleotides may be referred to as "RNA oligonucleotides," "RNA molecules," or simply "RNA." Deoxyribonucleotides consist of repeating structures of deoxyribonucleotides (containing adenine or guanine as purines, or cytosine or thymine as pyrimidines), wherein the phosphate of one deoxyribonucleotide is covalently bonded to the 3' carbon of the deoxyribose of another deoxyribonucleotide, forming an alternating, unbranched polymer. Ribonucleotides (containing adenine or guanine as purines, or cytosine or uracil as pyrimidines) consist of similar repeating structures, wherein the 5-carbon sugar is ribose. The structure resulting from the linkage of the phosphate and sugar of different nucleotides in an oligonucleotide is called a sugar-phosphate backbone, i.e., the oligonucleotide contains a sugar-phosphate backbone or a phosphate backbone. In the context of this disclosure, "thymine nucleotide," "uracil nucleotide," "guanine nucleotide," "cytosine nucleotide," or "adenine nucleotide" refers to a nucleotide containing the corresponding nitrogenous base, and particularly to a nucleotide containing these bases and being part of DNA or RNA.
[0170] In the context of this disclosure, oligonucleotide sequences are represented from left to right in a 5' to 3' direction, and the first nucleotide presented in the sequence is the residue at position 1. Therefore, in the context of this disclosure, the positions of nucleotides in an oligonucleotide or nucleotide sequence are provided from the 5' end to the 3' end (i.e., in a 5' to 3' direction), with the residue at the 5' end of the oligonucleotide at position 1.
[0171] In some embodiments, the miRNA inhibitor oligonucleotide contains modifications that help enhance its properties, particularly its binding affinity to miRNA targets, stability, and / or specificity. For example, increased stability can be achieved by combining ribonucleotides in the oligonucleotide with nucleotides.
[0172] The term "oligonucleotide" also includes oligomers that contain monomers that are functionally and structurally similar to, but not to, deoxyadenosine 3'-monophosphate, deoxyguanosine 3'-monophosphate, deoxycytidine 3'-monophosphate, deoxythymidine 3'-monophosphate, adenosine 3'-monophosphate, guanosine 3'-monophosphate, cytidine 3'-monophosphate, or uridine 3'-monophosphate. These are also referred to as oligonucleotide analogs, modified oligonucleotides, or DNA / RNA-like oligonucleotides. Such oligonucleotides may or may not be naturally occurring, and are sometimes superior to their natural forms due to properties such as enhanced binding affinity, enhanced cellular uptake, reduced immunogenicity, and increased stability in the presence of nucleases.
[0173] Therefore, oligonucleotide analogs are composed of nucleotide analogs (or modified nucleotides or RNA / DNA-like nucleotides), and one or more of the three parts (phosphate, pentose, or nucleobase) of these nucleotide analogs can be altered compared to the “standard” nucleotides mentioned above.
[0174] In some embodiments, the miRNA inhibitor oligonucleotide can be modified by replacing at least one nucleotide with at least one modified nucleotide, ideally such that the oligonucleotide has enhanced in vivo and in vitro stability compared to the corresponding unmodified oligonucleotide.
[0175] Non-limiting examples of nucleotide analogs include 2'-deoxyguanosine, 2'-deoxyadenosine, 2'-O-methylguanosine, 2'-O-methyl (e.g., 2'-O-methylcytidine, 2'-O-methylpseuuridine, 2'-O-methyluridine, 2'-O-methyladenosine (as mentioned in the sequence listing), 2'-O-methylguanosine) ribonucleotides, 2'-amino, 2'-thio, and 2'-fluorinated ribonucleotides, 2'-fluorocytidine, 2'- Fluorouracil, 2'-fluoro-guanosine, 2'-fluoro-adenosine, 2'-amino-cytidine, 2'-amino-uracil, 2'-amino-adenosine, 2'-amino-guanosine, 2'-amino-butyryl-pyrene-uracil, 2'-amino-adenosine, 5-iodo-uracil, ribothymidine, 5-bromo-uracil, 2-aminopurine, 5-methyl-cytidine, 5-fluoro-cytidine, and 5-fluoro-uracil, 2,6-diaminopurine, 4-thio-uracil, 5-amino-allyl-uracil, and combinations thereof.
[0176] In another embodiment, the miRNA inhibitor oligonucleotide includes a 5-position derivatization, for example selected from 5-(2-amino)propyluridine, 5-bromouridine, 5-propynyluridine, 5-propenyluridine; a 6-position derivatization, for example 6-(2-amino)propyluridine; and an 8-position derivatization of adenosine and / or guanosine, for example 8-bromoguanosine, 8-chloroguanosine, or 8-fluoroguanosine.
[0177] In other embodiments, the miRNA inhibitor oligonucleotide comprises a modified sugar moiety. Examples of modification of the sugar moiety of the nucleotide include replacing the 2' OH- group with a group selected from H, OR, R, F, CI, Br, I, SH, SR, H2, NHR, NR2, COOR, or OR, wherein R is a substituted or unsubstituted C1-C6 alkyl, alkenyl, alkynyl, aryl, etc. The phosphate group of the nucleotide may also be modified, such as by replacing one or more of the oxygen in the phosphate group with sulfur (e.g., by employing a thiophosphate). Modification can reduce the hydrolysis rate of polynucleotides containing modified bases, for example by inhibiting degradation by exonucleases. In a preferred embodiment, the oligonucleotide is resistant to ribonucleases. Oligonucleotides that may be used include those with modifications that promote resistance to exonucleases. Therefore, in the embodiments, the miRNA inhibitor oligonucleotides have been modified with a 2'-O-methyl group, also known as 2'-methoxy modification (e.g., 2'-O-methylcytidine, 2'-O-methylpseuuridine, 2'-O-methylguanosine, 2'-O-methyluridine, 2'-O-methyladenosine, 2'-O-methyl).
[0178] In another embodiment, the miRNA inhibitor oligonucleotide contains a modification that increases cellular uptake. Examples of modifications that improve cellular uptake include poly(ethylene glycol) (PEG), GalNAc (N-acetylgalactosamine), cell-penetrating peptide (CPP), RGD peptide, α-tocopherol, or cholesterol modifications. Such modifications can be added to the 5' or 3' end of the oligonucleotide. The attachment can be direct or via a linker. In a particular embodiment, any such modification is directly attached to or via a linker to an internal nucleotide of the oligonucleotide (i.e., a nucleotide that is not a 3' or 5' nucleotide). In a particular embodiment, a cholesterol group is added to the 5' or 3' end of the miRNA inhibitor oligonucleotide, particularly to the 3' end. As used herein, the term "cholesterol" refers to the molecule with the IUPAC name cholesterol-5-en-3β-ol.
[0179] In other embodiments, the miRNA inhibitor oligonucleotide contains at least one modification selected from the group consisting of: peptide nucleic acid (PNA), morpholino nucleic acid, glycerol nucleic acid (GNA), threononucleotide (TNA), and hexitol nucleic acid (HNA). In other embodiments, the miRNA inhibitor oligonucleotide contains locked nucleic acid (LNA) (an oligonucleotide comprising at least one 2'-C,4'-C-oxy-methylene-linked bicyclic ribonucleotide monomer), 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl)uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, β-D-galactosylpiperidine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5- Methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, β-D-mannosyl piracetamidine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid, wybutoxosine, pseudouracil, piracetamidine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methyl ester, 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl)uracil and / or 2,6-diaminopurine.
[0180] The backbone of oligonucleotides can also be modified. A common modification is the replacement of the phosphate backbone with a thiophosphate backbone, which provides increased resistance to nucleases compared to unmodified oligonucleotides (containing a 100% phosphate diester backbone). As is well known to those skilled in the art, the thiophosphate (PS) bond replaces the non-bridging oxygen in the oligonucleotide phosphate backbone with a non-bridging sulfur atom.
[0181] In some embodiments, the miRNA inhibitor oligonucleotide comprises a modification of the phosphate backbone, such as methylphosphonate, methylthiophosphonate, phosphoromorpholidate, phosphoropiperazidate, and phosphoramide. In some embodiments, the oligonucleotide contains a 2' lower alkyl moiety (e.g., a C1-C4 straight-chain or branched saturated or unsaturated alkyl group, such as methyl, ethyl, vinyl, propyl, 1-propenyl, 2-propenyl, and isopropyl).
[0182] In certain embodiments, the miRNA inhibitor oligonucleotide is a linear oligonucleotide. As used herein, the term "linear oligonucleotide" means an oligonucleotide having a 5' end and a 3' end as defined herein. Oligonucleotides that form secondary structures are not excluded from the definition of linear oligonucleotides, as long as they contain a 5' end and a 3' end. In the context of this invention, as used herein, a linear miRNA inhibitor means a miRNA inhibitor comprising or composed of a linear oligonucleotide.
[0183] In another specific embodiment, the miRNA inhibitor oligonucleotide is a cyclic oligonucleotide. As used herein, the term "cyclic oligonucleotide" refers to a closed single DNA, RNA, or DNA / RNA strand covalently linked at its ends. Cyclic oligonucleotides are more resistant to degradation by DNA and / or RNA degradation machinery compared to linear oligonucleotides. In the context of this invention, as used herein, a cyclic miRNA inhibitor refers to a miRNA inhibitor comprising or composed of a cyclic oligonucleotide. In a specific embodiment, the cyclic oligonucleotide comprises a nucleotide or backbone modification as indicated in the definition of "oligonucleotide".
[0184] Non-limiting examples of well-known miRNA inhibitors include anti-miRNA oligonucleotides (AMO), cyclic oligonucleotides, miRNA sponges, and tough decoys (TuD). Therefore, in specific embodiments, miRNA inhibitors as mentioned herein comprise, or consist of, oligonucleotides selected from, the list comprising AMO, cyclic oligonucleotides, miRNA sponges, and TuD. AMO can also be classified as (LNA)-AMO, phosphate thioester (PS)-AMO, peptide nucleic acid (PNA)-AMO, phosphoryl diamine morpholino (PMO)-AMO, or an AMO of the form of a non-nucleotide compound called N,N-dimethyl-4-(4-nitronaphthyl-1-ylazo)-aniline (ZEN) appended to the end of a 2'-O-methyl modified AMO (ZEN-AMO).
[0185] As used herein, the terms “anti-miRNA oligonucleotide,” “AMO,” “anti-miR,” or “antagomir” refer to antisense oligonucleotides (ASOs) that target miRNAs. An AMO is a single-stranded small RNA that binds complementary to its miRNA target, blocking the interaction between these targets and their corresponding endogenous mRNA targets, thereby increasing (or “de-inhibiting”) the expression of said endogenous mRNA targets. The mechanism of anti-miR-based oligonucleotides relies on complementary base pairing between the oligonucleotide sequence and its target miRNA. AMOs are typically designed to have perfect base pairing with miRNA targets, especially when inactivation requires a binding affinity between the miRNA and the AMO that is significantly higher than the binding affinity of the native miRNA’s guide strand / passer strand interaction. Because single-stranded RNA oligonucleotides are readily degraded by nucleases, various chemical modifications are applied to improve their stability, enhance their binding affinity, prolong their inhibitory effect, and thus increase their efficacy. These modifications are applied to the backbone of the AMO as well as the ribose and / or nucleobases, and include any modifications indicated above for oligonucleotide analogues. Generally, the modifications can be categorized as follows: (1) alteration of the phosphodiester bond, for example by placing at least one phosphate-thioester nucleotide linker (phosphate-thioester backbone) to confer resistance to nuclease degradation and increase bioavailability, forming phosphate-thioester (PS)-AMO (also referred to herein as “PS-AMO”); (2) modification of the nucleotide ribose to enhance the stability of AMO and its affinity for its target miRNA (e.g., by placing at least one 2'-O-methyl, 2'-O-methoxyethyl, or 2'-fluoro modification); (3) construction of locked nucleic acid (LNA)-AMO (also referred to herein as “LNA-AMO”) by placing at least one methyl bridge between the 2'-O and 4' positions of the ribose ring (forming a 2'-C,4'-C-oxy-methylene-linked bicyclic ribonucleotide monomer); or (4) The ribose-phosphate backbone between at least two nucleotides is replaced with a pseudopeptide sequence to produce a peptide nucleic acid (PNA)-AMO molecule (also referred to herein as "PNA-AMO"); or the ribose-phosphate backbone between at least two nucleotides is replaced with a 6-membered morpholino ring or phosphoryl diamine linkage to produce a phosphoryl diamine morpholino oligomer (also referred to herein as "PMO-AMO"). Both PNA and PMO are generally electroneutrally neutral and resistant to cleavage by nucleases. All of the above chemical modifications in AMO are described in detail in several publications, including Hammond SM et al., " Delivery of oligonucleotide-based therapeutics: challenges and opportunities [Oligonucleotide-based therapeutics delivery: challenges and opportunities], EMBO Mol. Med. [European Organization for Molecular Biology in Molecular Medicine] 2021; or Lima JF et al., Anti-miRNA oligonucleotides: a comprehensive guide for design[Anti-miRNA Oligonucleotides: A Comprehensive Design Guide]. RNA Biol. [RNA Biology] 2018; 15: 338-352. By incorporating this type of modification, anti-miRNA oligonucleotides can be pruned into shorter sequences with equal or even better performance, specifically binding to the common seed sequence of miRNAs, and blocking the entire miRNA family via a single sequence design. Additional modifications that can be placed in AMOs to increase binding affinity and exonuclease resistance include the placement of a non-nucleotide compound called N,N-dimethyl-4-(4-nitronaphth-1-ylazo)-aniline (ZEN) (attached to the end of a 2'-O-methyl modified AMO), forming the so-called ZEN-AMO (see KA Lennox et al., "Improved performance of Anti-miRNA oligonucleotides using a novel non-nucleotide modifier, molecular therapy", Nucleic Acids [Nucleic Acids] 2 (2013). (e117). Furthermore, as just defined, an AMO can further contain DNA residues, and therefore can be formed from a mixture of DNA residues and RNA residues.
[0186] In a specific embodiment, the AMO miRNA inhibitor is LNA-AMO, PS-AMO, PNA-AMO, PMO-AMO, or ZEN-AMO.
[0187] As used herein, the term "miRNA sponge" refers to a engineered RNA transcript that competitively binds to a target miRNA via multiple tandem MBS sequences (each recognizing one or more target miRNAs). Once transfected and stably expressed in cells, a miRNA sponge can produce long-term or permanent inhibition of a single target miRNA or an entire miRNA family. Various miRNA sponge structural designs have been developed to better adsorb target miRNAs. The first type of miRNA sponge design consists of a linear structure with MBS sequences arranged in tandem within the 3' UTR of a reporter gene, which can then be delivered to cells via a viral vector. Typically, most miRNA sponges are constructed with 4–16 MBS sequences for the same or different miRNAs. Another design for RNA sponges corresponds to the design of cyclic oligonucleotides, which, compared to linear miRNA sponges, exhibit greater resistance and stability to exonucleases due to the lack of free ends. In certain embodiments, miRNA inhibitors are miRNA sponges. In another specific embodiment, the miRNA inhibitor mentioned herein is a miRNA sponge containing any modifications indicated in the definition of oligonucleotides above, particularly any modifications indicated in the definition of miRNA inhibitor oligonucleotides above. In another specific embodiment, the miRNA inhibitor mentioned herein is a miRNA sponge containing any modifications indicated in the definition of AMO above, particularly at least one modification indicated in the definition of AMO above.
[0188] As used herein, the term "circular RNA" refers to a covalently closed RNA molecule. They can be transcribed and spliced from exons or introns of genes and are ubiquitous in eukaryotic cells and extracellular components, including blood. Due to the lack of free ends, circular RNAs are particularly resistant to exonucleases. Some circRNAs contain miRNA MBS, which isolate one or more corresponding miRNAs, thus inhibiting said miRNAs and acting as a circular miRNA sponge. In a particular embodiment, the miRNA inhibitor as referred to herein is a miRNA sponge. In another particular embodiment, the miRNA inhibitor as referred to herein is a circular miRNA sponge containing any modifications indicated above in the definition of oligonucleotides, particularly any modifications indicated above for miRNA inhibitor oligonucleotides. In yet another particular embodiment, the miRNA inhibitor as referred to herein is a circular miRNA sponge containing any modifications indicated above in the definition of AMO, particularly at least one modification indicated above in the definition of AMO.
[0189] An example of a circular miRNA inhibitor consists of has_circ_0012152, such as Erdogan C. et al. A Bioinformatics Analysis of circRNA / miRNA / mRNA Interactions in Acute Myeloid Leukemia [Bioinformatics Analysis of circRNA / miRNA / mRNA Interactions in Acute Myeloid Leukemia], Experimented [Experimental Medicine] 2023; 13(1): 45-53. In a particular embodiment, SEQ ID NO. 6 consists of the RNA sequence of has_circ_0012152, which was just cited.
[0190] As used herein, the term "strong decoy" or "TuD" refers to a miRNA inhibitor consisting of a hairpin-shaped RNA approximately 60 bp long containing large internal protrusions, such as those opposite the miRNA's position 10-11, exposing two miRNA target sites with incomplete base pairing. It has been proposed that incomplete base pairing prevents rapid endonuclease turnover of the inhibitor, thereby prolonging the interaction between the miRNA and the inhibitor. Examples of such miRNA inhibitors are provided by Haraguchi et al., " Vectors expressing efficient RNA decoys achieve the long- term suppression of specific microRNA activity in mammalian cells [“[Vectors expressing effective RNA decoys achieve long-term inhibition of specific microRNA activity in mammalian cells]”. Nucleic Acids Res, 2009, 37: e43. In a particular embodiment, the miRNA inhibitor as referred to herein is TuD. In another particular embodiment, the miRNA inhibitor as referred to herein is TuD containing any modifications indicated above in the definition of oligonucleotides, particularly any modifications indicated above for miRNA inhibitor oligonucleotides. In yet another particular embodiment, the miRNA inhibitor as referred to herein is TuD containing any modifications indicated above in the definition of AMO, particularly at least one modification indicated above in the definition of AMO.
[0191] As used herein in the context of miRNA inhibitors, the terms "specifically binds" or "specifically binding" refer to the fact that the nucleotide sequence of a miRNA inhibitor pairs, hybridizes, or is complementary to the sequence of its target miRNA. While the embodiments disclosed herein are not limited to specific base-pairing mechanisms, the most common base-pairing mechanisms involve hydrogen bonding, which can be Watson-Crick, Husstein, reverse Husstein, or wobble hydrogen bonds between complementary nucleobases or nitrogenous bases. For example, the natural nucleobase adenine is complementary to the natural nucleobases thymidine and uracil, which pair by forming hydrogen bonds. Similarly, the natural base guanine is complementary to the natural nucleobases cytosine and 5-methylcytosine. As will be fully appreciated by those skilled in the art, a sequence that specifically binds to a target sequence does not need to be 100% complementary to the target sequence (i.e., it is not assumed that all nucleotides in two complementary sequences are base-paired with each other). For example, miRNA inhibitors having MBS containing insertions, deletions, and single-point mutations relative to their target miRNA as defined above can also effectively inhibit their target miRNA. Therefore, two nucleotide sequences can be considered complementary when they are at least 30%, 40%, 50%, 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 97%, at least 99%, or 100% complementary to each other. In a particular embodiment, the miRNA inhibitor comprises or is composed of an oligonucleotide containing or composed of a nucleotide sequence (or MBS) that is at least 30%, 40%, 50%, 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% complementary to the target miRNA of the miRNA inhibitor, particularly to the target sequence of the miRNA inhibitor. In more specific embodiments, the miRNA inhibitor comprises or is composed of an oligonucleotide that contains or is composed of a nucleotide sequence (or MBS) that is 100% complementary to the target miRNA of the miRNA inhibitor, particularly to the target sequence of the miRNA inhibitor. In more specific embodiments, the miRNA inhibitor comprises or is composed of an oligonucleotide that contains or is composed of a nucleotide sequence that is 100% complementary to the target sequence of the miRNA inhibitor.
[0192] Methods for determining the percentage of complementarity between a first nucleotide sequence and a second nucleotide sequence are well known to those skilled in the art and include determining the percentage of sequence identity between the reverse complementary sequences of the first and second nucleotide sequences. Therefore, a nucleotide sequence or oligonucleotide complementary to a target sequence can alternatively be defined as a nucleotide sequence containing, or consisting of, a sequence that is identical to, its reverse complementary sequence relative to its target sequence. The identity relative to the reverse complementary sequence of the oligonucleotide target sequence is at least 30%, at least 40%, at least 50%, at least 60%, at least 65%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 93%, at least 95%, at least 97%, or 100%, particularly 100%. Sequence identity (including determining the sequence complementarity of nucleic acid sequences) can be determined using sequence comparison and alignment algorithms known in the art. To determine the percentage of identity between two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps may be introduced in the first or second sequence for optimal alignment). Nucleotides at the corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same residue at the corresponding position in the second sequence, the molecule is identical at that position. The percentage of identity between two sequences is a function of the number of shared positions (i.e., homology % = number of shared positions / total number of positions). 100), optionally penalize the score for the number of introduced gaps and / or the length of introduced gaps.
[0193] Sequence comparison and determination of the percentage of identity between two sequences can be accomplished using mathematical algorithms. In one embodiment, the alignment is generated for a portion of the sequences being compared that has sufficient identity, rather than for a portion that has a low degree of identity (i.e., local alignment). A preferred, non-limiting example of a local alignment algorithm for comparing sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences] 87:2264-68, as modified in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences] 90:5873-77. This algorithm is incorporated into the BLAST procedure (version 2.0) of Altschul et al. (1990) J. Mol. Biol. [Journal of Molecular Biology] 215:403-10. In another embodiment, the alignment is optimized by introducing appropriate gaps, and the percentage of identity is determined for the length of the sequences being compared (i.e., gap alignment). To obtain gap alignments for comparison purposes, gapped BLASTs, as described in Altschul et al., (1997) NucleicAcids Res. [Nucleic Acids Research] 25(17):3389-3402, can be used. In another embodiment, alignment is optimized by introducing appropriate gaps, and percentage identity (i.e., global alignment) is determined over the entire length of the aligned sequences. A preferred, non-limiting example of a mathematical algorithm for global sequence comparison is the algorithm of Myers and Miller, CABIOS [Computer Applications in the Biosciences] (1989). This algorithm is incorporated into the ALIGN program (version 2.0), which is part of the GCG sequence alignment software package. When comparing amino acid sequences using the ALIGN program, a PAM120 weighted residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.
[0194] As used herein, the term "treatment" refers to any type of therapy aimed at terminating, preventing, improving, or reducing susceptibility to a clinical condition as described herein. In a preferred embodiment, the term treatment refers to preventative treatment of a disorder or condition as defined herein (i.e., therapy aimed at reducing susceptibility to a clinical condition). Therefore, "treatment," "treating," and their equivalents refer to any treatment that achieves a desired pharmacological or physiological effect, encompassing any treatment of a pathological condition or disorder in mammals, including humans. The effect may be preventative in terms of complete or partial prevention of the disorder or its symptoms, and / or therapeutic in terms of partial or complete cure of the disorder and / or adverse effects attributable to the disorder. That is, “treatment” includes (1) preventing the occurrence or recurrence of a subject’s disorder; (2) inhibiting the disorder, such as preventing its development; (3) stopping or terminating the disorder or at least the symptoms associated with it, so that the host is no longer troubled by the disorder or its symptoms, such as causing the disorder or its symptoms to subside, for example by restoring or repairing lost, missing or defective functions, or stimulating inefficient processes; or (4) alleviating, reducing or improving the disorder or its associated symptoms, wherein improvement is used broadly to refer to at least reducing the magnitude of change in parameters associated with said disorder. In certain embodiments, as used herein, the term “treatment” also refers to the term “medical protocol” as defined in Section 1.1 – Definition above or in the first aspect of the invention.
[0195] As used herein, the term "pharmaceutical composition" refers to a composition comprising a therapeutically effective amount of a combination of miRNA inhibitors of the fourth aspect of the present invention or miRNA inhibitors of the fifth aspect of the present invention, and at least one pharmaceutically acceptable excipient or carrier. Pharmaceutical compositions according to the present invention can be prepared, for example, as injections, such as liquid solutions, suspensions, and emulsions.
[0196] The terms “pharmaceuticalally acceptable excipient,” or “pharmaceuticalally acceptable carrier,” “pharmaceuticalally acceptable diluent,” or “pharmaceuticalally acceptable medium” are used interchangeably herein and refer to any conventional type of non-toxic solid, semi-solid, or liquid filler, diluent, encapsulating material, or formulation excipient. A pharmaceutically acceptable carrier is substantially non-toxic to the recipient at the dose and concentration used and is compatible with other components in the formulation. Suitable carriers include, but are not limited to, water, dextran, glycerol, saline, ethanol, and combinations thereof. The carrier may contain additional agents such as wetting agents or emulsifiers, pH buffers, or adjuvants that enhance the effectiveness of the formulation. Adjuvants may be selected from the group consisting of sterile liquids, such as water, and oils, including those of petroleum, animal, plant, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. Water or saline solutions and aqueous solutions of dextran and glycerol (especially for injections) are preferred as media.
[0197] 2.2 Inhibitors of the present invention for use in the treatment of stroke In a fourth aspect, the present invention relates to a miRNA inhibitor targeting a list of miRNAs selected from miR-376c-3p, miR-199a, and combinations thereof, for use in the treatment or prevention of stroke in patients.
[0198] The terms “miRNA,” “miR-376-c-3p,” “miR-199a,” “stroke,” and “patient” have been described in the definitions and examples of the previous section “1. Method of the Invention,” and are equally applicable to the fourth aspect of the invention. The terms “treatment” and “prevention” have been defined in the previous section “2.1 - Definitions.”
[0199] In certain embodiments, all definitions and embodiments of the first, second, and third aspects are equally applicable to the fourth aspect of the invention.
[0200] The term "miRNA inhibitor" has been defined in Section 2.1 - Definition, and the methods for identifying it have also been provided in the definition of the term. The examples provided for the term "miRNA inhibitor" are also applicable to miRNA inhibitors in the fourth aspect.
[0201] In a specific embodiment of the fourth aspect, the term "miRNA inhibitor" is interchangeable with the term "miRNA inhibitor that inhibits the activity of a corresponding miRNA (i.e., a miRNA selected from the list provided in the fourth aspect). In another specific embodiment of the fourth aspect, the term "miRNA inhibitor" is interchangeable with the term "miRNA inhibitor whose miRNA target is a miRNA selected from the list of miRNAs provided in the fourth aspect," or with the term "miRNA inhibitor that targets a miRNA selected from the list of miRNAs provided in the fourth aspect."
[0202] In one embodiment, the miRNA inhibitor of the fourth aspect is a miR-376c-3p miRNA inhibitor. In another embodiment, the miRNA inhibitor of the fourth aspect is a miR-199a miRNA inhibitor. In another embodiment, the miRNA inhibitor of the fourth aspect is a miR-199a-3p miRNA inhibitor. In another embodiment, the miRNA inhibitor of the fourth aspect is a miR-199a-5p miRNA inhibitor. In another embodiment, the miRNA inhibitor of the fourth aspect is a miR-199a-3p and a miR-199a-5p miRNA inhibitor. In another embodiment, the miRNA inhibitor of the fourth aspect is a miR-199a-3p or a miR-199a-5p miRNA inhibitor. In another embodiment, the miRNA inhibitor of the fourth aspect is a miR-199a-3p miRNA inhibitor and a miR-199a-5p miRNA inhibitor.
[0203] In another embodiment, the miRNA inhibitor of the fourth aspect is a miRNA inhibitor of miR-376c-3p and a miRNA inhibitor of miR-199a. In another embodiment, the miRNA inhibitor of the fourth aspect is a miRNA inhibitor of miR-376c-3p and a miRNA inhibitor of miR-199a-3p. In another embodiment, the miRNA inhibitor of the fourth aspect is a miRNA inhibitor of miR-376c-3p and a miRNA inhibitor of miR-199a-3p and miR-199a-5p. In another embodiment, the miRNA inhibitor of the fourth aspect is a miRNA inhibitor of miR-376c-3p and a miRNA inhibitor of miR-199a-3p and miR-199a-5p. In another embodiment, the miRNA inhibitor of the fourth aspect is a miRNA inhibitor of miR-376c-3p and a miRNA inhibitor of either miR-199a-3p or miR-199a-5p. In another embodiment, the miRNA inhibitor of the fourth aspect is a miRNA inhibitor of miR-376c-3p, a miRNA inhibitor of miR-199a-3p, and a miRNA inhibitor of miR-199a-5p.
[0204] Therefore, in other words, the fourth aspect of miRNA inhibitors refers to miR-376c-3p and / or miR-199a miRNA inhibitors. Specifically, the fourth aspect of miRNA inhibitors refers to miR-376c-3p and miR-199a miRNA inhibitors, or miR-376c-3p or miR-199a miRNA inhibitors, or miR-376c-3p and miR-199a miRNA inhibitors.
[0205] In another specific embodiment, the miRNA inhibitors of miR199a-3p and miR-199a-5p mentioned herein comprise, or are composed of, cyclic oligonucleotides or miRNA sponges.
[0206] In another embodiment, the miRNA inhibitor of the fourth aspect is a miRNA inhibitor of miR-376c-3p and miR-199a, particularly wherein the miRNA inhibitor comprises or is composed of cyclic oligonucleotides or miRNA sponges. In another embodiment, the miRNA inhibitor of the fourth aspect is a miRNA inhibitor of miR-376c-3p and miR-199a-3p, particularly wherein the miRNA inhibitor comprises or is composed of cyclic oligonucleotides or miRNA sponges. In another embodiment, the miRNA inhibitor of the fourth aspect is a miRNA inhibitor of miR-376c-3p and miR-199a-5p, particularly wherein the miRNA inhibitor comprises or is composed of cyclic oligonucleotides or miRNA sponges. In another embodiment, the miRNA inhibitor of the fourth aspect is a miRNA inhibitor of miR-376c-3p, miR199a-3p, and miR-199a-5p, particularly wherein the miRNA inhibitor comprises or is composed of cyclic oligonucleotides or miRNA sponges.
[0207] In one embodiment, the miRNA inhibitor of the fourth aspect inhibits the activity of its target miRNA upon binding to it. In another specific embodiment, the miRNA inhibitor of the fourth aspect degrades or blocks (particularly by steric hindrance) its target miRNA upon binding to it. In yet another embodiment, compared to cases where the miRNA inhibitor does not bind to its miRNA target or where the miRNA inhibitor is absent, the miRNA inhibitor of the fourth aspect increases the gene expression of one or more mRNA targets of its target miRNA upon binding to it.
[0208] In a particular embodiment, the miRNA inhibitor of the fourth aspect binds specifically to its target miRNA, and more particularly, specifically to its miRNA target sequence. Therefore, in the embodiments, the term "binding" in the above embodiments or definitions may be replaced by "specific binding." The term "specific binding" has already been defined in Section 2.1 - Definitions above. In the embodiments, the miRNA inhibitor of the fourth aspect binds specifically to at least the seed region of its target miRNA, particularly to the seed region of its target miRNA. In another particular embodiment, the miRNA inhibitor of the fourth aspect binds specifically to at least the nucleotides at positions 2-8, 2-7, 3-7, or 3-8 in the 5' to 3' direction of its target miRNA, particularly at least to the nucleotides at positions 2-7 or 3-8. In a more specific embodiment, the miRNA inhibitor of the fourth aspect binds specifically to at least the nucleotides at positions 2-8 in the 5' to 3' direction of its target miRNA. In another specific embodiment, the miRNA inhibitor of the fourth aspect specifically binds to at least nucleotides at positions 3-7, 3-8, 3-9, 3-10, 3-11, 3-11, 3-12, 3-13, 3-14, 3-15, 3-16, 3-17, 3-18, 3-19, 3-20, 3-21, 3-22, or 3-23, particularly position 3-21, of its target miRNA in the 5' to 3' direction. In another specific embodiment, the miRNA inhibitor of the fourth aspect specifically binds to at least nucleotides at positions 2-7, 2-8, 2-9, 2-10, 2-11, 2-11, 2-12, 2-13, 2-14, 2-15, 2-16, 2-17, 2-18, 2-19, 2-20, 2-21, 2-22, or 2-23, of its target miRNA in the 5' to 3' direction. In another specific embodiment, the miRNA inhibitor of the fourth aspect specifically binds to at least the nucleotides at positions 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 1-11, 1-11, 1-12, 1-13, 1-14, 1-15, 1-16, 1-17, 1-18, 1-19, 1-20, 1-21, 1-22, or 1-23 of its target miRNA in the 5' to 3' direction, and in particular to all the nucleotides of its target miRNA.
[0209] In another specific embodiment, the miRNA inhibitor of the fourth aspect specifically binds to nucleotides at positions 3-7, 3-8, 2-7, or 2-8 of its target miRNA in the 5' to 3' direction, particularly nucleotides at positions 2-8. In another specific embodiment, the miRNA inhibitor of the fourth aspect specifically binds to nucleotides at positions 3-7, 3-8, 3-9, 3-10, 3-11, 3-11, 3-12, 3-13, 3-14, 3-15, 3-16, 3-17, 3-18, 3-19, 3-20, 3-21, 3-22, or 3-23 of its target miRNA in the 5' to 3' direction, particularly nucleotide 3-21. In another specific embodiment, the miRNA inhibitor of the fourth aspect specifically binds to nucleotides at positions 2-7, 2-8, 2-9, 2-10, 2-11, 2-11, 2-12, 2-13, 2-14, 2-15, 2-16, 2-17, 2-18, 2-19, 2-20, 2-21, 2-22, or 2-23 of its target miRNA in the 5' to 3' direction. In another specific embodiment, the miRNA inhibitor of the fourth aspect specifically binds to nucleotides at positions 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 1-11, 1-11, 1-12, 1-13, 1-14, 1-15, 1-16, 1-17, 1-18, 1-19, 1-20, 1-21, 1-22, or 1-23 of its target miRNA in the 5' to 3' direction, particularly all nucleotides of its target miRNA.
[0210] As indicated by the definition of "miRNA inhibitor," a miRNA inhibitor that specifically binds to, is base-paired with, or is complementary to its target miRNA should be understood herein to contain or consist of a nucleotide sequence or oligonucleotide that specifically binds to, is base-paired with, or is complementary to the target miRNA. As indicated above, the oligonucleotide is also referred to herein as a "miRNA inhibitor oligonucleotide."
[0211] More specifically, the fourth aspect of miRNA inhibitors are oligonucleotides as defined in this paper.
[0212] In another specific embodiment, the miRNA inhibitor of the fourth aspect comprises or is composed of an oligonucleotide that comprises or is composed of a nucleotide sequence that specifically binds to, or is composed of, the sequence of the target miRNA of the miRNA inhibitor, particularly the target miRNA of the miRNA inhibitor (also referred to herein as the target sequence of the miRNA inhibitor). In a more specific embodiment, the target sequence of the miRNA inhibitor corresponds to a nucleotide at any position of the target miRNA indicated in the above embodiments.
[0213] In a particular embodiment, the miRNA inhibitor of the fourth aspect comprises or is composed of an oligonucleotide comprising or is composed of a nucleotide sequence that is at least 30%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 97%, at least 99%, or 100% complementary to the miRNA target, particularly the target sequence of the miRNA inhibitor. In a more particular embodiment, the miRNA inhibitor of the fourth aspect comprises or is composed of an oligonucleotide comprising or is composed of a nucleotide sequence that is at least 70% complementary to the miRNA target, particularly the target sequence of the miRNA inhibitor. In another particular embodiment, the miRNA inhibitor of the fourth aspect comprises or is composed of an oligonucleotide comprising or is composed of a nucleotide sequence that is at least 75% complementary to the miRNA target, particularly the target sequence of the miRNA inhibitor. In another specific embodiment, the miRNA inhibitor of the fourth aspect comprises or is composed of an oligonucleotide that contains or is composed of a nucleotide sequence that is at least 80% complementary to the miRNA target, particularly the target sequence of the miRNA inhibitor. In another specific embodiment, the miRNA inhibitor of the fourth aspect comprises or is composed of an oligonucleotide that contains or is composed of a nucleotide sequence that is at least 85% complementary to the miRNA target, particularly the target sequence of the miRNA inhibitor. In another specific embodiment, the miRNA inhibitor of the fourth aspect comprises or is composed of an oligonucleotide that contains or is composed of a nucleotide sequence that is at least 90% complementary to the miRNA target, particularly the target sequence of the miRNA inhibitor. In another specific embodiment, the miRNA inhibitor of the fourth aspect comprises or is composed of an oligonucleotide that contains or is composed of a nucleotide sequence that is at least 95% complementary to the miRNA target, particularly the target sequence of the miRNA inhibitor. In another specific embodiment, the miRNA inhibitor of the fourth aspect comprises or is composed of an oligonucleotide that comprises or is composed of a nucleotide sequence that is 100% complementary to the miRNA target, particularly the target sequence of the miRNA inhibitor.
[0214] Methods for determining the percentage of complementarity between two nucleotide sequences are already provided in the definition of the term "specific binding".
[0215] In embodiments of the fourth aspect, the length of the miRNA inhibitor oligonucleotide is at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 27, at least 30, at least 32, at least 35, at least 40, at least 45, at least 50, at least 75, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 450, at least 500, at least 550, at least 600, at least 650, at least 700, at least 730, at least 740, at least 742, at least 750, at least 770, or at least 800 nucleotides. In a specific embodiment of the fourth aspect, the length of the miRNA inhibitor oligonucleotide is at least 15 nucleotides. In another specific embodiment, the miRNA inhibitor oligonucleotide is at least 19 nucleotides long. In another specific embodiment, the miRNA inhibitor oligonucleotide is at least 20 nucleotides long. In another specific embodiment, the miRNA inhibitor oligonucleotide is at least 21 nucleotides long. In yet another specific embodiment, the miRNA inhibitor oligonucleotide is at least 22 or at least 23 nucleotides long.
[0216] In another embodiment of the fourth aspect, the length of the miRNA inhibitor oligonucleotide is about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 30, 32, 35, 40, 45, 50, 75, 100, 150, 200, 250, 300, 400, 450, 500, 550, 600, 650, 700, 740, 742, 750, 770, or about 800 nucleotides. In a specific embodiment of the fourth aspect, the length of the miRNA inhibitor oligonucleotide is about 15 nucleotides. In another specific embodiment, the length of the miRNA inhibitor oligonucleotide is about 19 nucleotides. In another specific embodiment, the length of the miRNA inhibitor oligonucleotide is about 20 nucleotides. In another specific embodiment, the length of the miRNA inhibitor oligonucleotide is about 21 nucleotides. In another specific embodiment, the miRNA inhibitor oligonucleotide is about 22 or 23 nucleotides in length.
[0217] In another specific embodiment, the length of the miRNA inhibitor oligonucleotide is about 5-800, 5-750, 5-742, 5-740, 5-700, 5-650, 5-600, 5-500, 5-400, 5-300, 5-250, 5-200, 5-150, 5-100, 5-75, 5-50, 5-45, 5-40, 5-35, 5-30, 5-27, 5-25, 5-23, 5-22, 5-21, 5-20, 5-19, or 5-15 nucleotides. In another specific embodiment, the length of the miRNA inhibitor oligonucleotide is about 12-800, 12-750, 12-742, 12-740, 12-700, 12-650, 12-600, 12-500, 12-400, 12-300, 12-250, 12-200, 12-150, 12-100, 12-75, 12-50, 12-45, 12-40, 12-35, 12-30, 12-27, 12-25, 12-23, 12-22, 12-21, 12-20, 12-19, or 12-15 nucleotides. In another specific embodiment, the length of the miRNA inhibitor oligonucleotide is about 15-800, 15-750, 15-742, 15-740, 15-700, 15-650, 15-600, 15-500, 15-400, 15-300, 15-250, 15-200, 15-150, 15-100, 15-75, 15-50, 15-45, 15-40, 15-35, 15-30, 15-27, 15-25, 15-23, 15-22, 15-21, 15-20, or 15-19, particularly 15-23. In a more specific embodiment, the length of the miRNA inhibitor oligonucleotide is 15-22 nucleotides. In another more specific embodiment, the length of the miRNA inhibitor oligonucleotide is 15-21 nucleotides. In another, more specific embodiment, the miRNA inhibitor oligonucleotide is 15-20 nucleotides in length. In yet another, more specific embodiment, the miRNA inhibitor oligonucleotide is 15-19 nucleotides in length.
[0218] As used herein in the context of oligonucleotides, the term "length" is a term well known to those skilled in the art, and specifically refers to the number of nucleotides that form an oligonucleotide (i.e., from the 5' end to the 3' end of the oligonucleotide). In the case of cyclic oligonucleotides, the length of the oligonucleotide is the total number of nucleotides that form the cyclic oligonucleotide.
[0219] In another embodiment, the miRNA inhibitor oligonucleotide comprises ribonucleotides and deoxyribonucleotides, which are also referred to herein as RNA-DNA oligonucleotides. In a specific embodiment, the miRNA inhibitor oligonucleotide is an RNA-DNA oligonucleotide. In a specific embodiment, the miRNA inhibitor oligonucleotide comprises, or consists of, ribonucleotides and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 30, 35, 40, 45, 50, 100, 150, 200, 250, 300, 350, or 400 deoxyribonucleotides. In another specific embodiment, the miRNA inhibitor oligonucleotide comprises, or consists of, ribonucleotides and 1-400, 1-350, 1-300, 1-200, 1-150, 1-100, 1-75, 1-50, 1-40, 1-30, 1-25, 1-20, 1-17, 1-15, 1-12, 1-10, 1-7, or 1-5 deoxyribonucleotides.
[0220] In certain embodiments, the miRNA inhibitor oligonucleotide comprises, or consists of, nucleotide analogs bonded to each other. The term "nucleotide analog" has been defined above, and examples of such analogs that can be used in the miRNA inhibitor oligonucleotides described herein have been provided.
[0221] In another specific embodiment, the miRNA inhibitor oligonucleotide comprises or consists of ribonucleotide analogs bonded to each other. In yet another specific embodiment, the miRNA inhibitor oligonucleotide comprises or consists of ribonucleotides and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 30, 35, 40, 45, 50, 100, 150, 200, 250, 300, 350, or 400 nucleotide analogs. In another specific embodiment, the miRNA inhibitor oligonucleotide comprises, or consists of, a ribonucleotide and 1-400, 1-350, 1-300, 1-200, 1-150, 1-100, 1-75, 1-50, 1-40, 1-30, 1-25, 1-20, 1-17, 1-15, 1-12, 1-10, 1-7, or 1-5 nucleotide analogs.
[0222] In other embodiments, the miRNA inhibitor oligonucleotide comprises nucleotide analogs such as denitronucleotides, for example 7-denitroadenosine; O- and N-modified (e.g. alkylated, such as N6-methyladenosine) nucleotides; and other heterocyclic modified nucleotide analogs.
[0223] In a particular embodiment, a cholesterol group is added to the 5' or 3' end of the miRNA inhibitor oligonucleotide, particularly to the 3' end of the oligonucleotide.
[0224] In another specific embodiment, the miRNA inhibitor oligonucleotide comprises a nucleotide having a 2'-methoxy modification. As is well known to those skilled in the art, 2'-methoxy modification, 2'-O-methylation, or 2'-O-Me in a nucleotide consists of such common modifications in which a methyl group (i.e., a group with the chemical formula CH3) is added to the 2' hydroxyl group of the ribose portion of the nucleotide, particularly a ribonucleotide, to produce a methoxy group (-OCH3). In another specific embodiment, the miRNA inhibitor oligonucleotide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 30, 35, 40, 45, 50, 100, 150, 200, 300, 350, or 400 or all of the nucleotides having a 2'-methoxy modification. In a more specific embodiment, the miRNA inhibitor oligonucleotide comprises, or is composed of, a ribonucleotide having a 2'-methoxy modification. In another specific embodiment, the miRNA inhibitor oligonucleotide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 30, 35, 40, 45, 50, 100, 150, 200, 300, 350, or 400 or all of a ribonucleotide having a 2'-methoxy modification. In still more specific embodiments, all nucleotides of the miRNA inhibitor oligonucleotide are ribonucleotides having a 2'-methoxy modification.
[0225] In some embodiments, the miRNA inhibitor oligonucleotide comprises a phosphate-thioester backbone (i.e., the phosphodiester linker of the sugar-phosphate backbone is modified to a phosphate-thioester). In specific embodiments, the miRNA inhibitor oligonucleotide comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 30, 35, 40, 45, 50, 100, 150, 200, 300, 350, or 400 or all of the oligonucleotide bases having a phosphate-thioester backbone. In specific embodiments, the miRNA inhibitor oligonucleotide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 consecutive nucleotides, particularly 2 consecutive nucleotides, at the 5' end of the oligonucleotide having a phosphate-thioester backbone. In other specific embodiments, the miRNA inhibitor oligonucleotide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 consecutive nucleotides, particularly 4 consecutive nucleotides, at the 3' end of the oligonucleotide having a phosphate thioester backbone. In another embodiment, the miRNA inhibitor oligonucleotide comprises 2 consecutive nucleotides at the 5' end of the oligonucleotide having a phosphate thioester backbone, and 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 consecutive nucleotides, particularly 4 consecutive nucleotides, at the 3' end of the oligonucleotide. In yet another embodiment, the miRNA inhibitor oligonucleotide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 consecutive nucleotides, particularly 2 consecutive nucleotides, at the 5' end of the oligonucleotide having a phosphate thioester backbone, and 4 consecutive nucleotides at the 3' end of the oligonucleotide. In another embodiment, the miRNA inhibitor oligonucleotide comprises at least two consecutive nucleotides, particularly two consecutive nucleotides, at the 5' end of an oligonucleotide having a phosphate thioester backbone; and at least two consecutive nucleotides, particularly four consecutive nucleotides, at the 3' end of the oligonucleotide; and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 30, 35, 40, 45, 50, 100, 150, 200, 300, 350, or 400 additional nucleotides having a phosphate thioester backbone. In a particular embodiment, the nucleotides of the miRNA inhibitor oligonucleotide mentioned in this paragraph are deoxyribonucleotides or ribonucleotides, particularly ribonucleotides.
[0226] In embodiments, the miRNA inhibitor oligonucleotide comprises a phosphate-thioester backbone and additional modifications for enhancing resistance to ribonuclease. In a particular embodiment, the miRNA inhibitor oligonucleotide comprises at least one nucleotide having a 2'-methoxy modified structure and at least one nucleotide having a phosphate-thioester backbone. In a more specific embodiment, at least one nucleotide having a 2'-methoxy modified structure corresponds to the nucleotide having a 2'-methoxy modified structure indicated in any embodiment of the oligonucleotides having a 2'-methoxy modified structure defined above. In another embodiment, at least one nucleotide having a phosphate-thioester backbone corresponds to the nucleotide having a phosphate-thioester backbone indicated in any embodiment of the oligonucleotides having a phosphate-thioester backbone defined above. In a more specific embodiment, all nucleotides of the oligonucleotide comprise a 2'-methoxy modified structure, and at least one nucleotide has a phosphate-thioester backbone, particularly comprising the nucleotide having a phosphate-thioester backbone indicated in any embodiment of the preceding paragraph.
[0227] In another specific embodiment, the miRNA inhibitor oligonucleotide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 30, 35, 40, 45, 50, 100, 150, 200, 300, 350, or 400 or all of a nucleotide having a 2'-methoxy modified structure, and at least one nucleotide having a phosphate thioester backbone, particularly wherein the nucleotide having a phosphate thioester backbone corresponds to those nucleotides indicated in any embodiment of the oligonucleotide having a phosphate thioester backbone defined above. In still more specific embodiments, all nucleotides of the miRNA inhibitor oligonucleotide are ribonucleotides having a 2'-methoxy modification, and at least one nucleotide of the oligonucleotide has a phosphate-thioester backbone, particularly wherein the nucleotide having the phosphate-thioester backbone corresponds to those nucleotides indicated in any of the embodiments of the oligonucleotide having the phosphate-thioester backbone defined above. In even more specific embodiments, the nucleotide of the miRNA inhibitor oligonucleotide as defined in this paragraph is a deoxyribonucleotide or a ribonucleotide, particularly a ribonucleotide. In another specific embodiment, the miRNA inhibitor oligonucleotide as defined in this paragraph includes a cholesterol group at the 5' or 3' end of the oligonucleotide (particularly at the 3' end). In yet another specific embodiment, the miRNA inhibitor oligonucleotide as defined in this paragraph includes cholesterol groups at both the 5' and 3' ends of the oligonucleotide.
[0228] In another specific embodiment, the 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 consecutive nucleotides, particularly two consecutive nucleotides, at the 5' end of the oligonucleotide have a phosphate thioester backbone, and all nucleotides of the oligonucleotide are 2'-methoxy modified, more particularly wherein all nucleotides of the miRNA inhibitor oligonucleotide are ribonucleotides. In another specific embodiment, the 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 consecutive nucleotides, particularly four consecutive nucleotides, at the 3' end of the oligonucleotide have a phosphate thioester backbone, and all nucleotides of the oligonucleotide are 2'-methoxy modified, more particularly wherein all nucleotides of the miRNA inhibitor oligonucleotide are ribonucleotides. In another specific embodiment, at least two consecutive nucleotides, particularly two consecutive nucleotides, at the 5' end of the oligonucleotide and at least two consecutive nucleotides, particularly four consecutive nucleotides, at the 3' end of the oligonucleotide have a phosphate thioester backbone, and all nucleotides of the oligonucleotide are 2'-methoxy modified, more particularly wherein all nucleotides of the miRNA inhibitor oligonucleotide are ribonucleotides. In a more specific embodiment, the miRNA inhibitor oligonucleotide as defined in this paragraph includes a cholesterol group at the 5' or 3' end of the oligonucleotide (particularly at the 3' end). In another specific embodiment, the miRNA inhibitor oligonucleotide as defined in this paragraph includes cholesterol groups at both the 5' and 3' ends of the oligonucleotide.
[0229] In this embodiment, the miRNA inhibitor oligonucleotide is any oligonucleotide described in the definition of “oligonucleotide” in Section 2.1 of the previous article.
[0230] In a specific embodiment of the fourth aspect, the miRNA inhibitor oligonucleotide is selected from the list consisting of: anti-miRNA oligonucleotides (AMO), cyclic oligonucleotides, miRNA sponges, and strong decoys (TuD). Definitions for each of these terms have been provided in Section 2.1 - Definitions above.
[0231] In more specific embodiments, the miRNA inhibitor oligonucleotide is an anti-miRNA oligonucleotide (AMO) or a cyclic oligonucleotide, particularly AMO.
[0232] In another specific embodiment, the miRNA inhibitor oligonucleotide is an AMO selected from the list consisting of LNA-AMO, PS-AMO, PNA-AMO, PMO-AMO, and ZEN-AMO. The definition of each of these terms has been provided in Section 2.1 - Definitions above.
[0233] In even more specific embodiments, the miRNA inhibitor oligonucleotide is AMO, wherein all nucleotides of the AMO are 2'-methoxy modified. In another specific embodiment, the miRNA inhibitor oligonucleotide is AMO, wherein all nucleotides of the AMO are 2'-methoxy modified; at least two, particularly two consecutive nucleotides at the 5' end of the miRNA inhibitor oligonucleotide have a phosphate thioester backbone; at least two, particularly four consecutive nucleotides at the 3' end of the miRNA inhibitor oligonucleotide have a phosphate thioester backbone; and wherein a cholesterol group is attached to the 3' end of the oligonucleotide. In specific embodiments, the nucleotide of the AMO miRNA inhibitor as defined in this paragraph is a ribonucleotide.
[0234] In a specific embodiment, the miR-376c-3p miRNA inhibitor has SEQ ID NO. 1. In a specific embodiment, the miR-376c-3p miRNA inhibitor comprises or is composed of an oligonucleotide containing, or is composed of, a nucleotide sequence exhibiting at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, or 100% sequence identity with SEQ ID NO. 1. In another specific embodiment, the miR-376c-3p miRNA inhibitor has SEQ ID NO. 14. In a specific embodiment, the miR-376c-3p miRNA inhibitor comprises or is composed of an oligonucleotide containing, or is composed of, a nucleotide sequence exhibiting at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 99%, or 100% sequence identity with SEQ ID NO. 14. The above text has provided a method for determining sequence identity between two nucleotide sequences.
[0235] In another specific embodiment, the miRNA inhibitor of miR-199a-3p has SEQ ID NO. 2. In a specific embodiment, the miRNA inhibitor of miR-199a-3p comprises or is composed of an oligonucleotide that contains or is composed of a nucleotide sequence exhibiting at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 99%, or 100% sequence identity with SEQ ID NO. 2. In another specific embodiment, the miRNA inhibitor of miR-199a-3p has SEQ ID NO. 15. In a particular embodiment, the miRNA inhibitor of miR-199a-3p comprises or is composed of an oligonucleotide that comprises or is composed of a nucleotide sequence that exhibits at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 99%, or 100% sequence identity with SEQ ID NO. 15.
[0236] In another specific embodiment, the miR-199a-5p miRNA inhibitor has SEQ ID NO. 13. In a specific embodiment, the miR-199a-5p miRNA inhibitor comprises or is composed of an oligonucleotide containing, or is composed of, a nucleotide sequence exhibiting at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 99%, or 100% sequence identity with SEQ ID NO. 13. In another specific embodiment, the miR-199a-5p miRNA inhibitor has SEQ ID NO. 19. In a particular embodiment, the miRNA inhibitor of miR-199a-5p comprises or is composed of an oligonucleotide that comprises or is composed of a nucleotide sequence that exhibits at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 99%, or 100% sequence identity with SEQ ID NO. 19.
[0237] In another embodiment, the miRNA inhibitor oligonucleotide is a circular miRNA inhibitor having at least one miRNA target, particularly at least two miRNA targets, and more particularly at least three miRNA targets. In a more specific embodiment, the miRNA inhibitor comprises, or is composed of, a circular miRNA inhibitor or miRNA sponge having miRNA targets including miR-376c-3p and miR-199a, or is composed of thereof. In a more specific embodiment, the miRNA inhibitor comprises, or is composed of, a circular miRNA inhibitor or miRNA sponge having miRNA targets including miR-376c-3p and miR-199a-3p, or is composed of thereof. In another more specific embodiment, the miRNA inhibitor oligonucleotide comprises, or is composed of, a circular miRNA inhibitor or miRNA sponge having miRNA targets including miR-376c-3p and miR-199a-5p, or is composed of thereof. In another, more specific embodiment, the miRNA inhibitor oligonucleotide comprises, or is composed of, a circular miRNA inhibitor or miRNA sponge having a miRNA target comprising, or is composed of, miR-376c-3p, miR-199a-3p, and miR-199a-5p.
[0238] In another embodiment, the miRNA inhibitors of miR-376c-3p and miR-199a comprise, or are composed of, a circular miRNA inhibitor or a miRNA sponge. In a specific embodiment, the miRNA inhibitors of miR-376c-3p and miR-199a-3p comprise, or are composed of, a circular miRNA inhibitor or a miRNA sponge. In another specific embodiment, the miRNA inhibitors of miR-376c-3p and miR-199a-5p comprise, or are composed of, a circular miRNA inhibitor or a miRNA sponge.
[0239] In a still more specific embodiment of the fourth aspect, the miRNA inhibitors of miR-376c-3p and miR-199a comprise, or consist of, SEQ ID NO. 6. In a particular embodiment, the miRNA inhibitors of miR-376c-3p and miR199a, particularly miR199a-5p, comprise, or consist of, an oligonucleotide containing, or consist of, a nucleotide sequence exhibiting, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% sequence identity with SEQ ID NO. 6. In another specific embodiment, the miRNA inhibitors of miR-376c-3p, miR199-5p, and miR199-3p comprise or are composed of oligonucleotides containing nucleotide sequences exhibiting at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 99% sequence identity with SEQ ID NO. 6. In a specific embodiment, the miRNA inhibitor comprising or composed of SEQ ID NO. 6 is a circular miRNA inhibitor or a miRNA sponge.
[0240] In the fourth aspect of the embodiment, stroke refers to ischemic stroke.
[0241] In a specific embodiment of the fourth aspect, the patient is a Caucasian subject, particularly a European or European-American subject. In another specific embodiment, the patient is a non-Asian subject.
[0242] 2.3 Combinations of miRNA inhibitors used for the treatment or prevention of stroke in patients In a fifth aspect, the present invention relates to a combination of miRNA inhibitors for use in the treatment or prevention of stroke in a patient, wherein the combination of miRNA inhibitors comprises miRNA inhibitors as defined in the fourth aspect, and further comprises: - A miRNA inhibitor that targets miRNAs selected from the group consisting of miR134-5p, miR-4463, miR-584-5p, and combinations thereof. - Two miRNA inhibitors, each of which is a miRNA inhibitor selected from different miRNAs in the group consisting of miR134-5p, miR-4463, miR-584-5p, and combinations thereof. - Three miRNA inhibitors, each of which is a miRNA inhibitor selected from different miRNAs in the group consisting of miR134-5p, miR-4463, miR-584-5p and combinations thereof, and in particular, each miRNA inhibitor is a miRNA inhibitor selected from different miRNAs in the group consisting of miR134-5p, miR-4463 and miR-584-5p.
[0243] The terms “miRNA inhibitor,” “treatment,” “prevention,” “stroke,” and “patient” have been defined above, particularly in section 1 – Method of the Invention,” section 2.1 – Definitions, or in the fourth aspect of the invention, and are applicable to the fifth aspect of the invention.
[0244] In certain embodiments, all definitions and embodiments of the first, second, third, and fourth aspects are equally applicable to the fifth aspect of the invention.
[0245] All definitions and examples provided in this disclosure for miRNA inhibitors of the fourth aspect of the invention are equally applicable to combinations of miRNA inhibitors of the fifth aspect of the invention.
[0246] In one embodiment, the definition and examples of the miRNA inhibitors of the fourth aspect also apply to at least one miRNA inhibitor of the fifth aspect. In another embodiment, the definition and examples of the miRNA inhibitors of the fourth aspect also apply to at least two miRNA inhibitors of the fifth aspect. In another embodiment, the definition and examples of the miRNA inhibitors of the fourth aspect also apply to at least three miRNA inhibitors of the fifth aspect. In another embodiment, the definition and examples of the miRNA inhibitors of the fourth aspect also apply to at least four miRNA inhibitors of the fifth aspect. In yet another embodiment, the definition and examples of the miRNA inhibitors of the fourth aspect also apply to all miRNA inhibitors of the fifth aspect.
[0247] In one embodiment, the definition and examples of the miRNA inhibitor in the fourth aspect also apply to one miRNA inhibitor in the fifth aspect. In another embodiment, the definition and examples of the miRNA inhibitor in the fourth aspect also apply to two miRNA inhibitors in the fifth aspect. In another embodiment, the definition and examples of the miRNA inhibitor in the fourth aspect also apply to three miRNA inhibitors in the fifth aspect. In yet another embodiment, the definition and examples of the miRNA inhibitor in the fourth aspect also apply to four miRNA inhibitors in the fifth aspect.
[0248] In a particular embodiment, the combination of miRNA inhibitors in the fifth aspect comprises miRNA inhibitors as defined in the fourth aspect, and further comprises miRNA inhibitors selected from miR134-5p, miR-4463, miR-584-5p and combinations thereof, particularly miRNA inhibitors selected from the group consisting of miR134-5p, miR-4463, and miR-584-5p.
[0249] In another specific embodiment, the combination of miRNA inhibitors in the fifth aspect comprises miRNA inhibitors as defined in the fourth aspect, and further comprises two miRNA inhibitors, each of which is a miRNA inhibitor selected from the group consisting of miR134-5p, miR-4463, miR-584-5p and combinations thereof, particularly a miRNA inhibitor selected from the group consisting of different miRNAs of miR134-5p, miR-4463, miR-584-5p.
[0250] In another specific embodiment, the combination of miRNA inhibitors in the fifth aspect comprises miRNA inhibitors as defined in the fourth aspect, and further comprises three miRNA inhibitors, each of which is a miRNA inhibitor of a different miRNA selected from the group consisting of miR134-5p, miR-4463, miR-584-5p and combinations thereof, particularly wherein each miRNA inhibitor is a miRNA inhibitor of a different miRNA selected from the group consisting of miR134-5p, miR-4463 and miR-584-5p.
[0251] In one embodiment, the combination of miRNA inhibitors in the fifth aspect comprises two miRNA inhibitors, each targeting a different miRNA selected from the list consisting of miR-376c-3p and miR134-5p. In another embodiment, the combination of miRNA inhibitors in the fifth aspect comprises two miRNA inhibitors, each targeting a different miRNA selected from the list consisting of miR-376c-3p and miR-4463. In another embodiment, the combination of miRNA inhibitors in the fifth aspect comprises two miRNA inhibitors, each targeting a different miRNA selected from the list consisting of miR-376c-3p and miR-584-5p. In yet another embodiment, the combination of miRNA inhibitors in the fifth aspect comprises four miRNA inhibitors, each targeting a different miRNA selected from the list consisting of miR-376c-3p, miR134-5p, and miR-4463. In another embodiment, the combination of miRNA inhibitors in the fifth aspect comprises four miRNA inhibitors, each targeting a different miRNA selected from the list consisting of miR-376c-3p, miR134-5p, and miR-584-5p. In another embodiment, the combination of miRNA inhibitors in the fifth aspect comprises three miRNA inhibitors, each targeting a different miRNA selected from the list consisting of miR-376c-3p, miR-4463, and miR-584-5p. In yet another embodiment, the combination of miRNA inhibitors in the fifth aspect comprises four miRNA inhibitors, each targeting a different miRNA selected from the list consisting of miR-376c-3p, miR134-5p, miR-4463, and miR-584-5p.
[0252] In another embodiment, the combination of miRNA inhibitors in the fifth aspect comprises two miRNA inhibitors, each targeting a different miRNA selected from the list consisting of miR-199a and miR134-5p. In another embodiment, the combination of miRNA inhibitors in the fifth aspect comprises two miRNA inhibitors, each targeting a different miRNA selected from the list consisting of miR-199a and miR-4463. In another embodiment, the combination of miRNA inhibitors in the fifth aspect comprises two miRNA inhibitors, each targeting a different miRNA selected from the list consisting of miR-199a, miR134-5p, and miR-4463. In yet another embodiment, the combination of miRNA inhibitors in the fifth aspect comprises three miRNA inhibitors, each targeting a different miRNA selected from the list consisting of miR-199a, miR134-5p, and miR-4463. In another embodiment, the combination of miRNA inhibitors in the fifth aspect comprises three miRNA inhibitors, each targeting a different miRNA selected from the list consisting of miR-199a, miR134-5p, and miR-584-5p. In another embodiment, the combination of miRNA inhibitors in the fifth aspect comprises three miRNA inhibitors, each targeting a different miRNA selected from the list consisting of miR-199a, miR-4463, and miR-584-5p.
[0253] In another embodiment, the combination of miRNA inhibitors in the fifth aspect comprises three miRNA inhibitors, each targeting a different miRNA selected from the list consisting of miR-376c-3p, miR-199a, and miR-4463. In another embodiment, the combination of miRNA inhibitors in the fifth aspect comprises three miRNA inhibitors, each targeting a different miRNA selected from the list consisting of miR-376c-3p, miR-199a, and miR134-5p. In another embodiment, the combination of miRNA inhibitors in the fifth aspect comprises three miRNA inhibitors, each targeting a different miRNA selected from the list consisting of miR-376c-3p, miR-199a, and miR-584-5p. In yet another embodiment, the combination of miRNA inhibitors in the fifth aspect comprises four miRNA inhibitors, each targeting a different miRNA selected from the list consisting of miR-376c-3p, miR-199a, miR-4463, and miR134-5p. In another embodiment, the combination of miRNA inhibitors in the fifth aspect comprises four miRNA inhibitors, each targeting a different miRNA selected from the list consisting of miR-376c-3p, miR-199a, miR-4463, and miR-584-5p. In another embodiment, the combination of miRNA inhibitors in the fifth aspect comprises four miRNA inhibitors, each targeting a different miRNA selected from the list consisting of miR-376c-3p, miR-199a, miR134-5p, and miR-584-5p. In yet another embodiment, the combination of miRNA inhibitors in the fifth aspect comprises five miRNA inhibitors, each targeting a different miRNA selected from the list consisting of miR-376c-3p, miR-199a, miR134-5p, miR-4463, and miR-584-5p.
[0254] In one embodiment, the miRNA inhibitor targeting miR-376c-3p in any embodiment of the fifth aspect also targets miR-199a, particularly wherein the miRNA inhibitor comprises or is composed of a cyclic oligonucleotide or a miRNA sponge. In another embodiment, the miRNA inhibitor targeting miR-376c-3p in any embodiment of the fifth aspect also targets miR-199a-5p, particularly wherein the miRNA inhibitor comprises or is composed of a cyclic oligonucleotide or a miRNA sponge. In another embodiment, the miRNA inhibitor targeting miR-376c-3p in any embodiment of the fifth aspect also targets miR-199a-3p, particularly wherein the miRNA inhibitor comprises or is composed of a cyclic oligonucleotide or a miRNA sponge. In yet another embodiment, the miRNA inhibitor targeting miR-376c-3p in any embodiment of the fifth aspect also targets miR-199a-5p and miR-199a-3p, particularly wherein the miRNA inhibitor comprises or is composed of a cyclic oligonucleotide or a miRNA sponge.
[0255] In a specific embodiment, the miRNA inhibitor of miR-376c-3p has SEQ ID NO. 1. In a specific embodiment, the miRNA inhibitor of miR-376c-3p comprises or is composed of an oligonucleotide containing, or is composed of, a nucleotide sequence exhibiting at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 97%, at least 99%, or 100% sequence identity with SEQ ID NO. 1. In another specific embodiment, the miRNA inhibitor of miR-376c-3p has SEQ ID NO. 14. In a particular embodiment, the miRNA inhibitor of miR-376c-3p comprises or is composed of an oligonucleotide that comprises or is composed of a nucleotide sequence exhibiting at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 97%, at least 99%, or 100% sequence identity with SEQ ID NO. 14. Methods for determining sequence identity between two nucleotide sequences have been provided above.
[0256] In another specific embodiment, the miRNA inhibitor of miR-199a-3p has SEQ ID NO. 2. In a specific embodiment, the miRNA inhibitor of miR-199a-3p comprises or is composed of an oligonucleotide that contains or is composed of a nucleotide sequence exhibiting at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 97%, at least 99%, or 100% sequence identity with SEQ ID NO. 2. In another specific embodiment, the miRNA inhibitor of miR-199a-3p has SEQ ID NO. 15. In a particular embodiment, the miRNA inhibitor of miR-199a-3p comprises or is composed of an oligonucleotide that comprises or is composed of a nucleotide sequence that exhibits at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 97%, at least 99%, or 100% sequence identity with SEQ ID NO. 15.
[0257] In another specific embodiment, the miR134-5p miRNA inhibitor has SEQ ID NO. 3. In a specific embodiment, the miR134-5p miRNA inhibitor comprises or is composed of an oligonucleotide that contains or is composed of a nucleotide sequence exhibiting at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 97%, at least 99%, or 100% sequence identity with SEQ ID NO. 3. In another specific embodiment, the miR134-5p miRNA inhibitor has SEQ ID NO. 16. In a particular embodiment, the miRNA inhibitor of miR134-5p comprises or is composed of an oligonucleotide that comprises or is composed of a nucleotide sequence that exhibits at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 97%, at least 99%, or 100% sequence identity with SEQ ID NO. 16.
[0258] In another specific embodiment, the miRNA inhibitor of miR-4463 has SEQ ID NO. 4. In a specific embodiment, the miRNA inhibitor of miR-4463 comprises or is composed of an oligonucleotide containing, or is composed of, a nucleotide sequence exhibiting at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 97%, at least 99%, or 100% sequence identity with SEQ ID NO. 4. In another specific embodiment, the miRNA inhibitor of miR-4463 has SEQ ID NO. 17. In a particular embodiment, the miRNA inhibitor of miR-4463 comprises or is composed of an oligonucleotide that comprises or is composed of a nucleotide sequence that exhibits at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 97%, at least 99%, or 100% sequence identity with SEQ ID NO. 17.
[0259] In another specific embodiment, the miR-584-5p miRNA inhibitor has SEQ ID NO. 5. In a specific embodiment, the miR-584-5p miRNA inhibitor comprises or is composed of an oligonucleotide that comprises or is composed of a nucleotide sequence showing at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 97%, at least 99%, or 100% sequence identity with SEQ ID NO. 5. In another specific embodiment, the miR-584-5p miRNA inhibitor has SEQ ID NO. 18. In a particular embodiment, the miRNA inhibitor of miR-584-5p comprises or is composed of an oligonucleotide that comprises or is composed of a nucleotide sequence that exhibits at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 97%, at least 99%, or 100% sequence identity with SEQ ID NO. 18.
[0260] In another specific embodiment, the miRNA inhibitors of miR-376c-3p and miR-199a-5p have SEQ ID NO. 6. In another specific embodiment of the fourth aspect, the miRNA inhibitors of miR-376c-3p and miR-199a comprise or consist of an oligonucleotide comprising or consisting of a circular miRNA inhibitor having SEQ ID NO. 6. In a specific embodiment, the miRNA inhibitors of miR-376c-3p and miR-199a (particularly miR-199a-5p) comprise or consist of an oligonucleotide comprising or consisting of a nucleotide sequence showing at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 97%, at least 99%, or 100% sequence identity with SEQ ID NO. 6. In a particular embodiment, the miRNA inhibitors of miR-376c-3p and miR-199a (especially miR-199a-3p) comprise oligonucleotides containing, or consisting of, a nucleotide sequence exhibiting at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 97%, or at least 99% sequence identity with SEQ ID NO. 6. In another particular embodiment, the miRNA inhibitors of miR-376c-3p, miR-199-5p, and miR-199-3p comprise oligonucleotides containing a nucleotide sequence exhibiting at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 97%, or at least 99% or 100% sequence identity with SEQ ID NO. 6.
[0261] In a particular embodiment of the fifth aspect, the combination of miRNAs consists of the combination of miRNAs indicated in any embodiment of the fifth aspect.
[0262] In a particular embodiment of the fifth aspect, when the combination of miRNAs comprises an inhibitor targeting miR-134-5p, treatment is preferably administered to female subjects. In a sixth aspect, the present invention relates to a pharmaceutical composition for use in the treatment or prevention of stroke, the pharmaceutical composition comprising a miRNA inhibitor as defined in the fourth aspect or a combination of miRNA inhibitors as defined in the fifth aspect.
[0263] The terms “pharmaceutical composition”, “pharmaceuticalally acceptable carrier”, “treatment”, “prevention”, and “stroke” have been defined in section “1 - Method of the Invention” or section “2.1 - Definitions”, and also apply to aspect VII.
[0264] In the embodiments, all definitions and embodiments of the foregoing aspects also apply to the sixth aspect.
[0265] 3 - Other aspects The seventh aspect of the invention relates to the use of at least one miRNA selected from the group consisting of miR-376c-3p, miR-199a and combinations thereof as a prognostic biomarker for patients with stroke, or as a biomarker for determining or recommending whether to initiate a medical program for patients with stroke, or as a biomarker for determining the response of a patient already diagnosed with stroke to a medical program for treating stroke.
[0266] The eighth aspect of the invention relates to the use of a kit for the prognosis of patients with stroke, or for determining or recommending whether to initiate a medical program for patients with stroke, or for determining the response of patients already diagnosed with stroke to a medical program for treating stroke, the kit comprising components for detecting the level of at least one miRNA selected from a list consisting of miR-376c-3p, miR-199a, and combinations thereof, and optionally a solid support.
[0267] In a particular embodiment, the seventh aspect further includes the use of at least one additional miRNA selected from the list comprising miR134-5p, miR-4463, miR-584-5p, and combinations thereof as a biomarker, as indicated in the seventh aspect above. In another particular embodiment of the seventh aspect, the one or more miRNAs used as biomarkers in the seventh aspect are any of the combinations of miRNAs whose expression levels are determined in step (i) of the first or second aspect of the invention.
[0268] In another specific embodiment, the eighth aspect further includes the use of a kit as indicated in the eighth aspect above, wherein the kit further comprises a component for detecting at least one additional miRNA selected from the list consisting of miR134-5p, miR-4463, miR-584-5p, and combinations thereof. In another specific embodiment of the eighth aspect, one or more miRNAs that can be detected by the miRNA detection component of the kit are any of the miRNA combinations for which their expression levels are determined in the first or second aspect of the invention, or any of the miRNA combinations for the use of the invention.
[0269] The ninth aspect of the present invention relates to a miRNA inhibitor targeting miRNAs selected from the list consisting of miR-376c-3p, miR-199a, miR134-5p, miR-4463, miR-584-5p, and combinations thereof, for the treatment or prevention of stroke in patients.
[0270] In certain embodiments, all definitions and embodiments of the fourth aspect of the invention also apply to the ninth aspect.
[0271] The tenth aspect of the invention relates to an in vitro method for the prognosis and treatment of stroke in patients, the method comprising steps (i) and (ii) as defined in the first aspect of the invention, and (iii) administering treatment to a patient deemed to have a poor prognosis, particularly wherein the treatment is selected from stroke treatments indicated in the definition of “treatment” or “medical regimen” above.
[0272] The eleventh aspect of the present invention relates to an in vitro method for treating stroke, the method comprising administering to a patient in need a therapeutically effective amount of a miRNA inhibitor as defined in the fourth or ninth aspect of the present invention, a combination of miRNA inhibitors as defined in the fifth or twelfth aspect of the present invention, or a pharmaceutical composition as defined in the sixth or thirteenth aspect of the present invention.
[0273] The twelfth aspect relates to a combination of miRNA inhibitors for use in the treatment or prevention of stroke in patients, wherein the combination of miRNA inhibitors comprises at least one, particularly one, miRNA inhibitor targeting a miRNA selected from miR-376c-3p, miR-199a, miR134-5p, miR-4463, miR-584-5p, and combinations thereof. In a specific embodiment of the twelfth aspect, the combination of miRNA inhibitors comprises at least two, particularly two, miRNA inhibitors, each of which is a miRNA inhibitor of a different miRNA selected from miR-376c-3p, miR-199a, miR134-5p, miR-4463, miR-584-5p, and combinations thereof. In another specific embodiment of the twelfth aspect, the combination of miRNA inhibitors comprises at least three, particularly three miRNA inhibitors, each of which is a miRNA inhibitor selected from different miRNAs selected from miR-376c-3p, miR-199a, miR134-5p, miR-4463, miR-584-5p, and combinations thereof. In another specific embodiment of the twelfth aspect, the combination of miRNA inhibitors comprises at least four, particularly four miRNA inhibitors, each of which is a miRNA inhibitor selected from different miRNAs selected from miR-376c-3p, miR-199a, miR134-5p, miR-4463, miR-584-5p, and combinations thereof.
[0274] In a specific embodiment of the twelfth aspect, the combination of miRNA inhibitors comprises at least one miRNA inhibitor that inhibits miRNAs selected from the list consisting of miR-376c-3p, miR-199a, miR134-5p, miR-4463, miR-584-5p, and combinations thereof, particularly wherein miR199a is miR199a-3p. In a specific embodiment of the twelfth aspect, the combination of miRNA inhibitors comprises a miRNA inhibitor that inhibits miR199a, particularly miR199a-3p. In another specific embodiment of the twelfth aspect, the combination of miRNA inhibitors comprises a miRNA inhibitor that inhibits miR-376c-3p. In yet another specific embodiment of the twelfth aspect, the combination of miRNA inhibitors comprises a miRNA inhibitor that inhibits miR199a, particularly miR199a-3p, and a miRNA inhibitor that inhibits miR-376c-3p. In another specific embodiment of the twelfth aspect, the combination of miRNA inhibitors comprises a miRNA inhibitor that inhibits miR199a, particularly miR199a-3p, and at least one miRNA inhibitor that inhibits miRNAs selected from the list consisting of miR-376c-3p, miR134-5p, miR-4463, miR-584-5p, and combinations thereof. In another specific embodiment of the twelfth aspect, the combination of miRNA inhibitors comprises a miRNA inhibitor that inhibits miR-376c-3p, and at least one miRNA inhibitor that inhibits miRNAs selected from the list consisting of miR-199a, miR134-5p, miR-4463, miR-584-5p, and combinations thereof, particularly wherein miR199a is miR199a-3p. In another specific embodiment of the twelfth aspect, the combination of miRNA inhibitors comprises a miRNA inhibitor that inhibits miR199a, particularly miR199a-3p, and a miRNA inhibitor that inhibits miR-376c-3p, as well as at least one miRNA inhibitor that inhibits miRNAs selected from the list consisting of miR134-5p, miR-4463, and miR-584-5p. In another specific embodiment of the twelfth aspect, the combination of miRNAs consists of the combination of miRNAs indicated in any embodiment of this disclosure, particularly in the embodiments of the twelfth aspect.
[0275] In a particularly preferred embodiment, the embodiments and definitions of the fourth and fifth aspects also apply to the twelfth aspect. In a particular embodiment, all definitions and embodiments of the fifth aspect of the invention also apply to the twelfth aspect.
[0276] In a thirteenth aspect, the present invention relates to a pharmaceutical composition for use in the treatment or prevention of stroke, the pharmaceutical composition comprising a miRNA inhibitor as defined in the fourth or ninth aspect, or a combination of miRNA inhibitors as defined in the fifth or twelfth aspect.
[0277] In certain embodiments, all definitions and embodiments of the sixth aspect of the invention also apply to the thirteenth aspect.
[0278] In the fourteenth aspect, the present invention relates to the use of miRNA inhibitors as defined in the fourth or ninth aspect, or combinations of miRNA inhibitors as defined in the fifth or twelfth aspect, or pharmaceutical compositions as defined in the sixth or thirteenth aspect, in the manufacture of a medicament for the treatment of stroke.
[0279] In a fifteenth aspect, the present invention relates to an in vitro method for determining the prognosis of a patient suffering from stroke, the method comprising: (i) Determine the expression level of at least one miRNA selected from the group consisting of miR-376c-3p, miR-199a, miR134-5p, miR-4463, miR-584-5p and combinations thereof in samples isolated from the patient. (ii) Compare the expression level obtained in step (i) with the corresponding reference value. If the expression level determined in step (i) is higher than the corresponding reference value, the patient is considered to have a poor prognosis.
[0280] In certain embodiments, all definitions and embodiments of the first aspect of the invention also apply to the fifteenth aspect.
[0281] In a sixteenth aspect, the present invention relates to an in vitro method for determining or recommending whether to initiate a medical program for a patient suffering from stroke, the method comprising the following steps: (i) Determine the expression level of at least one miRNA selected from the group consisting of miR-376c-3p, miR-199a, miR134-5p, miR-4463, miR-584-5p and combinations thereof in samples isolated from the patient. (ii) Compare the expression level obtained in step (i) with the corresponding reference value. If the expression level determined in step (i) is higher than the corresponding reference value, then the decision is made or the initiation of the medical treatment plan is recommended.
[0282] In certain embodiments, all definitions and embodiments of the second aspect of the invention also apply to the fifteenth aspect.
[0283] In a seventeenth aspect, the present invention relates to an in vitro method for determining the response of a patient diagnosed with stroke to a medical regimen for treating stroke, the method comprising the steps of: (i) Determine the expression level of at least one miRNA selected from the group consisting of miR-376c-3p, miR-199a, miR134-5p, miR-4463, miR-584-5p and combinations thereof in samples isolated from the patient. (ii) Compare the expression levels obtained in step (i) with the expression levels of the same one or more miRNAs identified at the start of the treatment regimen or at an earlier stage of the treatment regimen. A decrease in the expression level of one or more miRNAs relative to their expression levels at the start of the treatment or at an earlier stage of the treatment indicates a good response to the treatment.
[0284] In certain embodiments, all definitions and embodiments of the third aspect of the invention also apply to the seventeenth aspect.
[0285] The eighteenth aspect of the invention relates to the use of at least one miRNA selected from the group consisting of miR-376c-3p, miR-199a, miR134-5p, miR-4463, miR-584-5p, and combinations thereof as a prognostic biomarker for patients with stroke, or as a biomarker for determining or recommending the initiation of a medical protocol for patients with stroke, or as a biomarker for determining the response of a patient already diagnosed with stroke to a medical protocol for treating stroke. In certain embodiments, all definitions and embodiments of the seventh aspect of the invention also apply to the eighteenth aspect.
[0286] The nineteenth aspect of the invention relates to the use of a kit for the prognosis of patients with stroke, or for determining or recommending the initiation of a medical protocol for patients with stroke, or for determining the response of a patient already diagnosed with stroke to a medical protocol for treating stroke. The kit comprises components for detecting the level of at least one miRNA selected from the list of miR-376c-3p, miR-199a, miR134-5p, miR-4463, miR-584-5p, and combinations thereof, and optionally a solid support. In certain embodiments, all definitions and embodiments of the eighth aspect of the invention also apply to the nineteenth aspect.
[0287] All definitions and embodiments of the first, second, third, fourth, fifth, and sixth aspects of this invention also apply to the aspects defined in Section 3 of this chapter.
[0288] Throughout this specification and claims, the word "comprising" and variations thereof are not intended to exclude other technical features, additives, components, or steps. Furthermore, the word "comprising" covers situations where it means "composed of". In another specific embodiment, a miRNA inhibitor having SEQ ID NO. or having SEQ ID NO. as mentioned in this disclosure should be understood as a miRNA inhibitor composed of said SEQ ID NO. In another specific embodiment, a miRNA having SEQ ID NO. or having SEQ ID NO. as mentioned in this disclosure should be understood as a miRNA composed of said SEQ ID NO.
[0289] Other objects, advantages, and features of the invention will become apparent to those skilled in the art upon review of this specification, or may be learned through practice of the invention. The following examples are provided by way of illustration and are not intended to limit the invention. Furthermore, the invention covers all possible combinations of the specific and preferred embodiments described herein.
[0290] For completeness, this specification also discloses examples in the following numbered embodiments: 1- An in vitro method for determining the prognosis of a patient with stroke, the method comprising: (i) Determine the expression level of at least one miRNA selected from miR-376c-3p, miR-199a, miR134-5p, miR-4463, miR-584-5p and combinations thereof in samples isolated from the patient, particularly selecting from miR-376c-3p, miR-199a and combinations thereof. (ii) Compare the expression level obtained in step (i) with the corresponding reference value. If the expression level determined in step (i) is higher than the corresponding reference value, the patient is considered to have a poor prognosis.
[0291] 2. A method for determining or recommending whether to initiate a medical program for a patient with a stroke, the method comprising the following steps: (i) Determine the expression level of at least one miRNA selected from miR-376c-3p, miR-199a, miR134-5p, miR-4463, miR-584-5p and combinations thereof in samples isolated from the patient, particularly selecting from miR-376c-3p, miR-199a and combinations thereof. (ii) The expression level obtained in step (i) is compared with the corresponding reference value, wherein if the expression level determined in step (i) is higher than the corresponding reference value, the medical treatment plan is decided or recommended to be initiated.
[0292] 3- An in vitro method for determining the response of a patient diagnosed with stroke to a medical regimen for treating stroke, the method comprising the following steps: (i) Determine the expression level of at least one miRNA selected from miR-376c-3p, miR-199a, miR134-5p, miR-4463, miR-584-5p and combinations thereof in samples isolated from the patient, particularly selected from miR-376c-3p, miR-199a and combinations thereof. (ii) Compare the expression levels obtained in step (i) with the expression levels of the same one or more miRNAs identified at the start of the treatment regimen or at an earlier stage of the treatment regimen. A decrease in the expression level of one or more miRNAs relative to their expression levels at the start of the treatment or at an earlier stage of the treatment indicates a good response to the treatment.
[0293] 4. The method according to any one of Examples 1-3, wherein step (i) includes determining the expression levels of miR-376c-3p and / or miR-199a, particularly miR-376c-3p and miR-199a.
[0294] 5. The method according to any one of Examples 1-4, wherein step (i) includes determining the expression level of at least one miRNA selected from the group consisting of miR-376c-3p, miR-199a and combinations thereof, and further includes determining the expression level of at least one miRNA selected from the group consisting of miR134-5p, miR-4463, miR-584-5p and combinations thereof.
[0295] 6- The method according to Example 5, wherein step (i) includes determining the expression levels of the following: miR-376c-3p, miR-199a, miR134-5p, miR-4463, and miR-584-5; miR-376c-3p, miR134-5p, miR-4463, and miR-584-5; miR-376c-3p, miR-199a, miR134-5p, miR-4463, and miR-584-5; miR-376c-3p, miR-199a, miR-134-5p, and miR-4463; miR-376-3p, miR-199a, miR-134-5p, and miR-584-5. 4-5p;miR-376-3p,miR-199a,miR4463 and miR-584-5p;miR-376-3p,miR-199a and miR-134-5p;miR-376-3p,miR-199a and miR-4463;miR-376-3p,m iR-199a andmiR-584-5p;miR-199a,miR134-5p,miR-4463 andmiR-584-5;miR-199a,miR-134-5p andmiR-4463;miR-199a,miR-134-5p andmiR-584-5p miR-199a, miR-4463, and miR-584-5p; miR-199a and miR-134-5p; miR-199a and miR-4463; miR-199a and miR-584-5p; miR-376c-3p, miR-134-5p, miR-4463, and miR-584-5p; miR-376c-3p, miR-134-5p, and miR-4463; miR-376-3p, miR-134-5p, and miR-584-5p; miR-376-3p, miR-4463, and miR-584-5p; miR-376-3 p and miR-134-5p; miR-376-3p and miR-4463; miR-376-3p and miR-584-5p; miR134-5p, miR-4463 and miR-584-5p; miR-134-5p and miR-4463; miR-134-5p and miR-584-5p; miR4463 and miR-584-5p; miR-134-5p; miR-4463; or miR-584-5p; especially miR-376c-3p, miR-199a, miR134-5p, miR-4463 and miR-584-5p.
[0296] 7. The method according to any one of the preceding claims, wherein the sample is a blood sample, particularly a plasma sample.
[0297] 8- Selected from the group consisting of miR-376c-3p, miR-199a, miR134-5p, miR-4463, miR-584-5p and combinations thereof, particularly at least one miRNA selected from the group consisting of miR-376c-3p, miR-199a and combinations thereof, for use as a prognostic biomarker for patients with stroke, or as a biomarker for determining or recommending the initiation of a medical program for patients with stroke, or as a biomarker for determining the response of patients already diagnosed with stroke to a medical program for treating stroke.
[0298] 9- According to the use described in Example 8, at least one miRNA selected from the group consisting of miR-376c-3p, miR-199a and combinations thereof, and at least one additional miRNA selected from the list consisting of miR-134-5p, miR-4463, miR-584-5p and combinations thereof are used as biomarkers for the prognosis of patients with stroke, or as biomarkers for determining or recommending whether to initiate a medical program for patients with stroke, or as biomarkers for determining the response of patients who have been diagnosed with stroke to a medical program for treating stroke.
[0299] 10- According to the use described in Example 8, wherein the at least one miRNA is miR-376c-3p, miR-199a, miR134-5p, miR-4463, and miR-584-5; miR-376c-3p, miR134-5p, miR-4463, and miR-584-5; miR-376c-3p, miR-199a, miR-134-5p, miR-4463, and miR-584-5; miR-376c-3p, miR-199a, miR-134-5p, and miR-4463; miR-376-3p, miR-199a, miR-134-5p, and miR-4463; miR-376-3p, miR-199a, miR-1 34-5p and miR-584-5p; miR-376-3p, miR-199a, miR4463 and miR-584-5p; miR-376-3p, miR-199a and miR-134-5p; miR-376-3p, miR-199a and miR-4463; miR-376-3p, miR-199a and miR-584-5p; miR-199a, miR134-5p, miR-4463 and miR-584-5; miR-199a, miR-134-5p and miR-4463; miR-199a, miR-134-5p and mi R-584-5p; miR-199a, miR4463 and miR-584-5p; miR-199a and miR-134-5p; miR-199a and miR-4463; miR-199a and miR-584-5p; miR-376c-3p, miR134-5p, miR-4463 and miR-584-5; miR-376c-3p, miR-134-5p and miR-4463; miR-376-3p, miR-134-5p and miR-584-5p; miR-376-3p, miR4463 and miR-584-5p; miR-3 76-3p and miR-134-5p; miR-376-3p and miR-4463; miR-376-3p and miR-584-5p; miR134-5p, miR-4463 and miR-584-5p; miR-134-5p and miR-4463; miR-134-5p and miR-584-5p; miR4463 and miR-584-5p; miR-134-5p; miR-4463; or miR-584-5p; especially miR-376c-3p, miR-199a, miR134-5p, miR-4463 and miR-584-5p.
[0300] 11 - A miRNA inhibitor targeting a list of miR-376c-3p, miR-199a, miR134-5p, miR-4463, miR-584-5p and combinations thereof, particularly miRNAs targeting the group consisting of miR-376c-3p, miR-199a and combinations thereof, for use in the treatment or prevention of stroke in patients.
[0301] 12 - The miRNA inhibitor for use according to Example 11, wherein the miRNA inhibitor specifically binds to at least one or more selected miRNAs at positions 2-7 or 3-8 in the 5' to 3' direction.
[0302] 13 - The miRNA inhibitor for use according to any one of Examples 11-12, wherein the miRNA inhibitor targets miR376c-3p and miR199a.
[0303] 14 - A combination of miRNA inhibitors for use in the treatment or prevention of stroke in a patient, wherein the combination of miRNA inhibitors comprises at least one miRNA inhibitor that inhibits miRNAs selected from the group consisting of miR-376c-3p, miR-199a, miR134-5p, miR-4463, miR-584-5p, and combinations thereof.
[0304] 15 - A combination of miRNA inhibitors for use according to Example 14, wherein the combination of miRNA inhibitors comprises a miRNA inhibitor that inhibits miR199a, particularly miR199a-3p.
[0305] 16 - A combination of miRNA inhibitors for use according to any one of Examples 14-15, wherein the combination of miRNA inhibitors comprises a miRNA inhibitor that inhibits miR-376c-3p.
[0306] 17 - A combination of miRNA inhibitors for use according to any one of Examples 14-16, wherein the combination of miRNA inhibitors comprises a miRNA inhibitor that inhibits miR134-5p.
[0307] 18 - A combination of miRNA inhibitors for use according to any one of Examples 14-17, wherein the combination of miRNA inhibitors comprises a miRNA inhibitor that inhibits miR-4463.
[0308] 19 - A combination of miRNA inhibitors for use according to any one of Examples 14-18, wherein the combination of miRNA inhibitors comprises a miRNA inhibitor that inhibits miR-584-5p.
[0309] 20 - A combination of miRNA inhibitors for use according to any one of Examples 14-19, wherein the combination of miRNA inhibitors comprises miRNA inhibitors that inhibit miR199a, particularly miR199a-3p and miR-376c-3p.
[0310] 21- The combination of miRNA inhibitors for use according to Example 20, wherein the miRNA inhibitors that inhibit miR199a, particularly miR199a-3p and miR-376c-3p are cyclic oligonucleotides or miRNA sponges.
[0311] 22 - A combination of miRNA inhibitors for use according to any one of Examples 14-21, wherein each of the at least one miRNA inhibitor is a miRNA inhibitor of a different miRNA selected from a list consisting of: miR-376c-3p, miR134-5p, miR-4463 and miR-584-5; miR-376c-3p, miR-199a, miR134-5p, miR-4463 and miR-584-5; miR-376c-3p, miR-199a, miR-134-5p and miR-4463; miR-376-3p, m iR-199a,miR-134-5p and miR-584-5p;miR-376-3p,miR-199a,miR4463 and miR-584-5p;miR-376-3p,miR-199a and miR-134-5p;miR-376-3p,miR-199a and m iR-4463;miR-376-3p,miR-199a and miR-584-5p;miR-199a,miR134-5p,miR-4463 and miR-584-5;miR-199a,miR-134-5p and miR-4463;miR-199a,miR-134 -5p and miR-584-5p; miR-199a, miR4463 and miR-584-5p; miR-199a and miR-134-5p; miR-199a and miR-4463; miR-199a and miR-584-5p; miR-376c-3p, miR134-5p, miR-4463 and miR-584-5p; miR-376c-3p, miR-134-5p and miR-4463; miR-376-3p, miR-134-5p and miR-584-5p; miR-376-3p, miR4463 and miR-584-5p; miR-3 76-3p and miR-134-5p; miR-376-3p and miR-4463; miR-376-3p and miR-584-5p; miR134-5p, miR-4463 and miR-584-5p; miR-134-5p and miR-4463; miR-134-5p and miR-584-5p; miR4463 and miR-584-5p; miR-134-5p; miR-4463; or miR-584-5p; especially the group consisting of miR-376c-3p, miR-199a, miR134-5p, miR-4463 and miR-584-5p.
[0312] 23 - A combination of miRNA inhibitors for use according to any one of Examples 14-22, wherein the combination of miRNA inhibitors comprises at least one miRNA inhibitor selected from the group consisting of miR-376c-3p, miR-199a, and combinations thereof, and further comprises: - A miRNA inhibitor that targets miRNAs selected from the group consisting of miR134-5p, miR-4463, miR-584-5p, and combinations thereof. - Two miRNA inhibitors, each of which is a miRNA inhibitor selected from different miRNAs in the group consisting of miR134-5p, miR-4463, miR-584-5p, and combinations thereof. - Three miRNA inhibitors, each of which is a miRNA inhibitor selected from different miRNAs in the group consisting of miR134-5p, miR-4463, miR-584-5p and combinations thereof, and in particular, each miRNA inhibitor is a miRNA inhibitor selected from different miRNAs in the group consisting of miR134-5p, miR-4463 and miR-584-5p.
[0313] 24 - A combination of miRNA inhibitors for use according to any one of Examples 14-23, wherein each miRNA inhibitor of the at least one miRNA inhibitor is a miRNA inhibitor of a different miRNA selected from the list of the following: miR134-5p, miR-4463 and miR-584-5p; miR-134-5p and miR-4463; miR-134-5p and miR-584-5p; miR4463 and miR-584-5p; miR-134-5p; miR-4463; or miR-584-5p; particularly miR-376c-3p, miR-199a-3p, miR134-5p, miR-4463 and miR-584-5p.
[0314] 25 - A combination of miRNA inhibitors for use according to any one of Examples 14-24, wherein the one or more miRNA inhibitors specifically bind to at least nucleotides 2-7 or 3-8 at the 5' to 3' ends of one or more selected miRNAs.
[0315] 26 - The miRNA inhibitor for use according to any one of Examples 11-13, or a combination of miRNA inhibitors for use according to any one of Claims 14-25, wherein at least one miRNA inhibitor is an oligonucleotide.
[0316] 27 - The miRNA inhibitor for use according to any one of Examples 11-13, or a combination of miRNA inhibitors for use according to any one of Claims 14-26, wherein each miRNA inhibitor is an oligonucleotide.
[0317] 28 - A miRNA inhibitor for use according to any one of Examples 26-27, or a combination of miRNA inhibitors for use according to any one of Examples 26-27, wherein the oligonucleotide is selected from the list consisting of anti-miRNA oligonucleotides (AMO), cyclic oligonucleotides, miRNA sponges, and strong decoys (TuD).
[0318] 29 - The miRNA inhibitors for use according to Example 28 or combinations of miRNA inhibitors for use according to Example 28, wherein the miRNA inhibitors of miR-376c-3p and miR-199a-5p, the miRNA inhibitors of 376c-3p and miR-199a-3p, or the miRNA inhibitors of miR-376c-3p, miR-199a-5p and miR-199a-5p are cyclic oligonucleotides or miRNA sponges.
[0319] 30 - The miRNA inhibitor for use according to any one of Examples 11-13 or 26-29, or a combination of miRNA inhibitors according to any one of Examples 14-29, wherein at least one miRNA inhibitor specifically binds to a nucleotide at position 3-21 in the 5' to 3' direction of one or more selected miRNAs.
[0320] 31 - The miRNA inhibitors used according to Example 30, or combinations of miRNA inhibitors used according to Example 30, wherein the one or more miRNA inhibitors specifically bind to nucleotides at positions 3-21 in the 5' to 3' direction of one or more selected miRNAs.
[0321] 32 - A pharmaceutical composition for use in the treatment or prevention of stroke, the pharmaceutical composition comprising a miRNA inhibitor as described in Examples 11-13 or 26-31, or a combination of miRNA inhibitors as described in any one of Examples 14-31.
[0322] 33 - The method according to any one of Examples 1-7, the use according to any one of Examples 8-10, the miRNA inhibitor for use according to any one of Examples 11-13 or 26-31, the combination of miRNA inhibitors for use according to any one of Examples 14-31, or the pharmaceutical composition for use according to Example 32, wherein the stroke is ischemic stroke.
[0323] 34 - The method according to any one of Examples 1-7 or 33, the use according to any one of Examples 8-9, the miRNA inhibitor for use according to any one of Examples 11-13 or 26-31 or 33, the combination of miRNA inhibitors for use according to any one of Examples 14-31 or 33, or the pharmaceutical composition for use according to Example 32 or 33, wherein the patient is a non-Asian subject, particularly a Caucasian subject, more particularly a European subject or a European American subject.
[0324] For completeness, this specification also discloses the following terms: 1- An in vitro method for determining the prognosis of a patient with stroke, the method comprising: (i) Determine the expression level of at least one miRNA selected from the group consisting of miR-376c-3p, miR-199a, and combinations thereof in samples isolated from the patient. (ii) Compare the expression level obtained in step (i) with the corresponding reference value. If the expression level determined in step (i) is higher than the corresponding reference value, the patient is considered to have a poor prognosis.
[0325] 2. A method for determining or recommending whether to initiate a medical program for a patient with a stroke, the method comprising the following steps: (i) Determine the expression level of at least one miRNA selected from the group consisting of miR-376c-3p, miR-199a, and combinations thereof in samples isolated from the patient. (ii) Compare the expression level obtained in step (i) with the corresponding reference value. If the expression level determined in step (i) is higher than the corresponding reference value, then the decision is made or the initiation of the medical treatment plan is recommended.
[0326] 3- A method for determining the response of a patient diagnosed with stroke to a medical regimen for treating stroke, the method comprising the steps of: (i) Determine the expression level of at least one miRNA selected from the group consisting of miR-376c-3p, miR-199a, and combinations thereof in samples isolated from the patient. (ii) Compare the expression levels obtained in step (i) with the expression levels of the same one or more miRNAs identified at the start of the treatment regimen or at an earlier stage of the treatment regimen. A decrease in the expression level of one or more miRNAs relative to their expression levels at the start of the treatment or at an earlier stage of the treatment indicates a good response to the treatment.
[0327] 4. The method according to any one of clauses 1-3, wherein step (i) includes determining the expression levels of miR-376c-3p and miR-199a.
[0328] 5. The method according to any one of clauses 1-4, wherein step (i) further comprises determining the expression level of at least one miRNA selected from the group consisting of miR134-5p, miR-4463, miR-584-5p and combinations thereof.
[0329] 6. The method according to any one of the preceding clauses, wherein the sample is a blood sample, particularly a plasma sample.
[0330] 7- At least one miRNA selected from the group consisting of miR-376c-3p, miR-199a and combinations thereof may be used as a biomarker for the prognosis of patients with stroke, or as a biomarker for determining or recommending the initiation of a medical program for patients with stroke, or as a biomarker for determining the response of patients already diagnosed with stroke to a medical program for the treatment of stroke.
[0331] 8 - A miRNA inhibitor targeting a list of miRNAs selected from miR-376c-3p, miR-199a, and combinations thereof, for use in the treatment or prevention of stroke in patients.
[0332] 9 - The miRNA inhibitor used as described in Clause 8, wherein the miRNA inhibitor specifically binds to at least one or more selected miRNAs at positions 2-7 or 3-8 in the 5' to 3' direction.
[0333] 10 - A combination of miRNA inhibitors for use in the treatment or prevention of stroke in a patient, wherein the combination of miRNA inhibitors comprises a miRNA inhibitor according to any one of clauses 8-9, and further comprises: - A miRNA inhibitor that targets miRNAs selected from the group consisting of miR134-5p, miR-4463, miR-584-5p, and combinations thereof. - Two miRNA inhibitors, each of which is a miRNA inhibitor selected from different miRNAs in the group consisting of miR134-5p, miR-4463, miR-584-5p, and combinations thereof. - Three miRNA inhibitors, each of which is a miRNA inhibitor selected from different miRNAs in the group consisting of miR134-5p, miR-4463, miR-584-5p and combinations thereof, and in particular, each miRNA inhibitor is a miRNA inhibitor selected from different miRNAs in the group consisting of miR134-5p, miR-4463 and miR-584-5p.
[0334] 11 - A combination of miRNA inhibitors for use as described in Clause 10, wherein the one or more miRNA inhibitors specifically bind to at least nucleotides 2-7 or 3-8 at the 5' to 3' ends of one or more selected miRNAs.
[0335] 12 - A miRNA inhibitor for use as described in any one of Clauses 8-9, or a combination of miRNA inhibitors for use as described in any one of Clauses 10-11, wherein at least one miRNA inhibitor is an oligonucleotide.
[0336] 13 - The miRNA inhibitor used in accordance with Clause 12, or a combination of miRNA inhibitors used in accordance with Clause 12, wherein the oligonucleotide is selected from the list consisting of anti-miRNA oligonucleotides (AMO), cyclic oligonucleotides, miRNA sponges, and strong decoys (TuD).
[0337] 14 - A pharmaceutical composition for use in the treatment or prevention of stroke, the pharmaceutical composition comprising a miRNA inhibitor according to any one of Clauses 8-9 or 12-13, or a combination of miRNA inhibitors according to any one of Clauses 10-13.
[0338] 15 - The method according to any one of Clauses 1-6, the use according to Clause 7, the miRNA inhibitor for use according to any one of Clauses 8-9 or 12-13, the combination of miRNA inhibitors for use according to any one of Clauses 10-13, or the pharmaceutical composition for use according to Clause 14, wherein the stroke is an ischemic stroke.
[0339] Throughout this specification and claims, the word "comprising" and variations thereof are not intended to exclude other technical features, additives, components, or steps. Furthermore, the word "comprising" covers situations where it means "composed of." Additional objects, advantages, and features of the invention will become apparent to those skilled in the art upon review of this specification, or may be learned through practice of the invention. The following examples are provided by way of illustration and are not intended to limit the invention. Moreover, the invention covers all possible combinations of the specific and preferred embodiments described herein.
[0340] Example A- miRNA identification Example 1 - Materials and Methods 1.1. Research Design A study involving 406 patients with acute ischemic stroke (IS) was conducted. The first discovery study was performed in 215 patients with acute IS by screening 2083 circulating miRNAs. Differential expression analysis was performed, and pathway enrichment analysis was conducted using those differentially expressed miRNAs. Following this phase, a replication validation phase was performed on 26 selected candidate miRNAs in 191 patients. Figure 1 ).
[0341] 1.2. Research Location and Participants 1.2.1. Discovery Queue This acute IS patient cohort is a subset of individuals nested in the BASICMAR registry (continuous patients diagnosed with stroke assessed at Hospital del Mar in Barcelona between 2009 and 2018, ISCIII, number PI051737). Selection criteria details are as follows.
[0342] Selection criteria for discovery queue and duplicate verification queue The discovery cohort is a cohort of acute IS patients nested in the BASICMAR registry (continuous patients diagnosed with stroke assessed at Del Mar Hospital in Barcelona from 2009 to 2018, ISCIII, number PI051737). The inclusion criteria for this study were: (1) a diagnosis of IS confirmed by computed tomography or magnetic resonance imaging in the brain; (2) an initial stroke severity score greater than 2 according to the National Institutes of Health Stroke Scale (NIHSS); (3) hospitalization within the first 24 hours of the onset of IS; (4) availability of clinical data supporting stroke subtype allocation according to ORG 10172 Trial (TOAST) classification 2 for acute stroke treatment; (5) information on NIHSS scores 24 hours after stroke; (6) prior functional independence before stroke, defined as a modified Rankine scale (mRS) score less than 3; (7) information on post-stroke functional status at 3 months (or alternatively between 3 and 6 months); (8) availability of plasma samples; and (9) absence of confounding diseases such as vegetations, demyelinating and autoimmune diseases, or vasculitis. All patients were assessed and classified by a neurologist.
[0343] Individuals with stroke recurrence during the follow-up period were excluded. Strokes in the cerebellum and brainstem, as well as lacunar strokes, were also excluded because the correlation between infarct size and clinical symptoms was low in these locations, and therefore the correlation between infarct size and functional outcomes was also low. In these cases, the recovery process may depend too much on the randomness of stroke location and less on the underlying biological recovery process, thus masking and distorting the potential role of epigenetic contributions in the degree of recovery.
[0344] The duplicate validation cohort met the same inclusion and exclusion criteria as the discovery cohort, but a 24-hour NIHSS score threshold greater than 3 enriched this cohort with more severe cases. This approach aims to allow for variations in patient recovery capacity. We recruited new patients from four independent cohorts at different research institutions: Basicmar 2 cohort at Del Mar Hospital in Barcelona, Albacete University Hospital Complex, Arnau de Vilanova Hospital in Lleida, and Son Espases Hospital in Mallorca. 1.2.2. Duplicate Validation Cohort A replication validation cohort was established based on four independent cohorts from different research institutions: the Basicmar 2 cohort at the Del Mar Hospital in Barcelona, the University Hospital Complex of Albacete, the Arnold Villanova Hospital in Lleida, and the Zon Espasés Hospital in Mallorca (see above). Selection criteria for discovery and duplicate verification queues ).
[0345] 1.3. Outcome Variables Clinical functional outcomes were assessed by trained neurologists using the Modified Rankine Rating Scale (mRS) at the 3-month follow-up visit. This scale was recorded for each patient on an ordinal scale from 0 to 6. For these analyses, the scale was also divided into two categories: good outcomes were considered mRS 0 to 2, and poor outcomes were considered mRS 3 to 6. Reperfusion therapy (intravenous recombinant tissue plasminogen activator - rtPA - or thrombectomy) was also recorded. All patients received standard post-stroke rehabilitation at our facility.
[0346] 1.4. Clinical Variables Document vascular risk factors as defined by international consensus recommendations in direct interviews with patients, relatives, or caregivers, as well as from medical records: clinical variables Vascular risk factors, as defined by international consensus recommendations, were documented in direct interviews with patients, relatives, or caregivers, as well as from medical records, as described elsewhere 1. During hospitalization, standardized questionnaires were administered by a team of neurologists and reviewed by another neurologist. We collected data on the following: age, sex, arterial hypertension (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg at least twice prior to stroke), diabetes (fasting blood glucose ≥ 126 mg / dL at least twice on admission or use of diabetes medication), and hyperlipidemia (cholesterol concentration > 220 mg / dL, low-density lipoprotein cholesterol (LDL-c) > 130 mg / dL, serum triglyceride concentration > 150 mg / dL, or use of medication). Blood glucose, total cholesterol, high-density lipoprotein cholesterol, and LDL-c were obtained via blood tests during hospitalization.
[0347] 1.5. miRNA quantification Plasma samples were collected from patients during the first 24 hours after arrival. In patients receiving rtPA treatment, samples were collected immediately after rtPA administration. Peripheral blood samples were first extracted into 4.5 mL citrate-treated tubes. Cells were then removed by centrifugation at 2000 x g for 15 min. The supernatant (plasma) was removed from the cell pellet using a Pasteur pipette and transferred to 1.8 mL cryovials for storage at -80°C.
[0348] 1.5.1. Discovery Phase A total of 224 plasma samples were processed in three different batches at the Valenciano de Oncología (IVO) laboratory for miRNA sequencing using HTG EdgeSeq (HTG Molecular Diagnostics, Inc., Tucson, Arizona). Nine samples failed quality control (QC) according to HTG standards and were therefore not used for subsequent analysis.
[0349] miRNA quantification during the discovery phase A total of 224 plasma samples were processed in three different batches at the Valencia Institute of Oncology (IVO) laboratory for miRNA sequencing using HTG EdgeSeq (HTG Molecular Diagnostics, Tucson, Arizona, a novel next-generation sequencing-based miRNA profiling platform) (Songia P. et al., 2018). Next-generation sequencing (NGS) technology has become the platform of choice for studying and discovering novel circulating miRNAs. It enables the simultaneous sequencing of multiple samples. Furthermore, it offers higher sensitivity and specificity than other technologies such as microarrays or RNA sequencing.
[0350] All samples were run using HTG EdgeSeq miRNA whole transcriptome sequencing (which contains probes for 2083 miRNA transcripts). Sequencing was performed on an Illumina NextSeq 550 platform using a standard NGS protocol. Data were acquired and analyzed from the sequencer as FASTQ files and processed using EdgeSeq parser software (HTG Molecular Diagnostics) to generate raw counts of 2083 miRNAs in each sample. Final counts of 2083 miRNAs in each sample were generated for downstream data analysis.
[0351] Data were generated for 224 samples. Nine of these failed quality control according to HTG standards and were therefore not used in subsequent analyses.
[0352] 1.5.2. Repeat Validation Phase miRNAs were extracted from 100 µl plasma from 238 patients using the MagMax™ mirVana™ Total RNA Isolation Kit (A27828, Thermo Fisher Scientific). To prepare cDNA templates for real-time quantitative polymerase chain reaction (RT-qPCR), the TaqMan™ Advanced miRNA cDNA Synthesis Kit (A28007, Thermo Fisher Scientific) was used. RT-qPCR was performed using TaqMan™ Fast Advanced premix (4444557, Thermo Fisher Scientific) and a custom TaqMan™ array card. After QC, 191 samples and 26 miRNAs were included in the analysis. (Supplementary Method 3.2 and...) Figure 1 ).
[0353] miRNA quantification in the replication validation phase miRNAs were extracted from 100 µl of plasma from 238 patients using the MagMax™ mirVana™ Total RNA Isolation Kit (A27828, Thermo Fisher Scientific). Four RNA incorpors were added as miRNA extraction controls (ath-miR159a, cel-miR-54-3p, cel-miR-39-3p, cel-miR-238-3p) following the protocol as indicated in the kit manual. 2 µl of each RNA incorporation (0.5 µM) was added to each sample after sample lysis and before the addition of binding beads. At the end of the protocol, miRNAs were eluted with 50 µl of elution buffer and quantified using a quorum analyzer.
[0354] The custom TaqMan™ array card contains 41 miRNA candidates, 4 RNA incorporations, 2 hemolysis controls (hsa-miR-451a, hsa-miR-23a-3p) and 1 endogenous control (hsa-miR-16-5p) (Solayman MHM. et al., 2016).
[0355] 1.6. Bioinformatics and Statistics 1.6.1. Descriptive Statistics Data are reported as mean (± standard deviation), median (interquartile range), and frequency (%), depending on the type and distribution of each variable. The 3-month mRS was our study endpoint, and it was divided into two categories using standard cutoff values: good outcome (0 to 2) and bad outcome (3 to 6).
[0356] First, a bivariate analysis was performed in the discovery cohort to determine which factors (demographic or clinical variables) were associated with stroke outcomes. For this purpose, t-tests, Kruskal-Wallis tests, and χ² tests were used as appropriate. Variables with a significant effect on stroke outcomes (p < .05) were considered covariates and included in the model used for subsequent analyses.
[0357] 1.6.2. Discovery Phase 1.6.2.1. Differential miRNA Expression Analysis Differential expression analysis was performed to identify which miRNAs were upregulated or downregulated in cases compared to controls (good outcomes) (bad outcomes). DESeq2, an R library, was used to efficiently analyze count data obtained from omics experiments (Love MI et al., 2014; Zhu A et al., 2019) (see DESeq2 workflow and analysis details below).
[0358] These models were adjusted for the following: age, previous mRS (before IS), 24h NIHSS, sex, and rTPA treatment (since both are known to affect miRNA expression profiles (He XW et al., 2019; Zhao YY et al., 2015; Xiang W. et al., 2017; Siegel C. et al., 2011; Sharma S. et al., 2014)), and batch number. The 24h NIHSS was incorporated into the adjustments instead of the initial NIHSS to treat baseline stroke severity as a neurological deficit established after possible acute reperfusion (spontaneous or after reperfusion therapy).
[0359] A total of 869 miRNAs were ultimately included in the analysis. After analysis, the p-values representing the association between stroke outcome and each miRNA were corrected for using multiple comparisons based on the false discovery rate (FDR) using the Benjamini-Hochberg method.
[0360] Differential expression analysis was repeated, and adjustments were made for the interaction between the main covariates defined above and stroke outcomes.
[0361] 1.6.2.2. Internal verification using bootstrapping After obtaining the first set of significant miRNAs and performing enrichment analysis during the discovery phase, a bootstrapping method was performed by running the same DESeq2 procedure on the resampled set of the original cohort (see supplementary information for details). Bioinformatics and Statistics A.2 This step helps filter which miRNAs are good candidates for repeated validation.
[0362] 1.6.2.3. Selection of candidates for repeated validation Considering those miRNAs that were significant after the bootstrap method and combined with those with higher FC values, 41 selected miRNAs were obtained for the replication validation phase.
[0363] 1.6.3. Repeat Validation Phase After obtaining RT-qPCR data, quality control (QC) was performed for detection rate, call rate, and hemolysis ratio. Following this QC, 191 patients and 26 miRNAs were retained for replication validation studies. Details are explained in Supplementary Information: Bioinformatics and Statistics, B-.
[0364] Batch effects corresponding to cDNA extraction were removed using an SVA library (Leek JT. et al., 2022), and the subsequent replication validation model used for RNA quantification was also adjusted. The following normalization was performed using a housekeeping miRNA (hsa-miR-16-5p) on each of the 26 candidate miRNAs that passed QC:
[0365] Lower ΔCt values indicated higher miRNA expression. Normalized Ct values were then used in multivariate regression models, adjusted for the same set of covariates selected in the discovery phase: age, sex, previous mRS, 24-hour NIHSS, rTPA treatment, and additional RNA quantification. A dichotomy for stroke outcome was the predictor of interest, and adjusted marginal means and fold changes for the good and bad outcome groups were calculated. Replication validation results were also subjected to bootstrapping using the same method as in the discovery study. A miRNA was considered replicated when the p-value was below 0.05 and the miRNA was significant after bootstrapping.
[0366] 1.6.4. Functional Enrichment Analysis To provide further insights into which biological functions are regulated by the significant set of miRNAs obtained in the discovery phase, functional enrichment analysis was performed. First, predicted target genes for those miRNAs with Q values below 0.05 in the previous phase were obtained. Four available databases were used, employing sequence-based prediction algorithms to predict miRNA-gene relationships: TargetScan v7.2 (Garcia-Moreno A. et al., 2020), miRDB v6 (Agarwal V. et al., 2015), Diana-microT v5 (Paraskevopoulou MD et al., 2013), and PicTar v2 (Krek A. et al., 2005) (see Supplementary Information: Bioinformatics & Statistics, C- for details of the full functional enrichment analysis).
[0367] Considering the background full set, infer the biological functions overrepresented in the target gene sets (e.g., indexed based on gene ontology (GO) databases). Query the Ensembl database (version 106, April 2022) to identify those GO gene sets that present at least one gene in the background full set. Consider the three main domains contained in GO: biological processes (BP), molecular functions (MF), and cellular components (CC). Proceed with hypergeometric tests (Fischer exact test) to determine whether each of these gene sets is overrepresented in experiments (TopGO R library). Consider only those GO entries with between 10 and 800 nodes. Apply FDR correction to the results.
[0368] Then the clusters are annotated using the automatic annotation plugin included in Cytoscape (version 3.9.1), but all text annotations are revised and modified as necessary based on literature on those GO entries.
[0369] Hierarchical clustering algorithm is used to find miRNA groups with similar functions (Euclidean norm is used as the distance metric and Ward is used as the connection function).
[0370] Finally, enrichment analysis was performed on the miRNA sets that were repeatedly validated, and Functional networks were constructed in which repeatedly validated miRNAs, their gene targets, and biological pathway families were observed (Supplementary Information: Bioinformatics and Statistics, C).
[0371] 1.6.5 Supplementary Information: Bioinformatics and Statistics A- Discovery Phase A.1 Differential miRNA Expression Analysis To identify which miRNAs were differentially expressed in the two groups, DESeq2 (R-library) was used. The DESeq2 workflow normalizes the data by dividing each count by a sample-specific size factor, determined by the median ratio of the miRNA count to the geometric mean of each miRNA. It then fits a negative binomial model to each miRNA to obtain a fold change (FC) value representing the difference in expression between cases and controls after estimating the characteristic dispersion using local fitting. Seven miRNAs with abnormal dispersion values were excluded from the analysis.
[0372] Regarding batch effects, detection was performed by conducting principal component analysis (PCA) on the miRNA dataset and plotting the first component against the second component according to the technique. Furthermore, several statistical hypotheses were tested using the DESeq2 procedure. Specifically, those miRNAs with low count characteristics and those with anomalous dispersion values were excluded.
[0373] Differential expression analysis was repeated, also adjusted for the interaction between the major covariates defined above and stroke outcomes. This analysis aimed to examine whether candidate miRNAs were associated with functional status in the entire sample or only in specific strata at month 3. Continuous variables (age and 24-hour NIHSS) were categorized into ternaries to facilitate the interpretation of these interactions.
[0374] A 2. Internal verification using bootstrapping After obtaining an initial set of significant miRNAs and performing enrichment analysis during the discovery phase, a bootstrapping process was performed by running the same DESeq2 procedure on a resampled set of the original cohort. This aimed to test whether the observed associations were biased by anomalous observations or by other sources of error corrected for with replacement resampling. After 1000 iterations, a new distribution of the β coefficients for each miRNA-stroke outcome relationship that was significant in the previous step was obtained. Within these distributions, the 2.5th and 97.5th percentiles (α = .05) were used to test whether the miRNAs were significantly associated with stroke outcomes after the bootstrapping process. This step helped filter which miRNAs were good candidates for repeated validation.
[0375] B- Repeat Validation Phase After obtaining the RT-qPCR data, quality control (QC) was performed. First, samples where at least one of the four RNA incorpors or housekeeping miRNAs was not detected (circulation threshold [Ct] value >35, N = 6) were excluded. Then, the hemolysis ratio (miR-451a / miR-23a ratio) was tested; it should be below 60. No samples were excluded based on this QC. Those miRNAs not detected in at least 80% of the samples were also filtered out, excluding 15 miRNAs from subsequent analyses. Finally, patients with a detection rate below 80% were excluded. Following this QC, 191 patients and 26 miRNAs were retained for repeat validation studies.
[0376] Batch effects were also detected by performing PCA on the raw Ct values of 26 miRNAs and plotting the first two components. This identified batch effects corresponding to cDNA extraction, which were subsequently removed via an SVA library. Finally, a second PCA was performed on the batch-corrected Ct values, and the two main components were correlated with RNA quantification measured via Qubit. This revealed that RNA quantification affected the overall RT-qPCR results. Therefore, the subsequent replication validation model used for RNA quantification was adjusted.
[0377] C-functional enrichment analysis To perform functional enrichment analysis, recommendations from previous studies were followed, and more than one database was used to reduce the number of false positives from the queries. Specifically, only those predicted target genes present in at least two of the four databases were retained. Queries were run against both significant miRNAs and group background (N = 2076 miRNAs) using an R library designed for this purpose (Ru Y. et al., 2014). Furthermore, only the top 20% of predictions from each database were retained as candidate target genes to obtain a high-quality set of miRNA-gene relationships.
[0378] Considering the background full set, infer the biological functions overrepresented in the target gene sets (e.g., indexed based on gene ontology (GO) databases). Query the Ensembl database (version 106, April 2022) to identify those GO gene sets that present at least one gene in our background full set. Consider the three main domains contained in GO: biological processes (BP), molecular functions (MF), and cellular components (CC). Proceed with hypergeometric tests (Fischer exact test) to determine whether each of these gene sets is overrepresented in experiments (TopGO R library). Consider only those GO entries with between 10 and 800 nodes. Perform FDR correction on the results.
[0379] To provide insights into which broad functions are overrepresented in the study and to summarize the results, the similarity between significant GO pathways obtained in the previous step (FDR-corrected p-value < 0.05) was calculated by applying the following formula:
[0380] Where ij represents two GO pathways. That is, the total number of genes in the union of the gene sets divided by their intersection. The enrichment graph (undirected graph) is then constructed, in which significant GO pathways are introduced as nodes, and the edges between nodes are weighted according to this similarity index explained above. This graph is viewed using Cytoscape (version 3.9.1). To find clusters of highly correlated GO gene sets, edges with a similarity index equal to or greater than 0.25 and nodes with a p-value < 10⁻⁵ are filtered. The clusters are then annotated using the automatic annotation plugin included in Cytoscape, but all text annotations are revised and modified as necessary based on literature review of those GO entries.
[0381] Using a set of GO entries obtained via Cytoscape and annotated based on similarity clustering, the number of miRNA target genes for each pathway was obtained and represented as a heatmap to visualize the broad functions involved in each significant miRNA. This count was log-normalized and corrected for the number of target genes and pathway size for each miRNA to achieve accurate visualization, penalizing miRNAs with many targets or gene sets with many nodes. Finally, a hierarchical clustering algorithm was used to find groups of miRNAs with similar functions (Euclidean norm as the distance metric and Ward as the connection function).
[0382] Finally, enrichment analysis was performed on the replicated miRNA set using the same methodology as in the discovery study, thereby obtaining clusters or families of pathways involving miRNAs using gene targets obtained in the discovery phase. It also aimed to construct a functional network in which the connections between replicated miRNAs, their gene targets, and biological pathway families could be observed. The connections between miRNAs and target genes were weighted according to whether the miRNA-gene relationship had been validated by experimental studies. The number of such manuscripts validating miRNA targets was obtained using the “miRNetR” library, and this number was scaled from 0 to 1 for each miRNA-target relationship. The strength of the connection between genes and pathway families was weighted by calculating the number of individual GO entries within a single family involving each gene and scaling this number from 0 to 1.
[0383] Example 2 - Results 2.1. Discovery Phase 2.1.1. Demography During the discovery phase, we evaluated 215 patients with IS. Demographic and clinical characteristics are summarized in Table 1. The mean age was 74.7 (± 10.2) years, 118 (54.9%) were male, and 142 individuals had a prior mRS of 0. As expected in a stroke cohort, we observed a high prevalence of vascular risk factors. The median initial NIHSS was 9 (interquartile range [IQR] = 5–18), and 75 (34.9%) subjects received intravenous rTPA treatment, while 19 (8.8%) received mechanical thrombectomy. Regarding stroke outcomes, 133 patients (61.9%) had adverse outcomes at discharge, while 114 (53%) had adverse outcomes at 3 months.
[0384] Discovery cohort demographic and clinical characteristics
[0385] Table 1. Demographic and clinical characteristics of the cohort. Data are reported as mean (± standard deviation), median (interquartile range), and frequency (%), based on the type and distribution of each variable. The right-hand column shows the bivariate analysis results from each covariate and stroke outcome. p value.
[0386] In the univariate analysis (Table 1), we found that age, stroke severity (measured by initial and 24-hour NIHSS) and previous mRS variables were all significantly associated with the 3-month outcome (all p values < 0.05).
[0387] 2.1.2. Differential Expression Analysis Differential miRNA expression analysis was performed, adjusted for age, 24-hour NIHSS, previous mRS, sex, and rTPA treatment. After QC, the analysis identified a total of 869 miRNAs in the cohort of 215 patients. 74 miRNAs were found to have a Q value <0.05. All of these miRNAs were overexpressed in patients with adverse outcomes, with FC values ranging from 1.2 to 2.2. The expression differences between patients with good and poor prognoses were visually apparent in the subset of miRNAs with FCs higher than 1.5. Figure 2 -B. Interestingly, these candidate miRNAs are highly positively correlated.
[0388] 2.1.3. Internal Validation Following bootstrapping, 64 miRNAs maintained their significant association with stroke outcomes. Figure 2-A). Differential expression analysis was repeated in a subset of 64 significant miRNAs after bootstrapping, but also adjusted for the interaction between the major covariates and stroke outcomes. Only a significant interaction with age was found (Q value < 0.05). To visualize these results, age was categorized according to a ternary distribution, and seven miRNAs were found to interact significantly with age. Six of these were primarily overexpressed in younger patients (45–72 years) with poor prognosis, while the other showed the opposite trend. These results indicate that most miRNA candidates are upregulated across the entire sample, and their association with stroke outcomes is independent of other variables.
[0389] 2.2. Repeat Validation Phase 2.2.1. Selection of miRNAs to be replicated Based on FC values and pathway analysis results, 41 miRNAs were selected for repeat validation (Table 2). Following QC procedures, 26 miRNAs were evaluated in 191 patients. Demographic and clinical characteristics of the repeat validation cohort are summarized in Table 3. As expected, higher NIHSS values were observed in the repeat validation cohort, as more severe strokes were selected in this phase of the selection criteria. A higher number of thrombectomies was also observed.
[0390]
[0391] Table 2: Differentially expressed miRNAs after internal validation during the discovery phase. Labels indicate which miRNAs were selected for repeated validation and whether this decision was based on fold change (FC) values or pathway analysis (PA).
[0392] Demographic and clinical characteristics of the repeated validation cohort
[0393] Table 3. Demographic and clinical characteristics of the repeated validation cohort. Data are reported as mean (± standard deviation), median (interquartile range), and frequency (%). P The value indicates whether there is a difference between the discovery queue and the duplicate verification queue.
[0394] 2.2.2. Differential Expression Analysis First, the correlations among 26 candidate miRNAs were explored, revealing that all candidates were highly correlated, as they were in the discovery cohort. The expression of these candidates was then compared between patients with good and poor prognoses. After adjusting for the same confounding factors selected in the discovery phase, all miRNAs were found to be overexpressed in patients with poor outcomes (lower ΔΔCt values), with five showing statistical significance at nominal levels (p < 0.05): miR-376c-3p, miR-4463, miR-134-5p, miR-199a-3p, miR-584-5p (…). Figure 4 Following the bootstrapping results, the same five significant miRNAs were observed. Figure 4 -B). Figure 4 -C reveals the differential expression of miRNAs based on the outcome. On the other hand, one of the candidates that underwent repeated validation (miR-134-5p) was found to be primarily associated with stroke prognosis in women. Figure 4 -D).
[0395] 2.3. Pathway Analysis 2.3.1 Pathway analysis of significant miRNAs during the discovery phase After merging predictions from four different databases, annotations were found for 53 of the 74 significant miRNAs, representing 2476 unique target genes involving 4223 miRNA-gene relationships. These 2476 targets received a median input of 1 miRNA (1–2), and each miRNA targeted a median number of 30 genes (14–81). Based on 77446 miRNA-gene interactions, effective gene targets for 1090 miRNAs were identified, and these miRNAs were annotated to 10079 unique target genes.
[0396] After applying FDR correction, 425 significant GO pathways were found to be overrepresented in the gene set. Specifically, 350 pathways were significant for BP-GO, 42 for CC-GO, and 33 for MF-GO.
[0397] Enrichment maps were then constructed, and significant GO entries were annotated into clusters based on their similarity (shared genes). Interestingly, several of these clusters grouped GO entries into those associated with biological processes such as angiogenesis, neuronal morphogenesis, transforming growth factor β (TGF-β), endothelial development, and cognition—all of which are related to stroke recovery. In terms of cellular components, many nodes were annotated with neuronal and synaptic GO entries.
[0398] Since a miRNA may interact with more than one gene target, it aims to calculate the number of target genes for each of the 53 effectively annotated significant miRNAs in a significant pathway. Figure 3 Using hierarchical clustering algorithms, we found that small clusters of four miRNAs had high counts in pathways related to angiogenesis, synaptic cell components, cognition, and neuronal morphogenesis. Two larger clusters were also observed related to myocardial hyperplasia, and another group was involved in TGF-β response-related pathways.
[0399] 2.3.2. Pathway analysis of miRNAs for repeated validation Finally, a second pathway enrichment analysis targeting the gene targets of the five replicated miRNAs revealed 353 unique target genes (Q value < 0.05) across 135 significant GO entries. As in the discovery study, these GO entries were clustered into several families of biological processes based on their shared genes, and it was examined which clusters were enriched for each replicated miRNA. Figure 5 -A). Several groups of GO entries observed in the discovery study were identified, such as TGF-β response or learning and memory. miR-199a-3p miRNA showed the highest involvement in multiple biological processes, followed by miR-376c-3p and miR-134-5p. These miRNAs are part of the same group of miRNAs and share similar functions. On the other hand, miR-584-5p is primarily involved in learning and remembering GO entries. Finally, miR-4463 is associated with protein signal transduction, serine phosphatase regulation, and steroid hormones. Furthermore, the relationships between validated miRNAs, target genes, and GO entry families are presented as an acyclic plot, with the miRNA-gene associations weighted according to the scientific evidence validating these relationships. Figure 5 -B). Interestingly, miR-199a-3p is the miRNA with the most validated gene targets, followed by miR-134-5p and miR-376c-3p. miR-4463 is the least known of the prominent miRNAs, as it has no validated gene targets.
[0400] B- Experimental data using model diseases Example 3 - Neuron Model (SH-SY5Y) 3.1 Materials and Methods SH-SY5Y cells were used as a neuronal model to evaluate the potential neuronal damage caused by the expression of miR-199a-3p and miR376c-3p under hypoxic and normoxic conditions. All experiments in this Example 3 were performed using SH-SY5Y cells. SH-SY5Y cells were obtained from the cell line biobank of our institution (Hospital del Mar Research Institute) and were routinely cultured in Duchenne Modified Igor Medium (DMEM) and F12 (1:1) supplemented with 10% fetal bovine serum (FBS), 100 units / mL penicillin, and 100 μg / mL streptomycin. Cultures were maintained in a humidified incubator at 37°C with 5% CO2, and the medium was changed every 2–3 days.
[0401] 3.1.1 - . miRNA mimic and inhibitor transfection (miR-199a-3p and miR376c-3p) The assays in Section 3 use hsa-miR-199a-3p and hsa-miR-376c-3p mimics (MedChemExpress®, HY-R00398 and HY-R00840, respectively), which are chemically synthesized small double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by upregulating miRNA activity. On the other hand, the assays in Section 3 use hsa-miR-199a-3p and hsa-miR-376c-3p inhibitors (MedChemExpress®, HY-RI00398 and HY-RI00840, respectively), which are chemically modified oligonucleotides that hybridize with mature miRNAs. These miRNA inhibitors are composed of SEQ ID NO. 2 and SEQ ID NO: 1, respectively. The miRNA inhibitors have a full-length nucleotide 2'-methoxy modification and strongly compete with mature miRNAs to prevent complementary pairing between the miRNA and its target genes, thereby inhibiting miRNA function.
[0402] Lipofectamine RNAiMAX transfection reagent (13778075, Invitrogen) was used in 96-well plates. TM Cells were reverse-transfected with 1.2 pmol / well of the simulant or a transfection control (fluorescent control BLOCK-iT™ Alexa Fluor™ Red, 14750100, Thermo Fisher Scientific) and 0.2 µl / well of Lipofectamine. Subsequently, a portion of the cells were exposed to hypoxia (hypoxia chamber) in glucose-free medium for 6 hours to simulate stroke. The other portion of cells was cultured in standard medium under normoxic conditions. Scratch assays were performed 24 hours after simulant transfection.
[0403] 3.1.2. Scratch Measurement A scratch was made in the center of the hole, and an image was taken at 0 hours. Images were taken at 24 hours and 48 hours in the following days. The images were analyzed using the wound healing size tool in ImageJ (Suarez-Arnedo A et al., PLoS One, 15(7):e0232565, 2020).
[0404] 3.1.3. qPCR To test the efficiency of miRNA inhibitors, as indicated in section 3.1.1 above, cells were transfected with miR-199a-3p or miR376c-3p miRNA mimics; and 24 hours after mimic transfection, the corresponding miRNA inhibitors (see above) were forward transfected using the RNAiMAX kit (Invitrogen). Four different conditions were tested: •Condition 1: 3 pmol inhibitor per well + 0.3 μL lipofectamine •Condition 2: 6 pmol inhibitor per well + 0.3 μL lipofectamine •Condition 3: 4.4 pmol inhibitor per well + 0.4 μL lipofectamine •Condition 4: 6 pmol inhibitor per well + 0.4 μL lipofectamine Forty-eight hours after transfection with the inhibitor, cells were collected and RNA was extracted. Reverse transcription was performed using the TaqMan™ microRNA Reverse Transcription Kit (4366596, Thermo Fisher Scientific), and expression levels were evaluated by qPCR using TaqMan primer oligonucleotides for miR199a-3p and miR376c-3p (for miR199a-3p, Thermo Fisher Scientific catalog number 002304, and for miR376c-3p, Thermo Fisher Scientific catalog number 002122).
[0405] 3.2 Results 3.2.1. In scratch assays, expression of miR199a-3P and miR376c-3P reduced wound closure. The results showed that, under normoxic conditions, scratch closure was delayed 24 h after transfection with miR-376c-3p mimic, while no delay was observed after transfection with miR-199a-3p, and both miRNAs achieved complete closure within 48 h. Figure 6However, under hypoxic conditions simulating stroke ( Figure 7 Both miRNAs exhibited delayed wound closure at 24 h, and their wound closure ability decreased at 48 h after transfection with miR-199a-3p mimics, particularly miR-376c-3p mimics, which was undetectable under normoxic conditions. These data support the negative role of miR-199a-3p and miR-376c-3p in stroke recovery.
[0406] 3.2.2 Inhibitors reduce miRNA expression qPCR results showed that transfection with their specific inhibitors reduced the expression of both miRNAs, with a reduction of up to 2 CT (cycle threshold) in the case of miR-199a-3p. Table 4 shows the CT values of miRNA expression after inhibitor transfection, with four different transfection conditions (lipofectamine and inhibitor concentrations) tested. In all cases, the mimics were transfected in the same manner, and the effects of different inhibitor conditions (1-4, explained in Methods section 3.1.3) were evaluated. Notably, transfection with the inhibitor 24 hours after mimic transfection resulted in up to a four-fold (equivalent to 2 CT) reduction. Furthermore, at basal levels (C+), the model did not express miR-376c-3p and showed extremely low expression of miR-199a-3p.
[0407]
[0408] Table 4. CT of miRNA expression after inhibitor transfection. 199- mimic: transfected with miR199a-3p; 199_1-4: transfected with miR199a-3p + inhibitor against miR199a-3p; 376- mimic: transfected with miR376c-3p; 376_1-4: transfected with miR376c-3p + inhibitor against miR376c-3p; C+: transfected with RNA control.
[0409] Example 4 - Brain Endothelial Model (hCMEC) 4.1. Materials and Methods The study in this cell model (hCMEC) focused on YAP1 (Yes-associated protein 1), which serves as a potential indicator of stroke recovery in the presence of miR199a-3p and / or its inhibitors, because YAP1 (a coactivator of the Hippo signaling pathway) plays a crucial role in regulating mechanodynamics in the vascular system and in angiogenesis (BoopathyGTK and Hong W (2019) Role of Hippo Pathway-YAP / TAZ Signaling in Angiogenesis. Front. Cell Dev. Biol. [Frontiers in Cell and Developmental Biology] 7:49.). On the other hand, angiogenesis is an important protective mechanism that promotes nerve regeneration and functional recovery during the pathophysiological process of stroke. Following ischemic stroke, it improves hemodynamics, promotes vascular remodeling, and facilitates the recovery of neurovascular function (Fang J, Wang Z, Miao CY. Angiogenesis after ischemic stroke. Acta Pharmacol Sin. July 2023;44(7):1305-1321. doi: 10.1038 / s41401-023-01061-2. Epub February 24, 2023). On the other hand, vascular stiffness promotes ischemic stroke and is a predictor of long-term functional outcomes in patients with ischemic stroke (Louka AM, Sagris D, Ntaios G. Immunity, Vascular Aging and Stroke. Curr Med Chem. 2022;29(34):5510-5521; Fu X, Chu C, Li X, Gao Q, Jia J. Cerebral arterial stiffness for predicting functional outcome in acute ischemic stroke. Hypertens Res. 2019 Dec;42(12):1916-1922.). Therefore, YAP1 appears to be a possible indicator of stroke recovery, especially IS recovery.
[0410] - Cell Culture: Immortalized human brain microvascular endothelial cells (hCMEC / D3), a gift from Dr. Anna Rosell's laboratory (Vall d'Hebron Institute of Research, Barcelona), were cultured in flasks coated with rat tail type I collagen (Corning, NY) in Lonza EBM-2 medium supplemented with EGM-2 SingleQuot (Lonza, Vauxville, MD, USA). The EGM-2 SingleQuot medium contained 2% fetal bovine serum, hydrocortisone, human basic fibroblast growth factor, vascular endothelial growth factor, R3-insulin-like growth factor-1, ascorbic acid, human epidermal growth factor, gentamicin sulfate-amphotericidal (GA-1000), and heparin. Cultures were maintained in a humidified incubator at 37°C with 5% CO2, and the medium was changed every 2–3 days.
[0411] - miRNA nuclear transfection: Electroporation was performed using Amaxa technology (Lonza). hCMEC / D3 cells grown to 90% confluence in 25 cm² flasks were trypsinized and counted to obtain 4.5 x 10⁻⁶ cells. 5 Cells were transfected with either synthetic human miR-199a-3p molecule (5 nmol miRIDIAN microRNA mimic, Dharmacon, catalog number C-300535-05-0005) or disordered RNA (5 nmol mimic with Dy547 as a transfection control, Dharmacon, catalog number CP-004500-01-05). Transfection was performed according to the manufacturer's protocol using the 4D-Nucleofector system and the P5 primary cell solution kit (Amaxa, Lonza). After transfection, cells were incubated in 6-well plates for 24 hours and then harvested for Western blot analysis.
[0412] - Western blot and antibody: Harvest hCMEC / D3 cells, centrifuge and wash with PBS 1X, then homogenize on ice in RIPA lysis buffer (50 mM Tris pH 8, 15 mM NaCl, 1 mM EDTA pH 8, 1% sodium deoxycholate, 0.1% SDS, 1% Triton X-100) for 2 hours, vortexing every 10 minutes. After sonicating the mixture and centrifuging at 12,000 xg for 10 min at 4°C, collect the supernatant. Determine total protein quantification using the DC™ Protein Assay Kit (Biorad) according to the manufacturer's instructions. Mix the protein sample with NUPAGE LDS sample buffer (4X) (Ingenium) and boil at 70°C for 10 min. For Western blotting analysis, 20 μg of hCMEC / D3 cell lysate proteins were separated by NuPAGE 4–12% Bis-Tris gel electrophoresis (Ingenieur Biosciences) and immobilized on 0.45 µm pore size polyvinylidene fluoride (PVDF) membranes (Merk, Darmstadt, Germany). Primary antibodies: rb anti-YAP (Cell Signalling, reference 14074S), anti-YAP / TAZ (Cell Signalling, reference 8418S), and rb anti-GAPDH (Cell Signalling, reference 2118L), purchased from Cell Signalling. Secondary antibodies: anti-rb800CW and anti-ms 700CW (LI-COR Biosciences). Proteins were visualized using fluorescence using an Odyssey imaging system (LI-COR Biosciences, Lincoln, Nebraska, USA). Band quantification was obtained using ImageJ software (National Institutes of Health, NIH).
[0413] 4.2. Results 4.2.1. miRNA 199a-3p induces YAP1 depletion Western blot analysis clearly showed that overexpression of the miR-199a-3p mimic induced YAP1 depletion in hCMEC cells. Figure 8 (B) Presents the relative quantification of target genes from four different imprint analyses. Figure 8 (A) shows the difference in YAP expression in cells transfected with the disordered form and the miR-199a-3p mimic. Note that mimic transfection led to downregulation of YAP. This data also supports the negative impact of miR-199a-3p on stroke recovery.
[0414] 4.2.2. Hippo Pathway - YAP / TAZ participates in angiogenesis As indicated above, YAP1 is believed to play a key role in regulating the mechanical forces in the vascular system and in the angiogenic response.
[0415] Figure 9 The results show that YAP1 negatively regulates actin filaments, which promote cell stiffness. Immunofluorescence of phalloidin (…) Figure 9 C) shows that cell morphology changes with YAP expression. When YAP is inhibited (KO), the number of filaments in the cells increases, and their stiffness also increases. Furthermore, Figure 9 D shows the results for Young's modulus, which measures a cell's ability to withstand changes in length under longitudinal stretching or compression, indicating that YAP-KO exhibits higher stiffness. Therefore, these data support the multiple functions of YAP1 that contribute to stroke recovery and support the negative impact of YAP1 inhibition (as shown above via miR199a-3p) on stroke recovery.
[0416] In conclusion, these data support the negative effects of miR199a-3p and miR376c-3p on stroke recovery, and therefore support that effective inhibition of these miRNAs and thereby elimination of this negative effect on stroke recovery would promote stroke recovery.
[0417] References -Dowdy and Wearden, Statistics for Research, John Wiley and Sons, NewYork, 2004 -Jaegil Kim et al. “ Racial Differences in Expression Levels of miRNA Machinery-Related Genes, Dicer, Drosha, DGCR8, and AGO2, in Asian Korean Papillary Thyroid Carcinoma and Comparative Validation Using the Cancer Genome Atlas ”, International Journal of Genomics, 2017; -Xianglin Yang et al., “ Association of miR-27a polymorphism with the risk of digestive system cancers ", Pathol Res Pract, 216(10):153115, 2020. -H.P. Adams Jr. et al., Baseline NIH Stroke Scale score stronglypredicts outcome after stroke: A report of the Trial of Org 10172 in AcuteStroke Treatment (TOAST). Neurology July 1, 1999 vol. 53 no. 1 126 -Burtis C. A. et al., 2008, Chapter 14, section “StatisticalTreatment of Reference Values” -Erdogan C. et al., A Bioinformatics Analysis of circRNA / miRNA / mRNA Interactions in Acute Myeloid Leukemia, Experimed 2023; 13(1): 45-53. -Stanzione R, Cotugno M, Bianchi F, Marchitti S, Forte M, Volpe M, etal. Pathogenesis of ischemic stroke: Role of epigenetic mechanisms. Vol. 11,Genes. MDPI AG; 2020; -Love MI, Huber W, Anders S. Moderated estimation of fold change anddispersion for RNA-seq data with DESeq2.Genome Biol. 2014 Dec 5; 15(12). -Zhu A, Ibrahim JG, Love MI. Heavy-Tailed prior distributions forsequence count data: Removing the noise and preserving largedifferences.Bioinformatics.2019 Jun 1; 35(12):2084-92 -Guo H, Ingolia NT, Weissman JS, Bartel DP.Mammalian microRNAspredominantly act to decrease target mRNA levels.Nature. 2010 Aug 12; 466(7308):835-40 -Kaminski M. M., Omar O. Abudayyeh, Jonathan S. Gootenberg, FengZhang&James J. Collins, CRISPR-based diagnostics.Nature biomedicalEngineering, 2021, 643:656 -Rotkrua P, Shimada S, Mogushi K, Akiyama Y, Tanaka H, Yuasa Y.Circulating microRNAs as biomarkers for early detection of diffuse-typegastric cancer using a mouse model. Br J Cancer.2013 Mar 5; 108(4):932-40 -Hammond S.M. et al., “ Delivery of oligonucleotide-based therapeutics: challenges and opportunities .”, EMBO Mol. Med. 13(4) 2021; DOI:10.15252 / emmm.202013243 -Lima J.F. et al., “ Anti-miRNA oligonucleotides: a comprehensive Guide for Design .” RNA Biol. 2018; 15:338-352. -K.A. Lennox, Richard Owczarzy, Derek M Thomas, Joseph A Walder, MarkA Behlke, “Improved performance of Anti-miRNA oligonucleotides using a novelnon-nucleotide modifier, molecular therapy”, Nucleic Acids 2 (2013) e117 -Erdogan C., Murat KAYA and Ilknur SUER, A Bioinformatics Analysis of circRNA / miRNA / mRNA Interactions in Acute Myeloid Leukemia, Experimed 2023; 13(1): 45-53 -Takeshi Haraguchi, Yuka Ozaki, and Hideo Iba., “ Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells ”. Nucleic Acids Res, 2009, 37: e43 -Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264-68 -Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-77 -Altschul, et al. (1990) J. Mol. Biol. 215:403-10 -Altschul et al, (1997) Nucleic Acids Res. 25(17):3389-3402 -Songia P. et al., Direct screening of plasma circulating microRNAs ,RNA Biol., 2018; 15(10):1268-1272 -Solayman MHM, Langaee T, Patel A, El-Wakeel L, El-Hamamsy M, BadaryO, et al. Identification of Suitable Endogenous Normalizers for qRT-PCRAnalysis of Plasma microRNA Expression in Essential Hypertension. MolBiotechnol. 2016 Mar 1; 58(3):179-87 -He XW, Shi YH, Liu YS, Li GF, Zhao R, Hu Y, et al. Increased plasmalevels of miR-124-3p, miR-125b-5p and miR-192-5p are associated with outcomesin acute ischaemic stroke patients receiving thrombolysis. Atherosclerosis.2019 Oct 1; 289:36-43. -Zhao YY, Wang WA, Hu H. Treatment with recombinant tissueplasminogen activator alters the microRNA expression profiles in mouse brainafter acute ischemic stroke. Neurological Sciences.2015 Aug 28; 36(8):1463-70. -Xiang W, Tian C, Lin J, Wu X, Pang G, Zhou L, et al. Plasma let-7iand miR-15a expression are associated with the effect of recombinant tissueplasminogen activator treatment in acute ischemic stroke patients. ThrombRes. 2017 Oct 1; 158:121-5. -Siegel C, Li J, Liu F, Benashski SE, McCullough LD. miR-23aregulation of X-linked inhibitor of apoptosis (XIAP) contributes to sexdifferences in the response to cerebral ischemia. Proc Natl Acad Sci U S A.2011 Jul 12; 108(28):11662-7. -Sharma S, Eghbali M. Influence of sex differences on microRNA generegulation in disease. Vol. 5, Biology of Sex Differences. BioMed CentralLtd.; 2014. -Leek JT, Johnson WE, Parker HS, Ertif EJ, Jaffe AE, Zhang Y, et al.Package “sva” Title Surrogate Variable Analysis [Internet].2022. Availablefrom: https: / / git.bioconductor.org / packages / sva -Garcia-Moreno A, Carmona-Saez P. Computational methods and softwaretools for functional analysis of mirna data.Vol. 10, Biomolecules. MDPI AG;2020. p. 1-16 -Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNAtarget sites in mammalian mRNAs. Elife. 2015 -Paraskevopoulou MD, Georgakilas G, Kostoulas N, Vlachos IS,Vergoulis T, Reczko M, et al. DIANA-microT web server v5.0: serviceintegration into miRNA functional analysis workflows. Nucleic Acids Res.2013; 41 -Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, et al.Combinatorial microRNA target predictions. Nat Genet.2005 May; 37(5):495-500. -Ru Y. et al., The multiMiR R package and database: integration ofmicroRNA-target interactions along with their disease and drug associations,Nucleic Acids Res, 2014; 42(17):e133 -Suarez-Arnedo A, Torres Figueroa F, Clavijo C, Arbeláez P, Cruz JC,Muñoz-Camargo C. An image J plugin for the high throughput image analysis ofin vitro scratch wound healing assays. PLoS One.2020 Jul 28; 15(7):e0232565.doi: 10.1371 / journal.pone.0232565. PMID: 32722676; PMCID: PMC7386569. -Boopathy GTK and Hong W (2019) Role of Hippo Pathway-YAP / TAZSignaling in Angiogenesis. Front. Cell Dev. Biol. 7:49. doi: 10.3389 / fcell.2019.00049 -Fang J, Wang Z, Miao CY. Angiogenesis after ischemic stroke.ActaPharmacol Sin.2023 Jul; 44(7):1305-1321. doi: 10.1038 / s41401-023-01061-2.Epub2023 Feb 24. PMID: 36829053; PMCID: PMC10310733. -Louka AM, Sagris D, Ntaios G. Immunity, Vascular Aging and Stroke. Curr Med Chem. 2022; 29(34):5510-5521. doi: 10.2174 / 0929867329666220103101700.PMID: 34979888. -Fu 31409919. Sequences in the sequence list: miRNA inhibitor : - miR-376c-3p inhibitors: -SEQ ID NO. 1: ACGUGGAAUUUCCUCUAUG (Full-length nucleotide 2'-methoxy modified) -SEQ ID NO. 14: (ACGUGGAAUUUCCUCUAUG) (2 phosphate thioesters at the 5' end, 4 phosphate thioesters at the 3' end, a cholesterol group at the 3' end, and a 2'-methoxy modification of the full-length nucleotide) - miR-199a-3p inhibitors: -SEQ ID NO. 2: (UAACCAAUGUGCAGACUACU) (Full-length nucleotide 2'-methoxy modified) -SEQ ID NO. 15: (UAACCAAUGUGCAGACUACU) (2 thiophosphate bonds at the 5' end, 4 thiophosphate bonds at the 3' end, a cholesterol group at the 3' end, and a 2'-methoxy modification of the full-length nucleotide) - miR-199a-5p inhibitors: -SEQ ID NO. 13: (GAACAGGUAGUCUGAACACUG) (Full-length nucleotide 2'-methoxy modified) -SEQ ID NO. 19: (GAACAGGUAGUCUGAACACUG) (2 phosphate thioester bonds at the 5' end, 4 phosphate thioester bonds at the 3' end, a cholesterol group at the 3' end, and a 2'-methoxy group modified on the full-length nucleotide) - miR134-5p inhibitors: -SEQ ID NO. 3: (CCCCUCUGGUCAACCAGUCA) (Full-length nucleotide 2'-methoxy modified) -SEQ ID NO. 16: RNA, (CCCCUCUGGUCAACCAGUCA) (2 phosphate thioesters at the 5' end, 4 phosphate thioesters at the 3' end, a cholesterol group at the 3' end, and a 2'-methoxy modification of the full-length nucleotide) - miR-4463 inhibitor: -SEQ ID NO. 4: (GGCCCCACCCCAGUC) (Full-length nucleotide 2'-methoxy modified) -SEQ ID NO. 17: RNA, (GGCCCCACCCCAGUC) (2 phosphate thioesters at the 5' end, 4 phosphate thioesters at the 3' end, a cholesterol group at the 3' end, and a 2'-methoxy modification of the full-length nucleotide) - miR-584-5p inhibitor: -SEQ ID NO. 5: (CUCAGUCCCAGGCAAACCAU) (Full-length nucleotide 2'-methoxy modified) -SEQ ID NO. 18: (CUCAGUCCCAGGCAAACCAU) (2 thiophosphates at the 5' end, 4 thiophosphates at the 3' end, a cholesterol group at the 3' end, and a 2'-methoxy modification of the full-length nucleotide) miRNA: SEQ ID NO. 6: Circular RNA inhibitor has_circ_0012152, such as Erdogan C. et al. A Bioinformatics Analysis of circRNA / miRNA / mRNA Interactions in Acute Myeloid Leukemia [Bioinformatics Analysis of circRNA / miRNA / mRNA Interactions in Acute Myeloid Leukemia], Experimental Medicine 2023; 13(1): 45-53 CAGAAUCCUCCCUUACUAAGGGGUCAUUAUAAGGGACGGGACUGGGUUUCACGACCAACCGGAGGGAGGGUCCCUUCUGACGAAGAACGCAUUGCGGCCGGUGUCUUUCUCUGAGGCUACCUGAAUGUGGCCCGUCGGAAGUUCUACCUCUUGAGUAGGAUGGAAGGGUUGGGAGACCGUAGGGGUCGUGACUACCAGGACCGUAGGUGCCGACUCCGGUCGGCACUACGAAGGUAGGGAACAGUCGUCGGUGCUGGGAAACCACAUGGACAGAGUCAACUGUUCCUGCACGUAUAAGGAAAGUGGUUGCCAAGGAUAUGGAAACGGAGAUACAUGGUAGCCGUUCCACCCCACGGUCCGUGAAAACGGUUAGCACUAAAGGGGGGAAGAGAUGAUGUGGAGGUGGGAGUUAAACGAGGGGGUUUAGAUCUAACGUGGGGUUAGUCAUACGACUUAGUAUCACCACACCCCCGAAAGGCCGGGAAACGGAGGUGGCUCCUGGCCCUCUCGAUAGUCAGUCGGAAAUGCGGCCGGUUCGCUGAAUUCUUGACGGUACUGUGUCUCAGAGGGGUGAACGCGAAGAGUCUACGUCUACCGUUCCUUAUACUGAAACCCUGUGUCGACGGUAGAUCGAGGGGGCCAAGUGAUUUCCAACUACUGUGACCCUUCUUCUAAAAACGACAGAGACCGGAGUAAAGACUAGCCCUUCGGAGUAGAUCGGGUCUCCUAGCCUUACUGUCUA SEQ ID NO. 7:miR-376c-3p AACAUAGAGGAAAUUCCACGU SEQ ID NO. 9:miR-199a-3p ACAGUAGUCUGCACAUUGGUUA SEQ ID NO. 10:miR-199a-5p CCCAGUGUUCAGACUACCUGUUC SEQ ID NO. 11:miR-4463 GAGACUGGGGUGGGGCC SEQ ID NO. 8:miR-134-5p UGUGACUGGUUGACCAGGGGG SEQ ID NO. 12:miR-584-5p UUAUGGUUUGCCUGGGACUGAG。
Claims
1. A miRNA inhibitor targeting a list of miRNAs selected from miR-376c-3p, miR-199a, miR134-5p, miR-4463, miR-584-5p, and combinations thereof, for use in the treatment or prevention of stroke in a patient.
2. The miRNA inhibitor for use according to claim 1, wherein the miRNA inhibitor is selected from the list of miR-376c-3p, miR-199a and combinations thereof.
3. The miRNA inhibitor for use according to any one of claims 1-2, wherein the miRNA inhibitor specifically binds to at least one or more nucleotides at positions 2-7 or 3-8 in the 5' to 3' direction of the selected miRNA.
4. A combination of miRNA inhibitors for use in the treatment or prevention of stroke in a patient, wherein the combination of miRNA inhibitors comprises at least one miRNA inhibitor that inhibits miRNAs selected from the group consisting of miR-376c-3p, miR-199a, miR134-5p, miR-4463, miR-584-5p, and combinations thereof.
5. The combination of miRNA inhibitors for use according to claim 4, wherein the combination of miRNA inhibitors comprises miRNA inhibitors that inhibit miR-199a, particularly miR199a-3p.
6. The combination of miRNA inhibitors for use according to any one of claims 4-5, wherein the combination of miRNA inhibitors comprises a miRNA inhibitor that inhibits miR-376c-3p.
7. The combination of miRNA inhibitors for use according to any one of claims 4-6, wherein the combination of miRNA inhibitors comprises a miRNA inhibitor that inhibits miR-199a, particularly miR199a-3p, and a miRNA inhibitor that inhibits miR-376c-3p.
8. The combination of miRNA inhibitors for use according to any one of claims 4-7, wherein the combination of miRNA inhibitors comprises at least one miRNA inhibitor that inhibits miRNAs selected from the list consisting of miR-199a, miR-376c-3p, and combinations thereof, particularly at least one miRNA inhibitor that inhibits miR-199a and one miRNA inhibitor that inhibits miR-376c-3p, and further comprises: - A miRNA inhibitor that inhibits miRNAs selected from the group consisting of miR134-5p, miR-4463, miR-584-5p, and combinations thereof. - Two miRNA inhibitors, each of which is a miRNA inhibitor that inhibits different miRNAs selected from miR134-5p, miR-4463, miR-584-5p, and combinations thereof. - Three miRNA inhibitors, each of which is a miRNA inhibitor that inhibits a different miRNA selected from the group consisting of miR134-5p, miR-4463, miR-584-5p and combinations thereof. In particular, each miRNA inhibitor is a miRNA inhibitor that inhibits a different miRNA selected from the group consisting of miR134-5p, miR-4463 and miR-584-5p.
9. The combination of miRNA inhibitors for use according to any one of claims 4-8, wherein the one or more miRNA inhibitors specifically bind to at least nucleotides 2-7 or 3-8 at the 5' to 3' ends of the selected miRNAs.
10. The miRNA inhibitor for use according to any one of claims 1-3, or a combination of miRNA inhibitors for use according to any one of claims 4-9, wherein at least one miRNA inhibitor is an oligonucleotide.
11. The miRNA inhibitor for use according to claim 10, or a combination of miRNA inhibitors for use according to claim 10, wherein the oligonucleotide is selected from the list consisting of anti-miRNA oligonucleotides (AMO), cyclic oligonucleotides, miRNA sponges, and strong decoys (TuD).
12. A pharmaceutical composition for use in the treatment or prevention of stroke, the pharmaceutical composition comprising a miRNA inhibitor according to any one of claims 1-3 or 10-11, or a combination of miRNA inhibitors according to any one of claims 4-11.
13. An in vitro method for determining the prognosis of a patient with stroke, the method comprising: (i) Determine the expression level of at least one miRNA selected from the group consisting of miR-376c-3p, miR-199a, miR134-5p, miR-4463, miR-584-5p and combinations thereof in samples isolated from the patient. (ii) Compare the expression level obtained in step (i) with the corresponding reference value. If the expression level determined in step (i) is higher than the corresponding reference value, the patient is considered to have a poor prognosis.
14. A method for determining or recommending whether to initiate a medical program for a patient with a stroke, the method comprising the steps of: (i) Determine the expression level of at least one miRNA selected from the group consisting of miR-376c-3p, miR-199a, miR134-5p, miR-4463, miR-584-5p and combinations thereof in samples isolated from the patient. (ii) Compare the expression level obtained in step (i) with the corresponding reference value. If the expression level determined in step (i) is higher than the corresponding reference value, then the decision is made or the initiation of the medical treatment plan is recommended.
15. A method for determining the response of a patient diagnosed with stroke to a medical regimen for treating stroke, the method comprising the steps of: (i) Determine the expression level of at least one miRNA selected from the group consisting of miR-376c-3p, miR-199a, miR134-5p, miR-4463, miR-584-5p and combinations thereof in samples isolated from the patient. (ii) Compare the expression levels obtained in step (i) with the expression levels of the same one or more miRNAs identified at the start of the treatment regimen or at an earlier stage of the treatment regimen. A decrease in the expression level of one or more miRNAs relative to their expression levels at the start of the treatment or at an earlier stage of the treatment indicates a good response to the treatment.
16. The method according to any one of claims 13-15, wherein step (i) comprises determining the expression level of at least one miRNA selected from the group consisting of miR-376c-3p, miR-199a, and combinations thereof.
17. The method according to any one of claims 13-16, wherein step (i) includes determining the expression levels of miR-376c-3p and miR-199a.
18. The method according to any one of claims 16-17, wherein step (i) further comprises determining the expression level of at least one miRNA selected from the group consisting of miR134-5p, miR-4463, miR-584-5p, and combinations thereof.
19. The method according to any one of claims 13-18, wherein the sample is a blood sample, particularly a plasma sample.
20. At least one miRNA selected from the group consisting of miR-376c-3p, miR-199a, miR134-5p, miR-4463, miR-584-5p and combinations thereof, may be used as a biomarker for the prognosis of patients with stroke, or as a biomarker for determining or recommending the initiation of a medical program for patients with stroke, or as a biomarker for determining the response of patients already diagnosed with stroke to a medical program for treating stroke.
21. The use according to claim 20, wherein the at least one miRNA is selected from the group consisting of 376c-3p, miR-199a, and combinations thereof.
22. The miRNA inhibitor for use according to any one of claims 1-3 or 10-11, a combination of miRNA inhibitors for use according to any one of claims 4-11, a pharmaceutical composition for use according to claim 12, a method according to any one of claims 13-19, or use according to any one of claims 20-21, wherein the stroke is an ischemic stroke.
